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Abstract 
During the course of this PhD, a number of potential PET and SPECT imaging agents were 
synthesised for particular in vivo targets. The first targets were monocarboxylate 
transporters 1 and 2 (MCT 1 and 2) which are responsible for the transport of 
moncarboxylates such as lactate and pyruvate across plasma membranes. The generation of 
imaging agents which bind to these MCTs could lead to the effective molecular imaging of 
epileptogenic regions of the brain. A potent and selective inhibitor of MCT 1 and 2 was 
previously synthesised by AstraZeneca (AR-C155858). In this project, a library of 
analogues of this compound was synthesised, containing potential sites for radiolabelling. 
A group of these compounds underwent preliminary biological evaluation to determine the 
inhibitory effect on lactate uptake against MCT 1, 2 and 4 (the most active being 
thienopyrimidine 73). The second target was poly(ADP-ribose) polymerase-1 (PARP-1), 
an enzyme used in the repair of DNA. Targeting PARP-1 with radiotracers could aid the 
diagnosis and monitoring of various tumours. A small library of potential PET imaging 
agents, which have the potential to undergo facile radiofluorination, were synthesised 
based on the PARP-1 inhibitor olaparib. This series of compounds were subject to a 
PARP-1 immunofluorescence assay and the most potent compound in the series was found 
to be phthalazinone 147. 
 
The second part of this thesis describes the development of novel radioiododeboronation 
methods using both gold(I) and potassium acetate catalysis. These methods were used in 
the radiosynthesis of a number of aromatic iodides, giving the radiolabelled products in 
high radiochemical yields. SPECT imaging agents [
125
I]MIBG and a PARP-1 tracer were 
also generated under these conditions. 
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1. Introduction to PET and SPECT imaging 
1.1. Molecular imaging 
Molecular imaging is a non-invasive technique used to detect the interactions of a specific 
cellular target in vivo using an injected molecular imaging agent.
1
 This can provide 
visualisation of biological processes at the molecular and cellular level and can be used for 
the diagnosis and characterisation of disease. Molecular imaging can also be used to 
ascertain a drug’s mechanism of action and therefore guide treatment and dosage decisions. 
The molecular imaging agents (often referred to as molecular probes or tracers) must bind 
to the biological targets with high affinity and specificity in order to obtain good 
visualisation. The nuclear imaging techniques, positron emission tomography (PET) and 
single photon emission computed tomography (SPECT) are the most sensitive techniques 
and can be used to provide a detailed picture of the in vivo target. However, the spatial 
resolution of these techniques is relatively low and as such, they are often used in 
conjunction with techniques like computed tomography (CT) or magnetic resonance 
imaging (MRI), which provide images of a higher resolution (Figure 1).
2
  
 
Figure 1: PET-CT images of a cancer using [
18
F]fluorodeoxyglucose (FDG). The 
cancerous tissue (indicated by the arrows) can be clearly seen in the combined image. 
(From Science, 2013, 342, 429. Reprinted with permission from AAAS).
2
 
1.2. PET imaging 
The information gained from a PET scan relies on imaging agents labelled with 
radionuclides which decay by the emission of a positron.
3
 The emitted positron annihilates 
on collision with a neighbouring electron, producing two 511 keV γ-rays which are emitted 
simultaneously in opposite directions (180° from each other). These γ-rays are detected by 
 
 
14 
 
surrounding γ-detectors (Figure 2). After emission from the nucleus, the positron travels a 
certain distance into the tissue before annihilation (this distance is referred to as the 
positron range). The distance travelled is important because a greater positron range leads 
to decreased spatial resolution. After several emissions, the information recorded about 
positron annihilation can be reconstructed into an image, which shows the spatial 
distribution of radioactivity as a function of time.
4,5 
 
Figure 2: Positron emission from a nucleus and subsequent γ-ray emission to generate a 
molecular image. (Reprinted with permission from Chem. Rev., 2008, 108, 1501. 
Copyright 2008 American Chemical Society).
5
 
There are several different radionuclides which can be employed for PET imaging (Table 
1). These isotopes have short half-lives, therefore, the synthesis and purification of 
molecular imaging agents for PET must be fast and normally an on-site cyclotron is 
required for isotope production. The most commonly used radioisotopes for small 
molecule imaging are carbon-11 and fluorine-18. The advantage of using carbon-11 
labelling is that this can be used to replace a carbon-12 atom in an organic compound. This 
should exhibit the same physiochemical properties, other than a negligible isotope effect.
6
 
However, fluorine-18 is a more useful nuclide for PET imaging due to its low positron 
energy and long half-life (when compared to other PET radionuclides).
7
 The low positron 
energy can lead to images with a higher resolution and the longer half-life allows for a 
more complex radiosynthesis and longer in vivo studies. Fluorine-18 is normally employed 
as a biosteric replacement for hydrogen and due to their similar size, this only causes a 
small change in the overall steric hindrance of the compound. The higher electronegativity 
of fluorine however, does result in a change of electronic and biochemical properties along 
with a general decrease in lipophilicity. In some cases, it has been reported that 
replacement of hydrogen with fluorine can have a beneficial effect on the potency of a 
molecular probe.
5
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Table 1: Radionuclides used for PET imaging. 
Radionuclide Half-life (mins) Maximum energy (MeV) 
11
C 20 0.97 
13
N 10 1.20 
18
F 110 0.64 
68
Ga 68 1.92 
 
1.2.1. Radiolabelling techniques for the production of PET imaging agents 
Carbon-11 can be generated in a cyclotron by the bombardment of nitrogen-14 with 
protons.
8
 Trace amounts of either oxygen or hydrogen are then added to produce either 
[
11
C]CO2 or [
11
C]CH4. These compounds are then usually converted into a more reactive 
species, the most common being [
11
C]methyl iodide or [
11
C]methyl triflate. The radiolabel 
can then be incorporated into an imaging agent by direct methylation of nitrogen, oxygen 
or thiol groups. For example, [
11
C]N-methylpiperidin-4-yl propionate ([
11
C]PMP), which is 
used to map the activity of acetylcholinesterase in Alzheimer’s patients, was synthesised 
via the N-methylation of 4-piperidinyl propionate with [
11
C]methyl triflate (Scheme 1).
9
 
This gave [
11
C]PMP in a 57% radioactivity yield (the isolated yield after purification) with 
a total reaction time of 35 minutes, including purification. 
 
Scheme 1: Synthesis of [
11
C]PMP 2 by N-methylation with carbon-11 labelled methyl 
triflate.
9
 
In the past decade, palladium mediated methylation has found wider applications in the 
synthesis of PET imaging agents. PET tracer [
11
C]4, used in the imaging of the 
metabotropic glutamate 1 receptor, was synthesised using a Stille cross-coupling reaction 
(Scheme 2).
10
 The highest radioactivity yield for this reaction was obtained when bulky 
ligand P(o-tolyl)3 was used. This is due to the large cone angle of the ligand, which 
relieves steric strain during the transmetallation step.
11
 Radiolabelling of stananne 3 to give 
PET tracer [
11
C]4 occurred in a 47% radioactivity yield.  
 
 
16 
 
 
Scheme 2: Synthesis of PET tracer [
11
C]4 via a Stille cross-coupling reaction.
10
 
Despite these reactions being effective, the use of stannanes is not ideal due to their 
toxicity, which can be problematic for use in vivo. Therefore, an attractive option for 
palladium-catalysed methylation using carbon-11 is via a Suzuki cross coupling reaction. 
For example, in 2005, Hostetler and co-workers demonstrated that boronic acids could be 
coupled with [
11
C]methyl iodide to give a range of radiolabelled products in high 
radiochemical yields (Scheme 3).
12
 Under microwave heating, these couplings also have 
the added advantage of very short reaction times. 
 
Scheme 3: The use of a Suzuki cross-coupling reaction to access carbon-11 labelled 
aromatic compounds. 
There are several methods available for the incorporation of 
18
F into a compound, either by 
electrophilic or nucleophilic radiofluorinations. For electrophilic fluorinations, labelled 
elemental fluorine (
18
F2) is produced in a cyclotron using enriched 
18
O2 gas.
7
 Due to the 
high reactivity of elemental fluorine, it is then commonly converted to [
18
F]acetyl 
hypofluorite which is a less reactive and more selective reagent. These materials can then 
participate in direct electrophilic substitution or demetalation reactions to generate the 
desired fluorine-18 labelled compound.
13
 For example, the synthesis of [
18
F]FDOPA 6, 
which is commonly used to study movement disorders like Parkinson’s disease, was 
achieved by a destannylation reaction using [
18
F]F2 as the fluorinating agent (Scheme 4).
14
 
After acidic removal of the protecting groups and HPLC purification, a radioactivity yield 
of 33% was achieved with a total synthesis time of 40 minutes. 
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Scheme 4: Synthesis of [
18
F]FDOPA 6 via a destannylation reaction. 
The disadvantage to electrophilic methods of radiofluorination is that only one of the 
atoms in the [
18
F]F2 source carries an 
18
F and therefore the maximum theoretical yield for 
electrophilic substitution is 50%. Therefore, nucleophilic fluorinations are more commonly 
used.  
Nucleophilic methods employ [
18
F]fluoride as the fluorinating agent, which can be 
prepared by irradiation of 
18
O enriched water.
7
 The nucleophilicity of the fluoride ion 
normally needs to be increased in order to participate in nucleophilic substitution reactions. 
The fluoride ion can be activated with cryptands and alkali salts. When activated, the 
[
18
F]fluoride can be used in an SN2 reaction. For example, [
18
F]FDG 9, which is the most 
commonly used tracer for imaging cancer, can be obtained through a nucleophilic 
substitution (Scheme 5).
15
  
 
Scheme 5: Synthesis of [
18
F]FDG 9 by nucleophilic substitution. 
Another common method for radiofluorination is through a nucleophilic aromatic 
substitution reaction (SNAr). This requires the aromatic ring to be activated towards SNAr, 
which can be achieved by the inclusion of an electron withdrawing substituent in the ortho- 
or para-position, with respect to the leaving group.
13
 [
18
F]Altanserin 11, which is used to 
study 5-HT2A neuroreceptors, was synthesised via SNAr and was obtained in a 23% 
radioactivity yield (Scheme 6).
16
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Scheme 6: The synthesis of [
18
F]altanserin 11 via nucleophilic aromatic substitution.
16
 
One way to radiofluorinate aromatic rings which are not activated towards nucleophilic 
substitution is via the reaction of diaryliodonium salts with the fluoride ion (Scheme 7).
1,17
 
This reaction can occur in the presence of electron-donating and electron-withdrawing 
substituents. The regioselectivity of the fluorination can be controlled electronically and 
sterically (via the ortho-effect). Without the presence of an ortho-substituent, the 
fluorination occurs preferentially on the most electron-deficient ring. However, electron-
rich rings can be fluorinated in this manner by incorporating a substituent ortho- to the 
labelling site, which will direct attack of the fluorine ion onto that ring. 
 
Scheme 7: Radiofluorination using diaryliodonium salts. 
This method has been used in the synthesis of [
18
F]DAA1106 16, a PET tracer used for the 
imaging of peripheral-type benzodiazepine receptors in the brain (Scheme 8).
18
 Reaction 
of diphenyliodinium salt 15 with radiolabelled fluoride and tetrabutylammonium 
bicarbonate gave the desired PET tracer 16 in a 61% radiochemical yield, with the 
fluorination occurring preferentially on the more electron-deficient ring. 
 
Scheme 8: Synthesis of [
18
F]DAA1106 16 using radiolabelled fluoride and 
diphenyliodinium salt 15.
18
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1.3. SPECT imaging 
SPECT operates in a similar fashion to PET however, the radionuclides used are of lower 
energy and emit γ-rays directly. A collimator is placed in front of a gamma-camera to 
detect the γ-rays and evaluate their angle of incidence.1 This technique is less sensitive and 
provides a less resolved image than PET, however radiolabelling of SPECT imaging 
agents is far more practical. Due to the longer half-lives of the commonly used 
radionuclides, a longer radiosynthesis is possible and unlike the synthesis of many PET 
tracers, an on-site cyclotron is not required (Table 2). The extended half-life of SPECT 
compounds is also advantageous since the imaging of a target or biological process can 
take place over a longer period of time.
 3
  
Radionuclide technetium-99m is popular for SPECT imaging as it can be formed simply 
from the decay of its parent nuclide molybdenum-99.
19
 However, the production of 
technetium-99m imaging agents involves chelation to an organic compound, forming a 
metal complex which can affect its permeability through the blood brain barrier (BBB). 
This limits the use of technetium-99m in the imaging of neurological processes. Therefore, 
it is often more practical to use radionuclides such as iodine-123, which can be more easily 
incorporated into an organic compound. 
Table 2: Radionuclides used for SPECT imaging. 
Radionuclide Half-life (h) Photon emission energy (MeV) 
99m
Tc 6 0.14 
123
I 13.2 0.16 
111
In 67.9 0.17/0.25 
67
Ga 78.3 0.09/0.19/0.30 
 
1.3.1. Raioiolabelling techniques for the production of SPECT imaging agents 
Radioiodine isotopes are usually produced in the form of radiolabelled sodium iodide.  
This can be oxidised in situ to an electrophilic form of iodine using an oxidant such as 
peracetic acid or chloramine-T, allowing it to facilitate efficient electrophilic reactions. 
Electrophilic radioiodination can occur directly, however this is limited to aromatic rings 
that are activated towards electrophilic substitution. Therefore, these reactions occur more 
commonly via a demetalation reaction.  In the Sutherland group, a destannylation reaction 
 
 
20 
 
was developed and adopted for the synthesis of [
123
I]PK11195 18 which can be used to 
assess neuroinflammation in the brain (Scheme 9).
20
  
 
Scheme 9: Synthesis of [
123
I]PK11195 18 via iododestannylation.
20
 
Another common method for iodination is using a halogen exchange reaction with aryl 
bromides or chlorides. In the Sutherland group, a radioiodination halogen exchange 
method was developed using nickel(0) catalysis. This allowed for the synthesis of iodine-
125 labelled aryl rings containing both electron-withdrawing and electron-donating 
substituents in high radiochemical yields (Scheme 10).
21
 The reaction proceeds via an 
oxidative addition of an aryl bromide with a nickel(0) catalyst to give a nickel(II) species. 
This species then undergoes a halogen exchange reaction with radiolabelled sodium iodide. 
Finally a reductive elimination occurs to give the desired aryl iodide and regenerate the 
nickel(0) species. 
 
Scheme 10: Examples of nickel(0)-catalysed halogen exchange for the radioiodination of 
aryl bromides.
21
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Another approach for the synthesis of aryl iodides is via a Sandmeyer type reaction using 
diazonium salts. The wider applications of this method were initially limited by the 
inherent instability of various diazonium salts, causing them to be potentially explosive. 
However, recently it has been shown that thermally stable diazonium salts can be prepared 
using polymer supported nitrite reagents and mildly acidic conditions.
22,23
 Within the 
Sutherland group a one-pot tandem diazotisation-radioiodination procedure was developed 
(Scheme 11).
24
 The reaction occurred via diazonium salt formation using a polymer 
supported nitrite and p-toluenesulfonic acid, followed by direct radioiodination using 
[
125
I]NaI. This method was used to successfully prepare a small library of iodine-125 
labelled aromatic rings, containing a variety of functional groups and substitution patterns, 
in high radiochemical yields. A number of SPECT imaging agents were also prepared in 
this fashion. For example, [
125
I]iomazenil 25 (a SPECT tracer for central type 
benzodiazepine recptors),
25
 [
125
I]CNS1261 26 (a radioligand of the N-methyl-D-aspartate 
receptor)
26
 and [
125
I]IBOX 27 (an imaging agent for amyloid plaques)
27
 were all 
synthesised using this method. 
 
Scheme 11: Synthesis of SPECT imaging agents using a one-pot diazotisation-
radioiodination reaction.
24
 *Reaction was carried out at 20 °C  
 
1.4. PET and SPECT imaging of neurological disorders  
All imaging agents used for the imaging of neurological disorders should follow a number 
of guidelines in order to be successful.  First of all, PET and SPECT imaging agents should 
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have high affinity and selectivity for the target receptor, with binding affinities in the sub-
nanomolar range. However, it has been observed that if the affinities are too high then the 
uptake of the tracer is no longer dependant on the rate of binding but becomes dependant 
on the blood flow rate, rendering the imaging agent unsuitable.
28
  The compounds should 
also have a relatively high specific activity so that the agents can be injected in small doses. 
A common source of failure for CNS imaging probes is an inability to permeate the BBB 
and for this reason the molecular weight of the compound should be low and the number of 
atoms capable of hydrogen bond formation with water should be kept to a minimum.
29,30
 
These imaging agents should also not be a substrate for P-glycoprotein 1 which operates at 
the BBB and is capable of actively back-transporting hydrophobic drugs out of cells and 
into the blood. Finally, it is also crucial that these agents are metabolically stable and have 
low plasma protein binding. 
PET and SPECT imaging probes have had a wide applicability in the imaging of 
neurodegenerative diseases and they have been used to target a variety of receptors. For 
example, both PET and SPECT imaging agents can target dopamine receptors and are 
therefore often used in the diagnosis of Parkinson’s disease. A common PET imaging 
agent for the dopamine receptor is [
18
F]FDOPA 6. For SPECT imaging, [
123
I]FP-CIT 28 is 
the most widely used tracer for this purpose.
31,32
 Dopamine allows messages to be sent to 
the parts of the brain which control movement but patients with Parkinson’s disease exhibit 
a loss of dopamine generating neurons. Therefore, by targeting dopamine receptors in the 
brain the progress of Parkinson’s disease can be effectively monitored by PET or SPECT 
(Figure 3).   
 
 
 
 
Figure 3: SPECT images using [
123
I]FP-CIT 28. (a) Image of a normal brain. (b) Image of 
a brain with Parkinson’s disease, showing a reduction in the binding of 28 to dopamine 
receptors (Chem. Soc. Rev., 2011, 40, 149–162. Reproduced by permission of The Royal 
Society of Chemistry).
1
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2. The synthesis of novel PET and SPECT imaging agents for MCT 1 and 2 
2.1. Introduction 
2.1.1. Epilepsy- Current treatments and the need for advanced imaging techniques  
Epilepsy is a life shortening brain disorder affecting more than 40 million people 
worldwide.
33
 It is characterised by spontaneous epileptic seizures and is often associated 
with mental health disorders including anxiety and depression. There are many different 
types of epileptic seizure and the visible effects can vary between momentary losses of 
awareness to uncontrollable jerking movements, all of which have a severe impact on the 
patient’s quality of life.  These seizures are due to a disturbance in neuronal activity within 
the cerebral cortex (usually caused by a spontaneous excess of electrical discharges). 
Epilepsy can be widely defined as generalised epilepsy (otherwise known as idiopathic 
epilepsy) or focal epilepsy (also referred to as symptomatic epilepsy).
33
 In generalised 
epilepsy, most or all of the brain is affected and the condition is thought to be caused by a 
genetic mutation.  In focal epilepsy, the seizures begin in a localised part of the brain and 
are normally caused by pathological changes in that region, like a tumour, severe head 
injury or specific parts of the brain not developing properly.   
Treatment of epilepsy is dominated by anti-epileptic drugs (AEDs). Currently, there are no 
drugs which prevent the progression of the disease before the onset of the first seizure. 
However, there are a large number of drugs which significantly reduce the amount of 
seizures experienced by the patient (Table 3).
34
 The overall effect of these drugs is 
primarily to reduce the amount of excessive electrical activity present in the cerebral cortex 
and therefore stop the generation of seizures. Different drugs have varying mechanisms of 
action depending on which receptor or channel in the brain is being targeted.  
Phenobarbital (29) is the oldest AED still in use and like many AED’s, it has a broad 
spectrum of activity for different seizure types.  It works by stimulating the production of 
gamma aminobutyric acid (GABA) which is an inhibitory neurotransmitter used to counter 
balance neuronal excitation by allowing the movement of chloride ions into neurons.
35
 A 
number of AED’s like phenytoin (30) and carbamazepine (31) bind to sodium ion channels 
with the aim of slowing down or disrupting ion movement in order to decrease neuronal 
firing.
36,37
 Drugs for treating absence seizures (a non-convulsive generalised seizure that is 
marked by the transient impairment or loss of consciousness) like ethosuximide (32) tend 
to target T-type calcium channels.
38
 These channels become blocked when the AED is 
bound, stopping the release of neurotransmitters and reducing neuronal excitability. Some 
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AED’s work on a combination of targets. For example topiramate (33) targets the GABA 
receptor and inhibits sodium and calcium ion channels. Lastly, topiramate also acts as an 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist.39 
These receptors are responsible for glutamate-mediated excitation of neural cells, so 
antagonistic drugs such as topiramate should counteract seizure onset.  
Table 3: Examples of clinically approved AED’s  
AED Main Use AED Target 
 
Phenobarbital (29) 
 
Broad use for 
generalised and 
focal seizures 
 
 
GABA Receptor 
 
Phenytoin (30) 
 
Generalised and 
complex focal 
seizures 
 
 
Sodium channel 
 
Carbamazepine (31) 
 
 
Focal seizures 
 
 
Sodium channel 
 
Ethosuximide (32) 
 
 
Absence seizures 
 
T-type calcium 
channel 
 
 
Topiramate (33) 
 
Broad use for 
generalised and 
focal seizures 
GABA receptor 
Calcium 
channel/sodium 
channel/AMPA 
receptor 
 
Despite the wide range of AED’s available, 30% of all patients are unresponsive to these 
and continue to suffer from regular seizures.
34
 This type of epilepsy is referred to as 
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medically intractable epilepsy (MIE) which is defined by persistent seizure activity despite 
maximal medical treatment. Patients are normally diagnosed with MIE after the failure of 
two or three different AED’s. There are many theories for AED resistance and it is most 
likely due to a combination of various different factors.
40,41
 A popular theory is the ‘drug 
transporter hypothesis’ where the reason for drug resistance is due to inadequate 
penetration of AED’s across the BBB. This is caused by the overexpression of drug efflux 
transporters, such as P-glycoprotein 1 at epileptogenic zones. A less studied but equally 
popular theory is the ‘drug target hypothesis’ where the targeted channels or receptors are 
structurally or functionally modified making them less sensitive to the drugs targeting them. 
A third theory is the ‘network hypothesis’ which proposes that structural brain alterations 
(for example, hippocampal sclerosis) are involved in resistance to AED’s. The type of 
epilepsy is crucial in choosing which treatment route to follow and in many cases, 
misdiagnosis results in ineffective medical treatment and pseudo-resistance.
  
For patients with epilepsy who are diagnosed with MIE, the best option for symptomatic 
treatment is through resective surgery.  In many cases, this results in complete seizure 
freedom or reduced seizure frequency.  In other cases, it can reverse certain drug resistance 
so that the patient’s condition can be kept under control via AED’s after surgery.42  The 
main aim of these surgeries is to resect the epileptogenic zones while leaving as much of 
the neo cortex intact as possible. Whether or not an individual is a candidate for resective 
surgery depends on the location of the epileptogenic zone and the extent to which this 
region which can be physically removed without causing major side effects.
43
  The most 
common type of MIE is temporal lobe epilepsy (TLE) and treatment for this condition 
involves resection of mesial temporal structures. The two most common surgeries 
(accounting for 80% of all epileptic resections) performed are anterior temporal 
lobectomies (ATL) and selective amygdalohippocampectomies (SAH).
44
 ATL involves 
complete removal of the anterior portion of the temporal lobe and SAH is the removal of 
the hippocampus and amygdalae.  There is little evidence to suggest which method is more 
effective as both result in seizure freedom in more than 60% of patients. The side effects of 
temporal lobe resection can include verbal memory impairment and visual perception 
deficits. The third most common type of resective surgery is for the treatment of focal 
extratemporal lobe epilepsy (ETLE). With these patients, the epileptogenic foci are located 
in various regions throughout the cortex, often near eloquent brain structures, which 
control speech, motor function and senses. Therefore, this type of surgery is significantly 
more difficult and higher risk than TLE resection. ETLE resective treatment is 
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significantly less effective than TLE treatment with only 36% of patients becoming 
completely seizure free. This is due to only partial resection of the epileptogenic zone 
being possible in many patients due to the close proximity to eloquent brain structures.  
Clearly, in performing resective surgery, imaging techniques showing the precise location 
of the epileptogenic foci are crucial. Common methods for locating the epileptogenic zone 
and determining the extent of resection include electroencephalography (EEG) and 
structural approaches like magnetic resonance imaging (MRI). However, 25% of patients 
being considered for epileptic resection have a normal structural MRI, so there is an 
extensive need for more advanced imaging methods (Figure 4).
43
 Radiological techniques 
like PET and SPECT are more sensitive than MRI and could be used to detect in a 
structural or behavioural manner, abnormal brain tissue in the epileptogenic zone more 
efficiently.    
 
Figure 4: Scans from a patient with frontal lobe epilepsy.  Left: MRI scan showing a 
normal brain image. Right:
 
[
18
F]FDG 9 PET scan showing decreased metabolism in left 
frontal lobe. (This figure was originally published J. Nucl. Med., 2002, 43, 1167 © 
SNMMI).
45 
2.1.2. Monocarboxylate transporters 1 and 2 and their role in epilepsy 
One way of imaging epilepsy and determining the affected areas of the brain is to target 
receptors that are disrupted by this disorder with molecular imaging agents.  Patients with 
epilepsy suffer from a severe disruption in energetic and metabolic brain function.
46
 
Therefore, the expressions of compounds crucial for brain metabolism are substantially 
affected by this disorder. Monocarboxylates; lactate, pyruvate, acetoacetate and β-
hydroxybutyrate have been found to play a role in the pathophysiology of epilepsy (TLE in 
particular). These compounds are crucial for regulating the energetics of brain metabolism. 
Lactate is particularly important since this is the end product of glycolysis and its 
intracellular build up results in glycolysis inhibition.
47
 Cerebral metabolism of lactate and 
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other carboxylates depends on the concentrations of these compounds in the blood but also 
on their ability to permeate the BBB. These compounds are transported across plasma 
membranes primarily by monocarboxylate transporter 1 (MCT 1) and monocarboxylate 
transporter 2 (MCT 2) and therefore brain metabolism has a dependence on the abundance 
of these monocarboxylate transporters.
46,48
 Monocarboxylate transporters are a family of 
proton-linked transporter proteins which facilitate the transport of monocarboxylates 
across plasma membranes.
49
 Each family member has 12 transmembrane helices (TM’s) 
with intracellular C- and N-termini and a large cystolic loop between TM’s 6 and 7. MCT 
1 is found on astrocytes and in endothelial cells of the blood brain barrier and MCT 2 is 
found in astrocytes and neurons. However, in epileptogenic zones of patients suffering 
from TLE, redistribution occurs and MCT 1 is predominantly found on astrocytes, whereas 
MCT 2 is found on astrocyte plasma membranes.
50
 The reason for this redistribution has 
not been proven, however, it is hypothesised that due to the increased uptake of glutamate 
during epileptic seizures, more ATP is needed to remove this from cells. More lactate is 
generated as the side product from this ATP formation leading to an increase in MCT’s for 
lactate clearance.
51
 Clearly, MCT 1 and MCT 2 play a major role in maintaining normal 
brain function and their distribution in the brain is majorly affected by epilepsy. Therefore, 
by using radiolabelled imaging agents that bind to MCT receptors, the epileptic regions of 
the brain could be visualised using PET or SPECT imaging. 
2.1.3. MCT 1 and 2 inhibitors 
In order to image MCT 1 and 2 and be able to monitor the parts of the brain affected by 
epilepsy, a radiolabel must be attached to a compound which binds to these receptors with 
high affinity and selectivity. There have been several compounds prepared which bind to 
MCT 1 or MCT 2 with the primary aim of being used as anti-cancer drugs. One commonly 
referenced compound is α-cyano-4-hydroxycinnamate (CHCA) 34 which was found to 
inhibit MCT 1 and cause hypoxic tumour cell death in mice (Figure 5).
52,53
 In 2015, 
Mereddy and co-workers attempted to create novel MCT 1 inhibitors based on CHCA.
54
 It 
was found that having a diarylamine or dialkylamine unit in place of the hydroxyl group 
led to increased potency. It was also observed that the inhibitory activity could be further 
optimised with the addition of a methoxy unit on the aryl ring. The most potent compound 
in this series was diarylamine 35, which was found to be active at low nanomolar 
concentration and inhibit tumour growth in nude mice xenograft models. 
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Figure 5: MCT 1 inhibitors that can potentially be used in cancer treatment. 
The synthesis of 35 occurred in three steps from m-anisidine (36), starting with the 
diarylation of the amino group, using bromobenzene and a catalytic amount of 
tetrabutylammonium bromide (TBAB). The next step is a Vilsmeier−Haack formylation to 
give aldehyde 38 followed by condensation with cyanoacetic acid to synthesise 
cyanocinnamic acid 35 (Scheme 12). 
 
Scheme 12: Synthesis of CHCA derivative 35, a potent inhibitor of MCT 1.
54
 
Despite the high potency, it has been shown that these types of compounds are not 
selective for MCT’s but are in fact several orders of magnitude more potent for the 
inhibition of the mitochondrial pyruvate carrier.
55,56
 If radiolabelled compounds were to be 
used as a guide for epileptic resection, it would be crucial for these compounds to be 
highly specific for the target receptors. Therefore, CHCA 34 and its derivatives would not 
be of use for this application.  
Bannister and co-workers synthesised a series of novel pteridinedione and trione 
compounds as dual inhibitors of MCT 1 and MCT 2.
57
 Figure 6 shows the two most potent 
inhibitors from each series. These compounds were also found to impair Raji lymphoma 
cell proliferation at submicromolar doses. It was observed that a hydrocarbon side chain 
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containing a hydroxyl group on either the 5- or 6-position of the scaffold was necessary to 
ensure high potency. If these compounds were to be used as imaging agents, the labelling 
site would likely be installed on the aryl ring at position 7. However, the nature of the aryl 
group and its effect on MCT 1 and 2 inhibition has not yet been investigated. Therefore, 
further investigation on the structure-activity relationship in this region would be required 
to ascertain whether a radiolabel could be installed, while maintaining high binding 
affinities to the target. 
 
Figure 6: MCT 1 and 2 inhibitors, pteridinetrione 39 and pteridinedione 40.
57
 
The most successful inhibitor of MCT 1 and 2 came from a series of thienopyrimidines 
synthesised by AstraZeneca.
58,59
 The compound with the best combination of potency and 
lipophilicity was AR-C155858 which has been advanced into clinical trials for treating 
various malignancies (Figure 7).
60
 
 
Figure 7: The most potent MCT 1 and 2 inhibitor synthesised by AstraZeneca as part of a 
thienopyrimidinedione series. 
Several analogues of this compound were synthesised with different amides at the 5-
position and various aromatic and heteroaromatic side chains at position 6. High binding 
affinities for MCT 1 and 2 were observed for many of these analogues, showing great 
potential for diversification. This, along with the highly selective binding, makes 
thienopyrimidinediones containing a potential labelling site an attractive target for the 
production of novel PET and SPECT imaging agents for MCT 1 and 2. 
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2.1.4. Proposed research 
Based on the success of AR-C155858 41 as an inhibitor of MCT 1 and 2, the main aim of 
this project was to design a variety of AR-C155858 analogues with a potential 
radiolabelling site. The first aim was the preparation of the thienopyrimidinedione core. 
The second objective was to create several small libraries of possible imaging agents with 
potential radiolabelling sites incorporated within the aryl ring which could target MCT 1 
and 2 (Figure 8). 
 
Figure 8: Structures of potential PET or SPECT imaging agents. 
AstraZeneca showed that for good binding affinities along with the appropriate 
lipophilicity, it was necessary to have an amide at the 5-position along with a substituent at 
the 6-position of the thiophene ring.
61
 Although the halogenated benzyl derivatives have no 
substituent at the 6-position, it was proposed that the benzyl amide may be able to access 
the same region of the 6-substituent binding pocket. In the halogenated phenoxy 
derivatives, the aryl group is attached via an ether linkage which based on similar 
AstraZeneca compounds, should lead to high biological activity. In the case of all the 
potential compounds, it was essential to ensure high rigidity, since it was shown that the 
compounds could exist as rotamers, complicating their pharmacology.
61
 With this in mind, 
the phenyl system was proposed, with the aryl group directly attached to the thiophene ring. 
In this final set of compounds, several different amides would also be explored in order to 
assess which type is most beneficial. 
All of these compounds would contain “cold” isotopes of fluorine, iodine or carbon in 
order to mimic their radiological counterparts. The aim was to prepare and then test these 
cold compounds for appropriate physiological properties such as lipophilicity, permeability 
and plasma protein binding. The compounds with the most suitable physiochemical 
properties would then be tested for their ability to bind to MCT 1 and 2. The compounds 
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with the highest affinity would then undergo radiolabelling with fluorine-18, carbon-11 or 
iodine-125 for PET or SPECT imaging, respectively.  
In summary, a small library of AR-C155858 analogues would be prepared using synthetic 
routes which allow for the late stage introduction of diversity. Moieties that can undergo 
activation and subsequent radiolabelling would then be introduced. Identification of active 
compounds with the appropriate physicochemical properties would lead to novel PET and 
SPECT imaging agents for MCT 1 and 2 receptors. 
2.2 Results and discussion 
2.2.1 Synthesis and optimisation of the thienopyrimidinedione core 
The first aim of the project was to synthesise the core structure before diversification. The 
original plan for the synthesis of 46 is shown in Scheme 13. It was proposed that the 
synthesis of 2-amino substituted thiophene 44 could be achieved by reaction of ethyl 
cyanoacetate (42) with ethyl pyruvate (43) in the presence of sulfur. The amine would then 
be alkylated with isobutyl bromide using sodium hydride to give 45. Then, reaction with 
acetyl chloride in the presence of silver cyanate followed by sodium ethoxide addition and 
subsequent methylation would complete the synthesis of 46. For the synthesis of 44, the 
reaction mixture was originally stirred for 3 hours using 1 equivalent of triethylamine.
62
 
This reaction gave the desired product in a 30% yield. It was found that increasing the 
timescale of the reaction to 6 hours did not significantly affect the yield. However, it was 
observed that adding more base did have a beneficial effect, with 5 equivalents of 
triethylamine being the optimum amount. Using these conditions, the yield was improved 
to 58%. 
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Scheme 13: Proposed synthesis of the thienopyrimidinedione core. 
It was proposed that compound 44 could be alkylated using isobutyl bromide and sodium 
hydride. However, none of the desired product was formed. Therefore, an alternative 
method towards compound 45 was employed (Scheme 14).
62
 This method involved a 
reductive coupling with isobutyric acid and sodium borohydride. The optimum yield of 72% 
was achieved by adding the sodium borohydride portionwise over 2 days and heating to 
50 °C.  
 
Scheme 14: Alternative route towards compound 45. 
The proposed next steps involved the reaction of acetyl chloride with silver cyanate to 
form acetyl isocyanate. Compound 45 would then be added to give intermediate 48. This 
would be followed by a sodium ethoxide mediated intramolecular cyclisation. Finally, 
methylation via the addition of methyl iodide would give the desired 
thienopyrimidinedione 46 (Scheme 15).
62
 The synthesis of 48 was successful, resulting in 
a 78% yield after 16 hours. However, the synthesis of 46 by this method was unsuccessful 
under a variety of conditions. After 3 hours of stirring at room temperature, NMR analysis 
showed decomposition of 48 and no desired product formation. It was proposed that the 
sodium ethoxide base was too nucelophilic for this reaction and was likely reacting at more 
than one position, causing 48 to fragment and decompose. It was proposed that using a 
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more sterically hindered base such as sodium tert-butoxide should solve the problem. 
However, when this base was used decomposition still occurred and no product was 
formed.   
 
Scheme 15: Attempted route towards compound 46. 
At this point it was decided that a different route towards 46 would be investigated 
(Scheme 16). The first step was the N-alkylation of 6-chloro-3-methyluracil (49) with 
isobutyl bromide. After stirring for 2 days at 60 °C a 10:1 mixture (better than reported 
literature ratio of 5:1) of N-alkylated to O-alkylated products was obtained (45% crude 
yield) however, the reaction had not gone to completion.
57
 The temperature of this reaction 
was then increased to improve the conversion from starting material to product. At 70 °C 
the crude yield was improved to 55% however, this gave a 5:1 ratio of N-alkylated to O-
alkylated products. Therefore, increasing the temperature yielded less of the desired 
product and so 60 °C was chosen as the optimum temperature. The reaction time was 
increased to 3 days and a yield of 84% was obtained. During the substitution reaction to 
form thioamide 52, it was found that only the N-alkylated product 51 reacted with sodium 
hydrosulfide. This allowed for the easy separation of thioamide 52 from the O-alkylated 
product 50 during work up. Overall, this gave 52 in a 90% yield.  Formation of compound 
46 was initially attempted via a two-stage process involving S-alkylation with ethyl 3-
bromopyruvate followed by a titanium tetrachloride mediated cyclisation.
61
  Although 
intermediate 53 was formed cleanly, cyclisation and dehydration with titanium 
tetrachloride gave only a 24% yield of 46 and a high number of side products. This 
reaction was also difficult to reproduce, with an average yield of 10% being achieved. As a 
result of the poor yields, other methods to synthesise 46 were investigated. 
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Scheme 16: Alternative route towards compound 46. 
Thienopyrimidinediones have been previously synthesised from the reaction of 52 with α-
halocarbonyl compounds. For example AstraZeneca synthesised 3-methyl-1-(2-
methylpropyl)thieno[2,3-d]pyrimidin-2,4(1H,3H)-dione (54) via deprotonation of 52, 
followed by nucleophilic substitution and intramolecular cyclisation of chloroacetaldehyde. 
This gave the desired product in a 95% yield (Scheme 17).
63
  
 
Scheme 17: Cyclisation using chloroacetaldehyde for the synthesis of 3-methyl-1-(2-
methylpropyl)thieno[2,3-d]pyrimidin-2,4(1H,3H)-dione (54). 
However, application of this method using thioamide 52 and ethyl bromopyruvate gave 
only a 10% yield of 46 (Table 4, entry 2). The next attempted method was based on a 
similar analogue synthesised by Ogura, Sakaguchi and co-workers (Scheme 18).
64
 In this 
method, uracil 55 was treated with bromoacetone to yield alkylated product 56. This was 
isolated, purified and then converted to thienopyrimidine 57 by dehydration with 
polyphosphoric acid (PPA). 
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Scheme 18: Acid mediated cyclisation reaction using bromoacetone. 
When this method was applied to the reaction of 52 with ethyl 3-bromopyruvate, the 
alkylation occurred efficiently. However, the product could not be isolated and purified 
due to significant decomposition. Therefore, 53 was directly converted to 46 via the PPA 
mediated cyclisation. The cyclisation was initially performed at 100 °C and gave a yield of 
35% in 12 hours (entry 3). Further optimisation of this step led to a yield of 54% in 3 
hours when a temperature of 145 °C was used (entry 5). This reaction was found to be 
reproducible and could be used for the multigram synthesis of 46. 
Table 4: Optimisation of the synthesis of thienopyrimidinedione 46. 
 
Entry Step 1 Step 2 Yield of 46 (%) 
1 K2CO3, DMF, rt, 16 h TiCl4, CH2Cl2, 0 °C–rt, 16 h 24% 
2 NaOAc, H2O, rt, 5 h 60 °C, 48 h 10% 
3 EtOH, rt PPA, 100 °C, 12 h 35% 
4 EtOH, rt PPA, 130 °C, 6 h 41% 
5 EtOH, rt PPA, 145 °C, 3 h 54% 
 
2.2.2 Synthesis of potential imaging agents 
2.2.2.1 Synthesis of benzyl amide derivatives 
The first set of target compounds incorporated a benzyl amide at the 5-position of the 
thienopyrimidinedione core. It was proposed that these structures would occupy the same 
binding pockets as the highly active AstraZeneca compounds which contain an aryl ring at 
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the 6-position. These compounds were synthesised by the hydrolysis of compound 46 
followed by an amide coupling to incorporate a benzylamide at the 5-position (Scheme 19). 
Different benzylamines were used with either fluorine or iodine atoms present on the aryl 
ring at various positions. 
 
Scheme 19: Route towards the first library of potential imaging agents where X= F or I. 
Compound 46 was first hydrolysed with sodium hydroxide and this gave carboxylic acid 
58 in a 92% yield (Scheme 20). Using 4-iodobenzylamine, several amide coupling 
methods were attempted in order to acquire the highest yield. The first method used oxalyl 
chloride and DMF to form the acid chloride from carboxylic acid 58, followed by direct 
coupling with 3-iodobenzylamine. However, as this gave a poor yield, it was decided to 
attempt the amide formation via a coupling agent. The best yield was achieved using 
HBTU and diisopropylethylamine, which gave 59 in an 80% yield. The optimised coupling 
was then applied using a range of benzylamines and this gave a small library of targets in 
good yields. 
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Scheme 20: Synthesis of benzylamides 59–62. 
The final step in the synthesis of the halogenated benzylamide derivatives was methylation 
of the amide. This reaction was carried out under standard conditions with methyl iodide 
and sodium hydride, using an optimal temperature of 50 °C (Scheme 21). From this series 
of reactions, four potential imaging agents were prepared with an N-methyl, N-
benzylamide at the 5-position of the thiophene ring. 
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Scheme 21: Final products obtained by a methylation reaction. 
 
2.2.2.2 Synthesis of halogenated phenoxy derivatives 
The next set of target compounds contained an aryl group at the 6-position of the thiophene 
ring via an ether linkage. Several of the analogues synthesised by AstraZeneca also 
contained an ether linkage and many of these compounds bound strongly to MCT 1 or 2.
61
 
It was therefore proposed that this library should yield highly active compounds. This set 
of potential imaging agents also incorporated a Weinreb amide at the 5-position. It was 
previously observed by AstraZeneca that many standard amide derivatives with a 
thienopyrimidinedione core existed as conformational isomers which complicated their 
pharmacology and that having a Weinreb amide in the 5-position circumvented this 
problem by reducing the barriers to rotation around the amide bond.
61
  
In order to install the aryl group, the first step was the halogenation of the 6-position, 
followed by a nucleophilic aromatic substitution reaction using fluorinated or iodinated 
phenols. The halogenation and subsequent substitution was attempted by chlorination and 
bromination to determine which would result in the highest yields over the two steps 
(Scheme 22).
61
 Both the chlorination and bromination of compound 46 were found to give 
an 82% yield using acetic acid with either N-chlorosuccinimide (NCS) or N-
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bromosuccinimide (NBS). When the substitution reaction was performed using 4-
iodophenol, a higher yield was achieved using the chlorinated analogue. Therefore, the 
synthesis of compound 67 was repeated on a large scale and the material was used to 
incorporate fluorinated and iodinated aryl units at the 6-position of the thiophene ring. 
 
Scheme 22: Synthesis of 69 using halogenation and substitution reactions. 
The nucleophilic aromatic substitution reaction worked well for para-substituted analogues 
and the ortho-substituted fluoro analogue (Scheme 23). When 2-iodophenol was used, the 
reaction was much slower due to increased steric hindrance. So, for this reaction, a 
temperature of 120 °C was required to fully react the starting material. Unfortunately, this 
also caused decomposition of the product and gave only a 22% yield for compound 70. 
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Scheme 23: Nucleophilic aromatic substitution products and yields. 
The final two steps in the synthesis of this library were the sodium hydroxide mediated 
hydrolysis of the ester functionality, followed by Weinreb amide formation (Scheme 24). 
The carboxylic acids formed after the hydrolysis step were found to be unstable even at 
low temperatures so it was essential that the product was used immediately in the amide 
coupling step in order to ensure the highest yields possible over the two steps. The amide 
coupling was performed using HBTU as the coupling partner, which gave the four 
halogenated phenoxy targets in good yields.  
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Scheme 24: Hydrolysis and amide coupling steps for products 73–76. 
 
2.2.2.3 Synthesis of phenyl derivatives 
The phenyl library of target compounds were designed with an aryl group at the 6-position 
of the thiophene ring. Due to the increased rigidity, various amide substituents would be 
incorporated at the 5-position with a reduced likelihood of rotamers. So as well as the 
Weinreb amide, it was proposed to incorporate morpholine and diethylamide groups at the 
5-position. In order to directly attach an aryl group to the thiophene ring, bromide 68 was 
used as a precursor for a Suzuki-Miyaura coupling. Conditions for a Suzuki-Miyaura 
cross-coupling had been optimised within the Sutherland group on a different project. The 
catalyst of choice was tetrakis(triphenylphosphine)palladium(0), which in combination 
with potassium phosphate as the base produced quinoline 79 in a 99% yield (Scheme 
25).
65
 
 
Scheme 25: Literature Suzuki-Miyaura coupling reaction. 
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Due to the success of these conditions on a sterically hindered biaryl system, this was the 
initial procedure applied to the Suzuki-Miyaura coupling of brominated pyrimidinedione 
68 with substituted phenylboronic acids. SPECT imaging agents were not prepared in this 
fashion because of the potential self-reaction of iodinated boronic acids. So, as well as 
using fluorinated phenylboronic acids, methoxyphenylboronic acids were also employed as 
mimics for carbon-11 labelled imaging agents. 
The literature method shown in Scheme 25 proved to be successful for this library of 
compounds and gave four coupled products in high yields (Scheme 26). The best yields 
were obtained when the mixture of reagents in DMF were degassed under argon for one 
hour prior to the addition of the palladium catalyst. 
 
Scheme 26: Suzuki-Miyaura cross-coupling products and yields. 
With these compounds synthesised, the next step was to install various amides at the 5-
position. In order to do this, the ester was hydrolysed as a precursor for the amide coupling. 
Using the previous hydrolysis method of sodium hydroxide in methanol and 
tetrahydrofuran at room temperature (Scheme 24) was unsuccessful for this library and 
only starting material was recovered. It was proposed that this was due to increased steric 
hindrance and therefore, more forceful conditions were required. With this in mind, the 
solvent system was changed to a 1:1 mixture of ethanol and water so that the reaction 
could be heated to higher temperatures. When using this system and heating the reaction to 
80 °C for 1 hour, quantitative yields were obtained (Scheme 27).  
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Scheme 27: Hydrolysis reaction to synthesise compounds 84–87. 
After the hydrolysis was complete, amide coupling conditions were explored, using 
morpholine and compound 84 for optimisation. The first attempt mimicked the coupling 
conditions used in the synthesis of the halogenated phenoxy derivatives (Scheme 24) 
however, the yield was only 32% (Table 5, entry 1). EDCI was then used as an alternative 
coupling reagent but this led to even lower yields (entry 2). It was thought that due to the 
enhanced steric hindrance caused by the aryl ring at the 6-position, coupling partners such 
as HBTU or EDCI might be too bulky to mediate a successful reaction. For this reason, 
efforts were turned to acid chloride formation. The first attempt at an amide coupling via 
an acid chloride involved carboxylic acid 84 being stirred at 50 °C in thionyl chloride for 
one hour prior to the addition of the amine. However, this reaction only gave a 21% yield 
after 48 hours and significant decomposition of the starting material was observed (entry 
3). This led to the use of oxalyl chloride, a milder reagent for the formation of acid 
chlorides. This set of conditions led to the best yield of 48% (entry 4). 
 
 
 
 
 
 
 
 
44 
 
Table 5: Attempted amide coupling conditions. 
 
Entry Coupling conditions Solvent Temperature (°C) Yield (%) 
1 HBTU, DIPEA, morpholine  MeCN 40 32 
2 EDCI, DMAP, DIPEA, 
morpholine 
DMF 50 9 
3 i) SOCl2 
ii) Morpholine 
1. Neat 
2. CH2Cl2 
1. 50 
2. 40 
21 
4 i) Oxalyl chloride, DMF 
ii) Morpholine 
CH2Cl2 1. 0–40  
2. 0–40 
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This method was then used to complete the synthesis of the phenyl derivatives, using 
various amines (Scheme 28). For the Weinreb amide series, N,O-dimethylhydroxylamine 
hydrochloride was used as the coupling partner. Therefore, Hünig's base was also used 
during this coupling reaction. To further explore the structure activity relationship of this 
series, a cyclic amine, morpholine and an acyclic amine, diethylamine were also used. The 
reaction worked less well for the diethyl carboxamides. This is likely due to the less rigid 
and less reactive nature of diethylamine. 
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Scheme 28: Synthesis of various phenyl derivatives. *Diisoproylethylamine was also used 
in the amidation step. 
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2.2.3 Synthesis of a known inhibitor of MCT 1  
With the series of target thienopyrimidinediones in hand, the next steps were to evaluate 
the physiochemical properties of each compound and test the most suitable compounds for 
biological activity against MCT 1 and 2. As a control for the various stages of assessment, 
a known high affinity MCT 1 agent was also prepared (Figure 8).
61
 
 
Figure 9: Standard MCT 1 inhibitor chosen as a control during biological testing. 
The core structure of compound 100 was synthesised by the reaction of 
mercaptopyrimidinedione 52 with methyl 3-bromo-2-oxobutanoate (102) (Scheme 29). 
The methyl 3-bromo-2-oxobutanoate (102) was prepared by the an α-halogenation of 
methyl 2-oxobutanoate (101). This reaction was complete in 1 hour, giving a quantitative 
yield of the desired product.
66
 Compound 102 was then used in the S-alkylation of 
compound 52, followed by a subsequent cyclisation and dehydration sequence. It was 
found that for this substrate, an additional dehydrating agent was not required for the 
formation of thienopyrimidinedione 103.  
 
Scheme 29: Bromination of methyl 2-oxobutanoate (101) followed by alkylation and 
cyclisation to give thienopyrimidinedione 103. 
The next step in the synthesis was to incorporate the aryl side chain at the 5-position of the 
thiophene ring. This was achieved by bromination of the methyl group via an AIBN 
initiated radical reaction with NBS. This gave brominated analogue 104 in a 57% yield. 
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Substitution with 4,5-dichloro-2-methylimidazole in the presence of sodium hydride 
incorporated the desired heteroaromatic substituent in a 67% yield (Scheme 30). 
 
Scheme 30: AIBN initiated radical bromination followed by a substitution reaction to give 
compound 105. 
The final step was the formation of a Weinreb amide unit at the 6-position. This was 
carried out by hydrolysis of the ester, followed by an amide coupling using HBTU to give 
the desired product in 38% yield over the two steps (Scheme 31). 
 
Scheme 31: Final steps towards the synthesis of compound 100. 
 
2.2.4 Assessment of physiochemical properties 
Some of the key physiochemical properties of all the synthesised compounds were 
assessed to provide an insight into the potential bioavailability of these scaffolds. The 
properties evaluated were the partition coefficient (LogP), permeability (Pm), membrane 
partition coefficient (Km) and percentage plasma protein binding (%PPB). These values 
were quantified using established HPLC methodology.
67
 
The biological targets for these compounds lie within the central nervous system which 
means that they must be able to penetrate the BBB. LogP acts as a descriptor of lipophilic 
character as it expresses the affinity of the compound for a lipophilic octanol phase relative 
to an aqueous water phase. This is defined according to the equation shown below. 
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LogP = Log (
[Compound]
octanol
[Compound]
water
) 
Some lipophilic character is required in order for a compound to cross the BBB via passive 
diffusion. However, compounds with too high LogP values are more likely to undergo 
rapid metabolic clearance and be involved in off-target binding.
68,69
 It was found that this 
value could be determined using HPLC methodology with a C18 column (see page 136). 
This method offers several advantages over the classic “shake flask” method.70 Since this 
process is automated, it allows for the rapid testing of a large number of compounds and it 
is also highly reproducible. 
Penetration of the BBB is greatly affected by solute-membrane interactions and therefore 
the membrane partition coefficient (Km) must be examined. Km represents all possible 
interactions between a solute and the membrane and is frequently a rate-limiting step in 
drug absorption. This can be measured using immobilised artificial membrane (IAM) 
chromatography where cell membrane phospholipid molecules are covalently bonded to 
silica particles and used to mimic the membrane-lipid environment of cells.
71,72
 Permeation 
of a drug through the membrane by passive diffusion is directly proportional to Km 
according to the equation shown below where MW refers to molecular weight. 
Pm = 
Km
MW
 
The percentage plasma protein binding (%PPB) refers to the degree to which a drug 
molecule will attach itself to proteins in the blood. The two most abundant plasma proteins 
are α1-acid glycoprotein (AGP) and human serum albumin (HSA). This parameter can 
have a large effect on the efficiency of a radiotracer, since only the unbound portion of the 
compound is free to penetrate the BBB. High %PPB also contributes to a higher degree of 
nuclear image noise, originating from a build-up of protein bound compound in the blood 
vasculature. This leads to images of a much poorer quality and accuracy. The %PPB can 
also be determined by HPLC methodology, using a column coated in HSA.
72
 
Previous work by Taveres et al. established the ideal values for these parameters based on 
the HPLC testing of ten molecules which had previously been used as radiotracers. The 
limits of these values are shown below (Table 6).
67
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Table 6: Ideal limits on the physiochemical properties of a potential imaging agent. 
Physiochemical Property Ideal Measurement 
LogP < 4.0 
Pm < 0.5 
Km < 250 
%PPB < 95% 
 
All the compounds prepared in this project were assessed using these methods (Table 7). 
The results which lie out with the desired parameters are shown in red. For the majority of 
these potential imaging agents, excellent physicochemical properties are shown, with all of 
the values falling well within the ideal limits. The LogP values were low, but as expected 
the iodinated compounds showed higher values than observed for the fluorinated 
counterparts. In the case of the C-6 phenyl derivatives, an increase in LogP was observed 
for the diethyl carboxamide analogues. However, the LogP values for these compounds 
were only marginally higher than the desired upper limit which is why some of these were 
chosen for further testing (see compound 95). In the case of several iodinated compounds, 
the %PPB is slightly higher than the ideal limit yet in the case of 63, where every other 
parameter is good, this was still deemed acceptable. Based on this preliminary assessment, 
a number of these compounds were selected for biological testing. 
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Table 7: Physiochemical properties of synthesised compounds 
Structure MW LogP Pm
 
Km
 
%PPB Selected for 
biological 
testing? 
 
 
 
488.38 
 
 
2.68 
 
 
0.07 
 
 
34.17 
 
 
84.9 
 
 
Yes 
 
 
 
511.38 
 
 
3.67 
 
 
0.45 
 
 
228.74 
 
 
96.3 
 
 
Yes 
 
 
 
511.38 
 
 
4.18 
 
 
0.39 
 
 
199.26 
 
 
96.6 
 
 
No 
 
 
 
403.47 
 
 
3.78 
 
 
0.18 
 
 
74.57 
 
 
88.9 
 
 
Yes 
 
 
 
403.47 
 
 
3.28 
 
 
0.17 
 
 
68.17 
 
 
87.8 
 
 
No 
 
 
 
435.47 
 
 
3.84 
 
 
0.21 
 
 
92.93 
 
 
91.1 
 
 
Yes 
 
 
 
543.38 
 
 
4.11 
 
 
0.57 
 
 
310.25 
 
 
98.9 
 
 
No 
 
 
51 
 
 
 
 
543.38 
 
 
4.01 
 
 
0.40 
 
 
216.53 
 
 
95.9 
 
 
No 
 
 
 
445.51 
 
 
3.02 
 
 
0.12 
 
 
248.28 
 
 
87.8 
 
 
Yes 
 
 
 
445.51 
 
 
2.97 
 
 
0.17 
 
 
77.39 
 
 
93.2 
 
 
Yes 
 
 
 
457.55 
 
 
2.94 
 
 
0.18 
 
 
82.00 
 
 
90.5 
 
 
Yes 
 
 
 
457.55 
 
 
2.87 
 
 
0.16 
 
 
75.01 
 
 
92.4 
 
 
Yes 
 
 
 
431.53 
 
 
3.67 
 
 
0.44 
 
 
189.16 
 
 
95.8 
 
 
Yes 
 
 
 
431.53 
 
 
3.63 
 
 
0.42 
 
 
181.54 
 
 
96.4 
 
 
No 
 
 
 
443.56 
 
 
3.69 
 
 
0.25 
 
 
111.51 
 
 
90.5 
 
 
No 
 
 
52 
 
 
 
 
443.56 
 
 
4.22 
 
 
0.33 
 
 
147.24 
 
 
93.4 
 
 
Yes 
 
 
 
419.47 
 
 
3.38 
 
 
0.23 
 
 
96.05 
 
 
87.8 
 
 
Yes 
 
 
 
419.47 
 
 
3.32 
 
 
0.17 
 
 
69.68 
 
 
88.2 
 
 
No 
 
 
 
431.51 
 
 
3.52 
 
 
0.20 
 
 
88.19 
 
 
88.4 
 
 
Yes 
 
 
 
431.51 
 
 
3.53 
 
 
0.18 
 
 
76.75 
 
 
86.3 
 
 
Yes 
 
2.2.5 Biological evaluation 
A selection of compounds then underwent preliminary testing in an activation assay 
performed by Dr Holger Becker at the Institute of Physiological Chemistry, University of 
Veterinary Medicine in Hannover, Germany. In this assay, the compounds were tested as 
lactate uptake inhibitors of monocarboxylates 1, 2, and 4 in Xenopus oocytes (Figure 10). 
Along with the selected compounds and the known inhibitor 100, a blank control 
experiment was carried out with no inhibitor included. Neither of the tested benzyl amide 
derivatives (63 and 65) showed any inhibitory effect against any of the moncarboxylate 
transporters. This suggests that having a substituent at the 6-position of the core structure is 
vital. None of the C-6 phenyl derivatives showed any reduction in lactate uptake against 
MCT 1 however, morpholine carboxamide 89 did exhibit substantial activity against MCT 
2 at a 1 µM concentration. Several other morpholine carboxamides also showed a small 
reduction in lactate uptake in MCT 2 and a considerable amount against MCT 4 (see 88 
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and 91). This indicates that a morpholine amide is more suitable for activity against MCT 2 
and MCT 4 than a Weinreb amide or a diethylamide. The only compound which showed 
any significant decrease in lactate uptake against MCT 1 was 73, which implies that the 
shape of the compound caused by the ether linkage at the 6-position of the thiophene ring 
is important.  
 
 
 
Figure 10: Graphs showing the amount of lactate uptake by MCT 1 (A), MCT 2 (B) and 
MCT 4 (C) at both 1 µM and 10 µM of injected compound. 
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Although most of these compounds are not extremely active, this study has demonstrated 
the structure activity relationship within these scaffolds. The next stage of biological 
evaluation will subject these compounds to a competitive binding assay since the most 
important aspect of a potential imaging agent is strong binding to the biological target. 
 
2.2.6 Second generation compounds 
Based on the results from physiochemical testing and the activation assay, a second series 
of compounds was proposed which would bind more strongly to MCT 1 and 2 (Figure 11). 
With 4-fluorophenoxy derivative, 73 being the most active compound against MCT 1, it 
was proposed that the shape of these compounds caused by the ether linkage, allowed 
access to a binding pocket which was unable to be reached when aryl groups were directly 
attached to the thiophene core. Therefore, the new scaffolds would either contain an ether 
or a methylene linkage to the aryl substituent at the 6-position. 
 
Figure 11: Potential scaffolds for a new series of potential imaging agents. 
Furthermore, these new compounds would be prepared with a (4S)-hydroxyisoxazolidine 
component at the 5-position. In studies conducted by AstraZeneca, this amide was found to 
yield extremely active compounds. (4S)-Hydroxyisoxazolidine was synthesised as the 
hydrochloride salt in two steps from N-hydroxyphthalimide (Scheme 32).
73
 Firstly, N-
hydroxyphthalimide was alkylated with epichlorohydrin, followed by chloride anion 
opening of the oxirane ring. Intermediate 111 then undergoes nucleophilic attack at the 
carbonyl of the phthalimide by methoxide. The next step is an intramolecular N-alkylation, 
giving compound 108 in a 54% yield. Acidic hydrolysis using 4 M hydrochloric acid was 
then carried out to furnish desired compound 109 in a 68% yield.  
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Scheme 32: The two-step synthesis of (4S)-hydroxyisoxazolidine hydrochloride. 
The first new compound contained the 4-fluorophenoxy component, installed via a 
substitution reaction between 67 and 4-fluorophenol (Scheme 33). Compound 71 then 
underwent base mediated hydrolysis, followed by an amide coupling with 109 to give 
compound 112 in a 40% yield over the two steps.  
 
Scheme 33: Route towards compound 112. 
In order to examine the effects of a methylene unit at the 6-position, 4-fluoroindole was 
chosen as a side chain. The presence of a heteroatom could lead to favourable hydrogen 
bonding interactions within the binding site. Compound 104 was employed for the 
alkylation with 4-fluoroindole (Table 8). Several conditions were examined to generate the 
alkylated compound 113. During the synthesis of compound 105, sodium hydride was used 
to facilitate the alkylation (Scheme 30). However, in this case no product was formed 
under these conditions (entry 1). It was thought that this was due to sodium hydride being 
a hard base, therefore other methods were investigated. In a second attempt, 4-fluoroindole 
was treated with n-butyllithium and zinc chloride (used in a transmetallation reaction to 
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furnish a softer nucleophile). Compound 104 was then added along with a catalytic amount 
of sodium iodide (used to improve the leaving group ability of 104). Although a reaction 
was observed in this method, the yield was poor and difficult to reproduce (entry 2). A 
final attempt used sodium hydrogen carbonate as a base for the alkylation (entry 3). This 
gave adduct 113 in a modest 30% yield. 
Table 8: Methods for the synthesis of compound 113. 
 
Entry Reagents Yield (%) 
1 NaH, THF, rt, 24 h,  No Reaction 
2 i) n-BuLi, ZnCl2, THF, 0°C–rt, 3 h 
ii) NaI, toluene, rt, 72 h 
 
15 
3 NaHCO3, CHCl3, H2O, rt, 72 h 30 
 
Compound 113 was then hydrolysed with sodium hydroxide and the resulting carboxylic 
acid was used to install the (4S)-hydroxyisoxazolidine moiety at the 5-position via an 
HBTU mediated coupling. This gave novel compound 114 in a 41% yield (Scheme 34). 
 
Scheme 34: The two-step synthesis of 114 by ester hydrolysis and HBTU mediated amide 
coupling. 
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2.3 Conclusions and future work 
Several series of AR-C155858 41 analogues have been synthesised with aryl groups in 
various positions which have the ability to be radiolabelled. The physiochemical properties 
were assessed, showing that the majority of these compounds will demonstrate good 
bioavailability. A select group of these compounds were tested for the inhibitory effect on 
lactate uptake against MCT 1, 2 and 4. These results led to the synthesis of a further series 
of compounds, which based on the structure-activity relationship observed, should bind 
more strongly to MCT 1 and 2. 
The next stage for these compounds is to undergo a displacement binding assay to assess 
whether or not they have high affinity for MCT 1 and 2. The best candidates will be 
radiolabelled for PET or SPECT imaging. For PET imaging, the most likely method will 
be via a fluorodestannylation reaction, using an electrophilic fluorine source (Scheme 35).
 
 
Scheme 35: An example of electrophilic radiofluorination using a fluorodestannylation 
reaction. 
For SPECT imaging, the iodine-125 unit would most likely be installed via a nickel 
catalysed halogen exchange reaction (Scheme 36).
21
 Once the lead candidates have been 
successfully radiolabelled, the development of these compounds for the imaging of MCT 
in mouse models would then begin. 
 
Scheme 36: An example of a nickel catalysed halogen exchange reaction for 
radioiodination. 
 
 
 
58 
 
3. The synthesis of novel PET imaging agents based on PARP-1 inhibitors 
3.1 Introduction 
3.1.1 PARP-1 and its function in DNA repair 
The poly(ADP-ribose) polymerase (PARP) family consists of 17 different proteins. Within 
this family, PARP 1–4 and tankyrases 1 and 2 have the ability to perform post-translational 
modifications via poly ADP-ribosylation.
74
 PARP-1, which accounts for more than 90% of 
ADP-ribosylation, consists of 3 domains. The DNA binding domain consists of two zinc 
fingers which are used in the binding of PARP-1 to single strand DNA breaks (SSB’s). The 
automodification domain includes glutamate and lysine residues which serve as acceptors 
of ADP-ribose and allow the enzyme to poly ADP-ribosylate itself. Finally, the catalytic 
domain is used to transfer ADP-ribose moieties from nicotinamide adenine dinucleotide 
(NAD
+
) to protein acceptors, forming ADP-ribose polymers.
75
 PARP-1 activity is 
stimulated by various types of DNA damage. Using the two zinc fingers, PARP-1 binds to 
the damaged DNA and ADP-ribosylation occurs, rapidly consuming NAD
+
. Due to the 
large size and charge density of the poly(ADP-ribose) (PAR) formed, the functions of 
modified proteins such as histones and DNA protein kinases are altered. This causes the 
DNA to unwind and for the damaged DNA to become exposed. The presence of PAR 
recruits various DNA repair proteins, which fix DNA via base excision repair (BER). 
Poly(ADP-ribose) glycohydrolase (PARG) is also recruited and is used to break down the 
ADP-ribose polymers so the site is more accessible for the DNA repair enzymes (Figure 
12).  
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Figure 12: The role of PARP-1 in the repair of damaged DNA. Reprinted with permission 
from Journal of Oncology, 2010, Article ID 151750.
76 
3.1.2 PARP-1 inhibitors in cancer treatment 
PARP-1 inhibitors can be used in the treatment of cancer via two different approaches. The 
first is the combination of PARP-1 inhibitors with DNA-damaging chemotherapy. When a 
chemotherapeutic agent is used in the destruction of cancer cells, PARP-1 can be used to 
repair these cells, leading to drug resistance and continued tumour growth. However, 
inhibition of PARP-1 would hinder cancer cell DNA repair and ultimately lead to cell 
death.
77,78
 The second type of therapeutic action is to target cells which are predisposed to 
die when PARP activity is lost. For example, PARP-1 inhibitors are particularly effective 
in tumours which are deficient in breast cancer susceptibility protein 1 (BRCA-1) and 2 
(BRCA-2). BRCA-1 and 2 are used in the repair of double strand DNA breaks through 
homologous recombination (HR). However, in BRCA-1 and 2 deficient tumours, this 
process cannot occur and therefore, cancer cells rely on the presence of PARP enzymes to 
repair DNA by base excision. Therefore, PARP-1 inhibition in these types of tumours lead 
to genomic instability and cell death. This process is referred to as synthetic lethality 
(Figure 13).
79 
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Figure 13: Synthetic lethality caused by PARP inhibition in BRCA-1 and 2 deficient 
tumours. (Reprinted with permission from J. Med. Chem., 2010, 53, 4561. Copyright 2010 
American Chemical Society).
77
 
There have been many PARP-1 inhibitors synthesised for this purpose, one of the most 
successful being olaparib 115 (Figure 14) which has recently been licensed as a drug for 
advanced BRCA deﬁcient ovarian cancer.80 
 
Figure 14: Olaparib- A potent PARP-1 inhibitor used in the treatment of BRCA deficient 
ovarian cancer. 
 
3.1.3 Imaging agents targeting PARP-1 
The non-invasive imaging of PARP-1 using a radiolabelled PARP inhibitor could have 
many clinical advantages. It could guide dosing decisions by assessing the extent of uptake 
and retention of the PARP-inhibitor in different tissues, and therefore the duration of the 
inhibition effect. This approach could be particularly important in cases where PARP 
inhibitors are used in combination with DNA damaging chemotherapy drugs since bone 
marrow toxicity has previously been observed as a result of these combinations.
81,82
 
Imaging of PARP-1 can also be used to diagnose and monitor various tumours. For 
example, glioblastomas (GBM) are known to overexpress PARP-1, therefore, this type of 
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cancer could be monitored via PET imaging assuming the tracers were able to penetrate the 
BBB. 
83
 
One of the first PARP-1 imaging agents was the phenathridinone PJ34 117 which was used 
initially to assess the PARP-1 activity in tissues undergoing necrosis.
84
 It was able to bind 
to PARP-1 with high affinity and was found to accumulate in tissues where PARP-1 is 
hyperactivated. The radiolabelling was carried out by a methylation using carbon-11 
labelled methyl iodide and sodium hydroxide, giving the desired product in a good 
radioactivity yield and high specific activity (Scheme 37). 
 
Scheme 37: Synthesis of [
11
C]PJ34 117 via radioactive methylation using carbon-11 
labelled methyl iodide.  
One of the most successful recent PARP-1 imaging agents is [
18
F]FluorThanatrace 119 
developed by Zou et al. 
84
 This tracer has been found to bind to PARP-1 with high affinity 
and also has proven to be metabolically stable. PET studies also showed an increased 
uptake of 119 in tumour cells. Pre-treatment with olaparib 115 was found to block the 
uptake of 119, proving that this binds to PARP-1 with high specificity in vivo. The 
radiolabelling of 118 was carried out via a substitution of the mesylate group using 
[
18
F]potassium fluoride to give 119 in a high radioactivity yield (Scheme 38). 
 
Scheme 38: Radiosynthesis of [
18
F]FluorThanatrace 119. 
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3.1.4 Previous work and proposed research 
Within the Sutherland group various analogues of olaparib 115 have been previously 
synthesised. Three lead compounds for the PET and SPECT imaging of PARP-1 were 
identified (Figure 15). 
 
Figure 15: Initial lead PARP-1 inhibitors to be used as PET or SPECT imaging agents. 
Compound [
123
I]120 was synthesised from corresponding bromide 123 using a solid state 
halogen exchange reaction to give the desired product in  high radioactivity yield (Scheme 
39).
85
 This compound was found to be a potent inhibitor of PARP-1 in two human 
glioblastoma cell lines and was also highly stable in mouse plasma. It was further 
evaluated via ex vivo biodistribution studies where tumour tissue retention and specific 
binding to PARP-1 was observed. However, the intrinsic clearance was significantly 
greater than for olaparib 115, suggesting a more rapid in vivo metabolism.  
 
Scheme 39: Solid state halogen exchange reaction used to synthesis [
123
I]120. 
The radiosynthesis of [
18
F]121 was examined to generate a potential PET imaging agent. 
However, under various conditions the radiochemical yields were very poor. Therefore, 
compound 122 was synthesised as an alternative PET tracer since the formation of an 
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alkyl-fluorine bond would be less challenging than aryl C-F bond formation. [
18
F]122 was 
synthesised by nucleophilic substitution of the chlorine analogue 124 (Scheme 40).
86
 The 
phthalazinone-NH had to first be protected with a Boc group, as it was found that self 
oligomerisation occurred through nucleophilic substitution between the phthalazinone core 
and the chlorine bearing carbon. After fluorination and subsequent Boc deprotection, a 
radiochemical yield of 49% was achieved. Unfortunately, this compound underwent partial 
in vivo metabolic defluorination in mouse studies, causing free radiofluoride to bind to the 
bone. This limits the use of [
18
F]122 as a PET imaging agent due to the potential signal 
noise radiating from the skull as a consequence of [
18
F]fluoride uptake. 
 
Scheme 40: Radiofluorination via nucleophilic substitution of 124 and successive Boc 
deprotection. 
In 2015, Reiner and co-workers synthesised [
18
F]121 and were able to show that this 
compound can be used to non-invasively image PARP-1 expression of gliomas in mouse 
models via PET imaging.
87
 This compound also does not appear to undergo the metabolic 
defluorination associated with [
18
F]122. However, the radiosynthesis of [
18
F]121 requires 
early incorporation of radiofluorine into a benzoic ester derivative, which then must be 
hydrolysed and coupled with a phthalazine-1-one (Scheme 41). Due to the early 
incorporation of the radiolabel and the relatively short half-life of fluorine-18, a 
radiochemical yield of only 10% was achieved.  
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Scheme 41: Route towards [
18
F]121 developed by Reiner and co-workers. 
Clearly having the fluorine-18 moiety installed onto an aromatic system could lead to a 
more promising PET imaging agent for PARP-1 than one with an alkyl-fluorine moiety 
present. However, installing the radiolabel should ideally be the last step for an efficient 
and high yielding synthesis. So based on these observations, this research project focused 
on the synthesis of novel PET imaging agents for PARP-1 with benzamide units activated 
towards facile radiofluorination.  
In 2016, Gouverner and co-workers published a review which quantified the features  
required on an aromatic ring to facilitate nucleophilic aromatic substitution reactions with 
radiofluorine.
13
 It is well known that having electron-withdrawing groups present can 
activate a ring towards SNAr reactions. It was found that in particular, having a nitro group 
present at either the ortho- or para- position to the leaving group resulted in the most 
successful reactions. Scheme 42 shows an example of a para-nitro group being used to 
facilitate the radiolabelling of [
18
F]PK14105 128, which is used in PET studies of 
peripheral type benzodiazepine binding site receptors.
88
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Scheme 42: The radiosynthesis of [
18
F]PK14105 128. 
The π-deficient ring of pyridine containing compounds can also promote easy 
radiofluorination. Scheme 43 shows radiofluorination via an SNAr reaction on a pyridine 
ring to give a [6-pyridinyl-
18
F]-labelled derivative of WAY-100635 130, a potential PET 
imaging agent for brain 5-HT1A receptors.
88
 
 
Scheme 43: Radiofluorination facilitated by the presence of a π-deficient pyridine ring. 
Therefore, it was proposed that the new potential imaging agents synthesised would either 
contain appropriately placed electron withdrawing groups on the aromatic ring to be 
labelled or a π-deficient pyridine ring with a potential labelling site (Figure 16).  
 
Figure 16: Proposed novel PET imaging agents (X= Fluorine-18). 
The new compounds were synthesised as the “cold” fluorine-19 analogues to act as a 
mimic for the radioactive counterparts during physiochemical and biological testing. 
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Analogues which contain appropriate leaving groups were also prepared in order to explore 
potential radiofluorination methods. 
 
3.2 Results and discussion 
3.2.1 Synthesis of the olaparib core structure 
The first project aim was to synthesis the olaparib core structure 131 (Figure 17).  It has 
previously been demonstrated that provided this core structure is present, groups of various 
size and electronic properties can be installed at the 4-position of the piperazine ring 
without significantly affecting the affinity of the compounds for the PARP-1 binding site, 
or their inhibition activities against the enzyme.
89
  
 
Figure 17: Olaparib core structure. 
Several key interactions have been identified between PARP inhibitors and the PARP-1 
binding site (Figure 18). It was found that non-polar π-π stacking occurs between the 
aromatic region of the phthalazinone core and tyrosine-907. The amide portion of the 
phthalazinone is able to hydrogen bond to a serine residue and also to a glycine residue via 
a bidentate interaction.  Finally, the meta-benzyl positioned carbonyl acts as a hydrogen 
bond acceptor and is able to interact with methionine-890.
90,91 
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Figure 18: An image showing olaparib 115 and the key interactions with the PARP-1 
binding site. 
The synthesis of this core structure was initially reported by Menear et al. and further 
optimised by Adele Blair, a previous member of the Sutherland group.
92
 The first step of 
this sequence is the phosphorylation of carboxybenzaldehyde 132. This was achieved by 
coupling with dimethylphosphite (133) in the presence of sodium methoxide to give 
phosphonate ester 134 in an 87% yield (Scheme 44). 
 
 
Scheme 44: Phosphorylation of carboxybenzaldehyde 132. 
The next stage involves a Horner-Wadsworth-Emmons (HWE) reaction with 2-fluoro-5-
formylbenzonitrile (135) and phosphonate ester 134, which gave 136 in a quantitative yield 
(Scheme 45). Due to the E-selective nature of the HWE reaction, a 75:25 mixture of the E 
and Z isomers was obtained (as observed by 
1
H NMR spectroscopy). These isomers were 
not separated because both react in the next step.  
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Scheme 45: Horner-Wadsworth-Emmons reaction to generate alkene 136. 
The phthalazinone moiety was prepared via a one-pot, two-step reaction which occurred in 
a quantitative yield over the two steps. The first step involved hydrolysis with 13 M 
sodium hydroxide, followed by reaction with hydrazine monohydrate to give 
phthalazinone 137 (Scheme 46). 
 
Scheme 46: Synthesis of phthalazinone 137 by a one-pot, two-step reaction. 
The piperazine ring was installed by coupling carboxylic acid 137 with a Boc-protected 
piperazine unit. This was achieved using HBTU as the coupling reagent and gave amide 
138 in a 72% yield. The final step was Boc-deprotection of the piperazine unit which gave 
the olaparib core 131 in a 68% yield (Scheme 47).  
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Scheme 47: Synthesis of the olaparib core structure via an amide coupling and hydrolysis. 
 
3.2.2 Synthesis of potential PARP-1 imaging agents 
With the olaparib core synthesised, the next stage was to install an electron-deficient 
benzamide group onto the 4-position of the piperazine ring. This was achieved by an amide 
coupling using various carboxylic acids and HBTU as the coupling agent (Scheme 48). 
Compounds 139–143 contain a nitro group in either the ortho- or para- position (with 
respect to the labelling site) as this aromatic system has previously been shown to aid 
nucleophilic aromatic substitution-type fluorination. Compounds 144–147 contain a 
pyridine ring with the labelling site ortho- to the nitrogen. These compound are also 
promising in terms of facile fluorination due to the π-deficient ring system. Each type of 
compound was prepared with a fluorine in the labelling site, mimicking the radioactive 
counterpart. Each scaffold was also synthesised with either a bromine or a chlorine in the 
labelling position to be used as a leaving group when examining radiofluorination methods. 
All of these novel olaparib analogues were synthesised in moderate to good yields. 
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Scheme 48: Synthesis of novel PARP-1inhibitors by an HBTU mediated amide coupling. 
 
3.2.3 Physiochemical testing and biological evaluation of potential PARP-1 imaging 
agents 
To determine whether these compounds would be appropriate imaging agents, their 
physiochemical properties were determined by HPLC methodology (see Section 2.2.4).
67
  
Based on all of the properties examined, all four scaffolds have significant potential as 
PARP-1 imaging agents (Table 9). The LogP and %PPB values are higher than reported 
for olaparib itself, however the given values still lie well below the upper limits for a 
suitable imaging agent (Section 2.2.4, Table 6). The membrane partition coefficient and 
permeability exhibited by these compounds is also extremely promising. Maria Clara 
Liuzzi of the Sutherland group recently tested these scaffolds for the ability to bind to and 
inhibit PARP-1. This was done via a PARP cellular immunofluorescence assay, performed 
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in G7 stem cell lines. The IC50 value for olaparib 115 was also obtained using this method 
to act as a standard. The inhibitory properties of compound 143 could not be assessed 
because the compound itself showed some fluorescent properties which interfered with the 
immunofluorescence assay. The tested compounds were all shown to be effective PARP-1 
inhibitors, with compounds 141 and 147 being even more potent than olaparib 115.  
Table 9: Physiochemical properties and IC50 values of potential PARP-1 imaging agents. 
Structure MW LogP Pm Km %PPB IC50 
 
 
 
 
434.47 
 
 
 
1.95 
 
 
 
N/A 
 
 
 
N/A 
 
 
 
75.9 
 
 
 
1.17 
 
 
 
 
533.49 
 
 
 
2.66 
 
 
 
0.07 
 
 
 
33.51 
 
 
 
89.7 
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2.69 
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489.48 
 
 
 
2.18 
 
 
 
0.03 
 
 
 
13.92 
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1.23 
 
 
 
 
489.48 
 
 
 
2.16 
 
 
 
0.03 
 
 
 
13.62 
 
 
 
83.6 
 
 
 
0.38 
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3.2.4 Synthesis of a novel olaparib based scaffold 
As mentioned in section 3.2.1, it has been extensively demonstrated that capping groups of 
various size and shape can be installed onto the 4-position of the piperazine ring, without 
affecting compound potency, assuming the phthalazinone core is present. In 2010, Reiner 
et al. demonstrated that even very large functional groups, with long hydrocarbon chains 
could be installed without a detrimental effect on PARP-1 binding affinity or its inhibition 
(e.g. Figure 19).
93
 This can be rationalised by the presence of a large hydrophobic pocket 
in the PARP-1 binding site.  
 
Figure 19: PARP-1 inhibitor with large capping group at the 4-NH-piperazine moiety. 
Based on the success of these structures, it was proposed that potential novel imaging 
agents could be synthesised using a similar scaffold. It was suggested that a reaction 
between the piperazine moiety of phthalazinone 131 and succinic anhydride could occur to 
acetylate the amine and incorporate a pendent carboxylic acid group. Several fluorinated 
anilines would then be used in an amide coupling reaction to generate new potential 
imaging agents and further explore the structure activity relationship within the PARP-1 
binding site (Scheme 49). 
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Scheme 49: Proposed route to alternative imaging agents with a succinic acid linker. 
The acetylation was initially attempted by heating under reflux in dichloromethane (Table 
10, entry 1). However, when no conversion was observed it was thought that a base may 
be required to initiate the reaction. Triethylamine was used in a second attempt (entry 2). 
Unfortunately, after 48 hours only starting material was present. The next attempt 
investigated the use of 4-dimethylaminopyridine as a catalyst (entry 3). This reaction was 
very slow and after 72 hours only a 20% conversion was achieved. Addition of a base did 
not seem to increase the rate of the reaction (entry 4). Therefore, the solvent was changed 
to DMF so that higher temperatures could be used (entry 5). This led to complete 
decomposition. Therefore, acetonitrile and a temperature of 80 °C was chosen as an 
alternative (entry 6). Under these optimised conditions, the desired carboxylic acid 
product was synthesised in an 82% yield.  
 
 
 
 
 
 
 
 
74 
 
Table 10: Optimisation of the acetylation reaction between olaparib core 131 and succinic 
anhydride. 
 
Entry Solvent Temperature (°C) Additive Time (h) Result 
1 CH2Cl2 40 None 48 No reaction 
2 CH2Cl2 40 Et3N 48 No reaction 
3 CH2Cl2 40 DMAP 72 20% conversion 
4 CH2Cl2 40 Et3N, DMAP 48 No reaction 
5 DMF 120 Et3N, DMAP 12 Decomposition 
6 MeCN 80 DMAP 24 82% yield 
 
With the successful synthesis of the hydrocarbon linker, the next step will be to incorporate 
various aromatic amines with the potential for radiofluorination. These compounds will 
then be tested to ascertain whether they have the appropriate physiochemical properties 
and whether they are capable of specifically binding to the PARP-1 enzyme.  
 
3.3 Conclusions and future work 
A small library of novel potential imaging agents for PARP-1 have been synthesised. 
These compounds all exhibit excellent physiochemical properties and due to the electron 
deficient ring systems, have great potential for facile radiofluorination. These compounds 
were also tested via a PARP cellular immunofluorescence assay to determine whether they 
bind to PARP-1. Compounds 141 and 147 were found to be potent inhibitors of PARP-1 in 
G7 stem cell lines. The next stage is to find a suitable method for the radiofluorination of 
these compounds. To do this, a “cold” fluorination reaction will first be optimised using 
the brominated or chlorinated analogues. This method will then be adapted for the 
radiochemical version. A likely successful method would be a nucleophilic aromatic 
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substitution reaction using labelled potassium fluoride and K222, used to complex the 
potassium and increase the nucleophilicity of the fluorine anion (Scheme 50). 
 
Scheme 50: Radioflurorination of compound 139 via nucleophilic aromatic substitution. 
A new scaffold based on Reiner’s work has also been synthesised to further explore the 
structure activity relationships within the PARP-1 binding site. The carboxylic acid moiety 
of compound 149 will next undergo amide couplings with several fluorinated anilines 
(Scheme 51). 
 
Scheme 51: Example of a potential PARP PET imaging agent formed by an amide 
coupling with carboxylic acid 149. 
These new compounds will also be tested for binding affinity to PARP-1 and for 
appropriate physiochemical properties. One of the ways to potentially radiolabel this class 
of compound is via a copper catalysed fluoro-deboronation using conditions developed by 
Gouverneur et al.
94
 The Gouverneur group has shown this reaction to be successful for a 
wide range of substrates, many of which would not be amenable to nucleophilic aromatic 
substitution. This method would first require the synthesis of a boronate ester derivative 
via an amide coupling with carboxylic acid 149 (Scheme 52).  
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Scheme 52: Potential radiofluorination using a copper catalysed fluoro-deboronation 
procedure. 
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4. Gold catalysed radioiododeboronation 
4.1 Introduction 
4.1.1 Modern radioiodination methods 
Due to the increasing need for novel SPECT imaging agents, many efforts have focused on 
the development of the efficient radioiodination of aromatic rings. A common method is  
iododestannylation, discussed in section 1.3.1 (Scheme 53).
20
 Although this method tends 
to be high yielding, the organotin species is unstable and highly toxic, so there are many 
safety concerns as well as restrictions in distribution and storage. 
 
Scheme 53: Raioiodination using a destannylation reaction.
20
 
Another method developed within the Sutherland group involves a nickel-catalysed 
halogen exchange reaction, discussed in section 1.3.1 (Scheme 54).
21
 This method was 
successful for the radioiodination of aromatic rings containing both electron-donating and 
electron-withdrawing substituents and could also be used to generate SPECT imaging 
agents. A disadvantage of this method is the high temperature of 180 °C, which could 
make it unsuitable for the synthesis of less stable substrates. 
 
Scheme 54: Nickel-catalysed radioiodination via a halogen exchange.
21
 
Another common method for iodination is via the ipso-substitution of aryl boronic acids 
using N-iodosuccinimide (NIS). The reaction was initially developed by Olah and co-
workers and high yields were obtained for electron-rich substrates (Scheme 55).
95
 
However, poor yields were observed for aryl boronic acids containing electron-
withdrawing groups, even when long reaction times were employed. Therefore, this 
method has not been widely adopted in radiosynthesis. 
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Scheme 55: Iodination via an ipso-substitution of aryl boronic acids.
95
 
Many variations of this work have been developed with the aim of improving the substrate 
scope and finding an effective method for the synthesis of SPECT imaging agents. Most 
recently, there have been various examples of copper-catalysed iododeboronations. For 
example, in 2016 the groups of Gouverneur and Zhang described a method for the copper-
catalysed radioiodination of aryl boronic acids and esters (Scheme 56).
96
 The reaction 
could be performed at room temperature, using a copper catalyst and 1,10-phenanthroline 
as the ligand. This method is tolerant of electron-rich and electron-poor substrates and can 
be used to generate SPECT imaging agents in high radiochemical yields. Despite the 
improved substrate scope, this method does have its limitations. There is still a need to 
develop a faster radioiodination procedure for arenes, which utilises green solvents and is 
operationally simple. 
 
Scheme 56: Copper-catalysed radioiododeboronation or boronic acids and esters.
96
 
 
4.1.2 Previous work and proposed research 
In 2015, the Lee group developed a gold-catalysed protodeboronation procedure (Scheme 
57).
97
 This reaction was found to proceed via transmetallation of the gold(I) catalyst with 
an aryl boronic acid to give an organogold intermediate.
98
 The reaction was tolerant of a 
wide range of functional groups and was able to be extended to deuterodeboronations.  
 
Scheme 57: Gold catalysed protodeboronation and deutereodeboronation.
97
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Based on the success of this procedure, a method for radioiodination was developed using 
the same gold(I) phosphine catalyst (Gagosz’s catalyst) and the environmentally friendly 
solvent dimethyl carbonate.
99,100
 It was proposed that if the organogold intermediate was to 
react with NIS, it could provide easy access to the corresponding aryl iodide (Scheme 
58).
101
  
 
Scheme 58: Proposed synthesis of aryl iodides by a gold-catalysed iododeboronation. 
This reaction was found to be successful for a wide range of substrates, including electron-
deficient ring systems. The iododeboronation can be performed in the presence of air and 
water, simplifying the practicalities of the reaction procedure. Moreover, for the majority 
of substrates, these iodinations occurred within 5 minutes when heated to 90 °C.
101
  
Due to the reaction being practically simple and very fast, it was proposed that the 
synthesis of SPECT imaging agents via this method would be very effective. Therefore, 
this project focused on the further development of this reaction for radioiodinations. 
Initially, the aim of the project was to optimise the transformation and explore the scope of 
the reaction for the rapid and efficient radioiodination of aryl boronic acids. The second 
aim was to apply this optimised method for the production of SPECT imaging agents. 
 
4.2 Results and discussion 
4.2.1 The development of a gold-catalysed radioiododeboronation procedure and the 
synthesis of radiolabelled aryl iodides 
To adapt this procedure for radioiodination, NIS had to be formed in situ from NCS and a 
source of radioactive iodide, [
125
I]NaI. Therefore, the first step was to compare the 
iododeboronation procedure developed by the Lee group with an iodination using in situ 
formation of NIS (Scheme 59). When using 4-methoxybenzeneboronic acid (153) and NIS, 
the reaction was complete within 5 minutes giving an 88% yield of iodinated product 21. 
To form NIS in situ, sodium iodide and NCS were stirred together at room temperature for 
10 minutes before the addition of boronic acid 153 and the gold(I) phosphine catalyst. 
Under these conditions, 4-iodoanisole (21) was synthesised in a 74% yield, with a total 
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reaction time of 15 minutes. Both reactions gave comparable yields and the products could 
be easily purified using silica gel chromatography.  
 
Scheme 59: Iododeboronation directly and via the in situ formation of NIS. 
Since the “cold” iododeboronation reaction was comparable with the literature procedure, 
the next step was to attempt this using [
125
I]NaI (4–6 MBq solution in water) as the 
limiting reagent. Using 50 mol% of the catalyst and the standard reaction time of 5 minutes, 
a 63% radiochemical yield of [
125
I]21 was achieved (Table 11, entry 1). Extending the 
reaction time to 20 minutes was found to be optimal (entry 3) and gave a quantitative 
radiochemical yield. To understand the role of the gold catalyst, a control reaction with no 
catalyst present was carried out (entry 4). It was observed that the rate of reaction was 
significantly reduced without gold catalysis and only a 47% radiochemical yield was 
achieved in 20 minutes. Therefore, the catalyst is vital in ensuring a high yield within the 
desired reaction time. Under the optimised conditions, the radiochemical reaction occurred 
cleanly, with no other radioactive by-products observed by radio-HPLC (Figure 20). 
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Table 11: Optimisation of the radioiododeboronation procedure using 4-
methoxybenzeneboronic acid (153). 
 
Entry Time (mins) Ph3PAuNTf2 (mol%) RCY (%) 
1 5 50 63 
2 15 50 96 
3 20 50 100 
4 20 0 47 
 
 
Figure 20: Chromatogram obtained by analytical radio-HPLC (blue) of the reaction 
mixture from the radioiodination of boronic acid 153. An overlay of the UV/Vis HPLC 
trace (black) of unlabelled product 21 is also shown. 
The scope of the gold mediated radioiodination was then examined using a variety of aryl 
boronic acids (Scheme 60).
101
 Under these conditions, electron-rich and electron-deficient 
boronic acids with a variety of substitution patterns were found to be suitable for the 
iodination procedure, giving the iodine-125 labelled products in excellent radiochemical 
yields. Initially the reactions of the trifluoromethyl 158 and the ethyl ester 159 analogues 
under the optimised conditions, gave several radiolabelled by-products. By reducing the 
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temperature to 80 °C and using a longer reaction time of 30 minutes, a much cleaner 
transformation occurred and high radiochemical yields of the desired labelled products 
were achieved. Due to significant steric hindrance, 2,4,6-triisopropylphenylboronic acid 
showed no reaction under these conditions. Even after 30 minutes at 90 °C, only unreacted 
iodide was observed by radio-HPLC.  
 
Scheme 60: Substrate scope of the gold(I)-catalysed radioiododeboronation procedure 
showing radiochemical yields. 
4.2.2 Synthesis of SPECT imaging agents 
Having developed an effective radiosynthesis of simple aromatic iodides, the next step was 
to investigate the use of gold-catalysed radioiododeboronation to prepare [
125
I]-labelled 
SPECT imaging agents. The first target was phthalazinone 120, a SPECT imaging agent 
for PARP-1. In order to investigate the iododeboronation process, the boronic acid 
precursor 162 was synthesised (Scheme 61). This was achieved by an HBTU mediated 
amide coupling of phthalazinone 131 (synthesis shown in section 3.2.1) with 4-
carboxyphenylboronic acid (161). Boronic acid 162 was then subject to the 
radioiododeboronation procedure. However, under the standard conditions of 90 °C for 20 
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minutes, the reaction was very slow and a large amount of unreacted iodide remained. 
When the temperature was increased to 100 °C and the reaction time increased to 40 
minutes, all of the iodide was consumed and a radiochemical yield of 41% was achieved.  
Due to the complex structure of this substrate, several radioactive side products were also 
observed by radio-HPLC. 
 
Scheme 61: Synthesis of PARP-1 SPECT imaging agent [
125
I]120 using the gold(I)-
catalysed radioiodination procedure.  
It was proposed that a cleaner reaction may occur if the radioiodination took place via the 
boronic acid pinacol ester precursor 164. This was synthesised in the same way as the 
boronic acid, giving the olaparib-derived pinacol ester in a 50% yield (Scheme 62). 
Unfortunately, the gold-catalysed radioiodination reaction to furnish the desired SPECT 
imaging agent [
125
I]120 was not improved. Due to the less reactive nature of the pinacol 
ester, the highest radiochemical yield was 14% after heating at 80 °C for 2 hours. 
 
 
84 
 
 
Scheme 62: Synthesis of SPECT imaging agent [
125
I]120 via radioiododeboronation of the 
boronic acid pinacol ester precursor 164. 
The next imaging agent synthesised was [
125
I]MIBG 169 (Scheme 63). As the iodine-123 
form, MIBG is a commercially available radiopharmaceutical that is used for the SPECT 
imaging of human norepinephrine transporter-expressing cancers.
102
 The boronic acid 
precursor 167 was synthesised by the coupling of 3-(aminomethyl)benzeneboronic acid 
(165) with Boc-protected carboxamidine 166 to give the desired product in a 75% yield. 
The gold catalysed radioiodination was found to be most effective at a temperature of 
80 °C, giving Boc-protected [
125
I]MIBG 168 in a quantitative radiochemical yield after 30 
minutes. The reaction mixture was then treated with hydrochloric acid and heated to 90 °C 
to remove the protecting groups giving [
125
I]MIBG 169 in a 91% radiochemical yield over 
the two steps. Due to the success of this reaction, [
125
I]MIBG 169 was then resynthesised 
via this method and purified by HPLC. The radioiodinated product was isolated in a 28% 
radioactivity yield with a radiochemical purity >98% and a molar activity >2.73 GBq 
µmol
˗1
 Identification of the product was confirmed using analytical HPLC by co-elution 
with a sample of unlabelled MIBG (Figure 21).  
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Scheme 63: Radiosynthesis of [
125
I]MIBG 169 using the gold(I)-catalysed 
iododeboronation process.  
 
Figure 21: Chromatogram obtained by analytical radio-HPLC (blue) of the reaction 
mixture from the radioiodination of boronic acid 167. An overlay of the UV/Vis HPLC 
trace (black) of unlabelled product 169 is also shown. 
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4.3 Conclusions and future work 
A novel gold(I)-catalysed ipso-radioiododeboronation procedure has been developed. This 
method was found to be fast, air and water stable and uses an environmentally friendly 
solvent. A small library of substrates with a variety of electronic and steric properties as 
well as two SPECT imaging agents were radioiodinated in excellent radiochemical yields. 
The general method was then further validated by the efficient synthesis and isolation of 
[
125
I]MIBG 169 in a radioactivity yield which compares favourably with previous 
approaches. This demonstrates the potential of this methodology for widespread use in 
generating radioiodine-labelled imaging agents. The next step is to investigate the 
extension of this methodology for the preparation of existing and novel SPECT imaging 
agents. 
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5. Base catalysed radioiododeboronation for the development of SPECT tracers 
5.1 Introduction 
5.1.1 Transition metal-free halodeboronations 
With the majority of efficient iododeboronation reactions relying on transition metal 
catalysis, the development of a metal free radioiodination is highly desirable. As well as 
this being more cost effective, eliminating the use of a metal catalyst can significantly 
simplify the purification procedures for the synthesis of SPECT imaging agents. There are 
already examples in the literature of halodeboronations occurring in high yields without the 
use of a metal catalyst. For example, in 2011, Molander and co-workers developed a 
metal-free chlorodeboronation of organotrifluoroborates using trichloroisocyanuric acid 
(TCICA) as the chlorinating agent.
103
 Using aryl potassium trifluoroborate 170, the 
chlorination occurred in an 87% yield in 2 hours. It was proposed that this reaction 
proceeded via an ipso-substitution pathway (Scheme 64). 
 
 
 
Scheme 64: Example of a chlorodeboronation reaction using TCICA as the chlorinating 
agent and a proposed ipso-substitution mechanism.
103
 
In 2014, Fu and co-workers developed a base promoted iodination of aryl boronic acids 
using iodine and potassium carbonate (Scheme 65).
104
 The reaction gave high yields for a 
wide variety of substrates using a temperature of 80 °C (example shows boronic acid 172 
undergoing an iododeboronation in a 93% yield). However, to obtain high yields, it was 
necessary to perform these reactions under a nitrogen atmosphere.  
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Scheme 65: Metal-free iododeboronation promoted by the use of potassium carbonate.
104
 
Although it has been shown that aryl boronic acid derivatives can be iodinated without the 
use of metal catalysis, there have not been many attempts to extend this methodology to 
include radioiodinations. Therefore, the development of a cost and time effective 
radioiododeboronation method without the use of a metal catalyst is highly desirable.  
5.1.2 Previous work and proposed research 
Recently, the Watson group developed a novel base-catalysed iododeboronation procedure 
using potassium acetate and NIS. A range of aryl iodides with different electronic 
properties were synthesised in moderate to high yields using only 20 mol% of potassium 
acetate and a temperature of 50 °C (Scheme 66). It was found that this reaction occurred 
by an ipso-substitution pathway via a boronate intermediate. 
 
 
 
Scheme 66: Potassium acetate mediated iododeboronation and proposed ipso-substitution 
mechanism via a boronate intermediate. 
This method is operationally simple and can be performed in the presence of air and water. 
For these reasons, along with the low cost of the potassium acetate catalyst, it is an 
attractive option for radioiodination and the metal-free synthesis of SPECT imaging agents. 
Therefore, the aim of this research was to develop a radioiododeboronation method using 
NIS and a potassium acetate catalyst. Firstly, a small library of simple radioiodinated aryl 
compounds were synthesised, followed by the production of SPECT imaging agents. 
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5.2 Results and discussion 
5.2.1 Development of a radioiododeboronation procedure 
To ascertain whether this method was suitable for radiosynthesis, a “cold” reaction was 
performed using 4-methoxybenzeneboronic acid (153). The NIS was formed in situ and 
after heating to 50 °C for 2 hours a yield of 65% was achieved (Scheme 67). 
 
Scheme 67: Potassium acetate catalysed iododeboronation of 4-methoxybenzeneboronic 
acid (153). 
The iododeborontion was then performed using [
125
I]NaI (4–6 MBq solution in water) as 
the limiting reagent. Under the standard conditions of 20 mol% potassium acetate loading 
and heating to 50 °C, the radiochemical yield was only 30% after 3 hours (Table 12, entry 
1). Increasing the amount of potassium acetate to 30 mol% improved the yield to 45% 
(entry 2). Using 50 mol% did not improve the product yield as it was found that increasing 
the amount of potassium acetate led to the formation of more radioactive impurities (entry 
3).  The next attempt was to increase the temperature of the reaction and lower the amount 
of potassium acetate. It was thought that this would increase the rate of the reaction as well 
as minimising radioactive impurities. When a temperature of 70 °C was used along with 10 
mol% of potassium acetate, the radiochemical yield was increased to 74% (entry 4). This 
was a clean reaction and no radioactive impurities were observed by radio-HPLC, however, 
a large amount of unreacted iodide was present. To improve the conversion, the amount of 
potassium acetate was then increased to 20 mol% and under these conditions a product 
yield of 98% was achieved in 3 hours (entry 5). As time is an important factor in 
radiosynthesis, the temperature was then increased further to achieve shorter reaction times 
(entries 6–8). It was found that the optimal reaction conditions were a temperature of 
100 °C and 20 mol% of potassium acetate (entry 8). Using the optimised conditions a 
radiochemical yield of 93% was obtained after 1.5 hours. 
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Table 12: Optimisation of the base catalysed radioiododeboronation procedure. 
 
Entry Temperature (°C) KOAc (mol%) Time (h) RCY (%) 
1 50 20 3 30 
2 50 30 3 45 
3 50 50 3 45 
4 70 10 3 74 
5 70 20 3 98 
6 80 20 2 73 
7 90 20 2 93 
8 100 20 1.5 93 
 
5.2.2 Radiosynthesis of labelled aryl iodides 
Under the optimised conditions a range of aryl boronic acids were radioiodinated (Scheme 
68).  The substrate scope includes electronically diverse aryl rings with substituents in 
various substitution patterns. In some cases, the reaction time was increased to 3 hours in 
order to achieve a high radiochemical yield. In the iodination of 2-bromobenzeneboronic 
acid, the yield after 3 hours was only 61%, likely due to the increased steric hindrance 
arising from the ortho-substituent. The lower radiochemical yield observed for the 
iodination of 3-trifluoromethylbenzeneboronic acid can be attributed to the fact that many 
radioactive impurities were observed by radio-HPLC. When this reaction was attempted at 
a lower temperature, the yield was not improved since the rate of reaction was significantly 
decreased. In the synthesis of the 3-nitro derivative [
125
I]155 and the 3-bromo derivative 
[
125
I]178, acetonitrile had to be added as a co-solvent in order to improve the solubility of 
the boronic acids. No radioiodination was observed when using 
ethoxycarbonylbenzeneboronic acid despite performing the reaction at a variety of 
temperatures and catalyst loadings. Likewise, the best radiochemical yield observed when 
using 3-formylphenylboronic acid was only 15%. 
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Scheme 68: Substrate scope of the potassium acetate-catalysed radioiododeboronation 
procedure showing radiochemical yields. *Acetonitrile was added as a co-solvent. 
5.2.3 Synthesis of SPECT imaging agents 
With the successful radiosynthesis of a range of aryl iodides using the potassium acetate 
catalysed iododeboronation, the utility of this procedure was then demonstrated with the 
preparation of iodine-125 labelled SPECT imaging agents. The first imaging agent 
synthesised was Boc-protected [
125
I]MIBG 168 (Scheme 69). The boronic acid precursor 
167 was synthesised as previously shown in Scheme 63. Under the standard conditions of 
100 °C with 20 mol% of potassium acetate, only unreacted iodide was observed by radio-
HPLC. Therefore, the amount of potassium acetate was increased to 50 mol% and a 
radiochemical yield of 51% was obtained.  
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Scheme 69: The synthesis of Boc-protected MIBG 168 via the potassium acetate-catalysed 
radiodiododeboronation of boronic acid 167. 
The next SPECT imaging agent investigated was phthalazinone [
125
I]120 for the imaging 
of PARP-1 (Scheme 70). The boronic acid precursor 162 was synthesised according to the 
method shown in Scheme 61. The radioiodination of boronic acid 162 was very slow and 
even when the amount of potassium acetate was increased to 50 mol% there was no 
conversion to product after 4 hours. Therefore, in order to increase the reaction rate, one 
equivalent of potassium acetate was used. At 100 °C, although the iodide was completely 
consumed, no product was observed due to decomposition. Therefore, the best 
radiochemical yield of 38% was observed when the reaction temperature was decreased to 
80 °C. 
 
Scheme 70: Synthesis of PARP-1 imaging agent [
125
I]120 via the radioiodination of 
boronic acid 162. 
Current work is ongoing to improve the radiochemical yields of both [
125
I]MIBG 168 and 
PARP-1 imaging agent [
125
I]120 by this method, with the focus on decreasing the amount 
of radiochemical impurities formed. 
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5.3 Conclusions and future work 
A novel and transition metal-free ipso-radioiododeboronation procedure has been 
developed. This method is operationally simple and requires only a catalytic amount of 
potassium acetate. A small library of substrates with a variety of electronic and steric 
properties were synthesised in high radiochemical yields. Preliminary work on the 
synthesis of two SPECT imaging agents was also investigated. 
Current and future work will focus on extending the substrate scope of this reaction to 
include different functional groups and aromatic heteroatoms. The more efficient synthesis 
of both [
125
I]MIBG 168 and PARP-1 imaging agent [
125
I]120 will be explored along with 
the production of other SPECT imaging agents. For example, work is on-going to synthesis 
SPECT imaging agents [
125
I]CNS1261 26 and [
125
I]IBOX 27 (Figure 22).
27,26 
 
Figure 22: SPECT imaging agents which could potentially be radiolabelled using the 
potassium acetate-catalysed iododeboronation procedure.
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6. Experimental 
6.1 General experimental 
All reactions were performed under an atmosphere of air unless otherwise stated. All 
reagents and starting materials were obtained from commercial sources unless otherwise 
stated. Brine refers to a saturated solution of sodium chloride. All dry solvents were 
purified using a PureSolv 500 MD solvent purification system. Flash column 
chromatography was carried out using Merck Feduran Si 60 (40–63 µm). Macherey-Nagel 
aluminium-backed plates pre-coated with silica gel 60 were used for thin layer 
chromatography and were visualised under a UV lamp. 
1
H NMR and 
13
C NMR spectra 
were recorded on a Bruker DPX 400 spectrometer or Bruker DPX 500 spectrometer with 
chemical shift values in ppm relative to trimethylsilane or residual chloroform as standard. 
J values are reported in Hz. The assignment of 
1
H NMR spectra are based on COSY and 
HSQC experiments and 
13
C NMR spectra are based on DEPT experiments. Infrared 
spectra were recorded using a Shimadzu FTIR-84005 spectrometer directly as either a solid 
or liquid and mass spectra were obtained using a JEOL JMS-700 spectrometer or a Bruker 
MicroTOFq high resolution mass spectrometer. Melting points were determined on a 
Gallenkamp melting point apparatus Optical rotations were determined as solutions 
irradiating with the sodium D line (λ = 589 nm) using a polarimeter. [α]D values are given 
in units 10
−1
 deg cm
2
 g
−1
. 
 
6.2 MCT 1 and 2 experimental 
Diethyl 2-amino-thiophene-3,4-dicarboxylate (44)
62
  
 
 
To a stirred solution of ethyl pyruvate (43) (0.339 g, 2.92 mmol), ethyl cyanoacetate (42) 
(0.300 g, 2.65 mmol) and sulfur (0.084 g, 2.65 mmol) in N,N’-dimethylformamide (10 mL) 
was added triethylamine (1.85 mL, 13.5 mmol) dropwise. The reaction mixture was heated 
to 50 °C and stirred for 6 h. The mixture was diluted with water (30 mL) and an aqueous 
solution of 5% lithium chloride (20 mL). The product was extracted with diethyl ether (3 × 
30 mL). The combined organic layers were washed with brine (30 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The resulting material was filtered through a large pad 
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of silica, eluting with 100% diethyl ether to give diethyl 2-amino-thiophene3,4-
dicarboxylate (44) as an orange solid (0.373 g, 58%). Spectroscopic data were consistent 
with the literature.
62 
Mp 115–117 °C; δH (400 MHz, CDCl3) 1.30 (3H, t, J 7.2 Hz, 
OCH2CH3), 1.35 (3H, t, J 7.2 Hz, OCH2CH3), 4.25 (2H, q, J 7.2 Hz, OCH2CH3), 4.28 (2H, 
q, J 7.2 Hz, OCH2CH3), 5.95 (2H, br s, NH2), 6.59 (1H, s, 5-H); δC (101 MHz, CDCl3) 
14.2 (CH3), 14.3 (CH3), 60.2 (CH2), 61.2 (CH2), 105.0 (C), 111.1 (CH), 132.9 (C), 162.9 
(C), 164.6 (C), 165.1 (C); m/z (EI) 243 (M
+
, 100%). 
 
Diethyl 2-isobutyl-amino-thiophene-3,4-dicarboxylate (45)
62
  
 
 
To a stirred suspension of diethyl 2-amino-thiophene-3,4-dicarboxylate (44) (0.800 g, 3.29 
mmol) in isobutyric acid (47) (4.80 mL, 52.6 mmol) was added sodium borohydride (0.498 
g, 13.2 mmol) portionwise. The mixture was stirred at room temperature for 16 h. Further 
sodium borohydride (0.248 g, 6.58 mmol) was added portionwise and the mixture heated 
to 50 °C and stirred for 5 h. The reaction mixture was diluted with water (50 mL), 
neutralised with sodium bicarbonate (1.00 g) and the product extracted with diethyl ether 
(3 × 40 mL). The combined organic layers were dried (MgSO4), filtered and concentrated 
in vacuo. Purification by flash column chromatography eluting with 30% diethyl ether in 
hexane gave diethyl 2-isobutyl-amino-thiophene-3,4-dicarboxylate (45) as a yellow oil 
(0.702 g, 72%). Spectroscopic data were consistent with the literature.
62 δH (400 MHz, 
CDCl3) 0.99 (6H, d, J 6.7 Hz, CH(CH3)2), 1.29 (3H, t, J 7.2 Hz, OCH2CH3), 1.34 (3H, t, J 
7.2 Hz, OCH2CH3), 1.92–2.03 (1H, m, 2’-H), 3.04 (2H, d, J 7.6 Hz, 1’-H2), 4.24 (2H, q, J 
7.2 Hz, OCH2CH3), 4.30 (2H, q, J 7.2 Hz, OCH2CH3), 6.49 (1H, s, 5-H), 7.70 (1H, br s, 
NH); δC (101 MHz, CDCl3) 14.2 (CH3), 14.3 (CH3), 20.1 (2 × CH3), 28.4 (CH), 55.4 (CH2), 
59.9 (CH2), 61.2 (CH2), 101.5 (C) 108.8 (CH), 133.5 (C), 165.1 (C), 165.6 (C), 166.4 (C); 
m/z (ESI) 322 (MNa
+
, 100%). 
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Ethyl 2-[(acetylamino)carbonyl-2’-methylpropyl]amino-thiophene-3,4-dicarboxylate 
(48)
62
 
 
Acetyl chloride (0.063 mL, 0.89 mmol) was added dropwise to a stirred suspension of 
silver cyanate (0.132 g, 0.890 mmol) in anhydrous toluene (10 mL). The mixture was 
stirred under an argon atmosphere at room temperature for 1 h. Diethyl 2-isobutyl-amino-
thiophene-3,4-dicarboxylate (45) (0.107 g, 0.360 mmol) was then added as a solution in 
anhydrous toluene (10 mL) and the mixture stirred at room temperature for 16 h. The 
mixture was then diluted with diethyl ether (10 mL) and filtered. The filtrate was washed 
with an aqueous saturated solution of sodium bicarbonate (10 mL) and the product 
extracted with diethyl ether (2 × 10 mL). The organic layers were combined, dried 
(MgSO4), filtered and concentrated in vacuo to give ethyl 2-[(acetylamino)carbonyl-2’-
methylpropyl]amino-thiophene-3,4-dicarboxylate (48) as a colourless oil (0.108 g, 78%). 
Spectroscopic data were consistent with the literature.
62
  δH (400 MHz, CDCl3) 0.91 (6H, d, 
J 6.7 Hz, CH(CH3)2), 1.34 (3H, t, J 7.2 Hz, OCH2CH3), 1.35 (3H, t, J 7.2 Hz, OCH2CH3), 
1.82–1.93 (1H, m, 2’-H), 2.42 (3H, s, COCH3), 3.49 (2H, d, J 7.2 Hz, 1’-H2), 4.33 (2H, q, 
J 7.2 Hz, OCH2CH3), 4.34 (2H, q, J 7.2 Hz, OCH2CH3), 7.70 (1H, s, 5-H), 8.00 (1H, s, 
NH); δC (101 MHz, CDCl3) 13.9 (CH3), 14.1 (CH3), 19.9 (2 × CH3), 24.5 (CH), 27.0 (CH3), 
58.5 (CH2), 61.1 (CH2), 62.4 (CH2), 131.4 (C), 132.1 (CH), 133.1 (C), 143.2 (C), 152.3 (C), 
161.1 (C), 163.3 (C), 172.5 (C); m/z (ESI) 407 (MNa
+
, 100%). 
6-Chloro-1-isobutyl-3-methyl-2,4-(1H,3H)-pyrimidinedione (51)
57
 
 
Isobutyl bromide (8.90 mL, 82.2 mmol) was added to a solution of 6-chloro-3-methyluracil 
(49) (12.0 g, 74.7 mmol) and potassium carbonate (12.4 g, 89.7 mmol) in dimethyl 
sulfoxide (120 mL). The mixture was heated to 60 °C and stirred for 72 h. The mixture was 
then cooled to room temperature and diluted with water (40 mL) and brine (40 mL). The 
product was then extracted with diethyl ether (3 × 40 mL). The organic layers were 
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combined, dried  (MgSO4), filtered and concentrated in vacuo to provide a 10:1 mixture of 
the N- and O-alkylated products 50 and 51 (13.7 g, 84%) as an orange oil. This mixture 
was used directly in the next step without further purification. The following 
characterisation data refers to the major product 6-chloro-1-isobutyl-3-methyl-2,4-
(1H,3H)-pyrimidinedione (51). Spectroscopic data were consistent with the literature.
57
 δH 
(400 MHz, CDCl3) 0.96 (6H, d, J 6.8 Hz, CH(CH3)2), 2.11–2.22 (1H, m, 2’-H), 3.34 (3H, s, 
3-CH3), 3.90 (2H, d, J 7.6 Hz, 1’-H2), 5.92 (1H, s, 5-H); δC (101 MHz, CDCl3) 19.7 (2 × 
CH3), 28.1 (CH3), 28.3 (CH), 53.5 (CH2), 101.9 (CH), 146.0 (C), 151.2 (C), 160.9 (C); m/z 
(CI) 217 (MH
+
, 95%), 183 (17), 69 (10). 
1-isobutyl-6-mercapto-3-methyl-2,4-(1H,3H)-pyrimidinedione (52)
61
 
 
Sodium hydrosulfide monohydrate (1.28 g, 22.7 mmol) was added to a stirred solution of 
6-chloro-1-isobutyl-3-methy-2,4(1H,3H)-pyrimidinedione (51) (4.10 g, 18.9 mmol) in 
ethanol (60 mL). The mixture was stirred at room temperature for 24 h before further 
sodium hydrosulfide monohydrate (1.28 g, 22.7 mmol) was added and stirring continued at 
room temperature for a further 16 h under an atmosphere of argon. The solution was 
concentrated in vacuo and the resulting oil diluted with water (30 mL) and washed with 
ethyl acetate (30 mL).  The aqueous layer was acidified with an aqueous solution of 1 M 
hydrochloric acid and extracted with ethyl acetate (3 × 30 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated in vacuo to give 1-isobutyl-6-
mercapto-3-methyl-2,4-(1H,3H)-pyrimidinedione (52) as a pale yellow solid (3.69 g, 90%). 
Spectroscopic data were consistent with the literature.
61
 Mp 111–113 °C; δH (400 MHz, 
CDCl3) 0.92 (6H, d, J 6.8 Hz, CH(CH3)2), 2.24–2.31 (1H, m, 2’-H), 3.29 (3H, s, 3-CH3), 
4.14 (2H, s, 5-H2), 4.27 (2H, d, J 7.4 Hz, 1’-H2); δC (101 MHz, CDCl3) 20.1 (2 × CH3), 
26.6 (CH3), 28.6 (CH), 49.2 (CH2), 54.5 (CH2), 150.3 (C), 164.8 (C), 197.2 (C); m/z (ESI) 
237 (MNa
+
, 60%), 159 (20), 307 (5), 449 (2). 
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Ethyl 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (46)
61
 
 
Ethyl bromopyruvate (1.70 mL, 13.3 mmol) was added to a solution of 1-isobutyl-6-
mercapto-3-methyl-2,4-(1H,3H)-pyrimidinedione (52) (1.90 g, 8.87 mmol) in ethanol (40 
mL) and stirred at room temperature for 0.75 h. The reaction mixture was concentrated in 
vacuo to give a red oil. A mixture of the crude intermediate and polyphosphoric acid (10.0 
g) was heated to 145 °C for 3 h and then cooled to room temperature. A saturated aqueous 
solution of sodium carbonate (15 mL) was added and the mixture extracted with ethyl 
acetate (3 × 25 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography eluting with 20% 
ethyl acetate in petroleum ether gave ethyl 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (46) as a dark pink solid (1.41 g, 54%). 
Mp 62–66 °C. Spectroscopic data were consistent with the literature.61 δH (400 MHz, 
CDCl3) 1.00 (6H, d, J 6.9 Hz, CH(CH3)2), 1.40 (3H, t, J 7.4 Hz, OCH2CH3), 2.26–2.38 (1H, 
m, 2’-H), 3.42 (3H, s, 3-CH3), 3.81 (2H, d, J 7.6 Hz, 1’-H2), 4.41 (2H, q, J 7.4 Hz, 
OCH2CH3), 7.29 (1H, s, 6-H); δC (101 MHz, CDCl3) 14.2 (CH3), 20.0 (2 × CH3), 27.0 
(CH), 28.5 (CH3), 56.2 (CH2), 61.9 (CH2), 112.6 (C), 119.4 (CH), 132.3 (C), 150.8 (C), 
154.2 (C), 157.0 (C), 162.9 (C); m/z (ESI) 333 (MNa
+
, 100%). 
1-Isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylic 
acid (58)
61
 
 
To a stirred solution of ethyl 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (46) (0.060 g, 0.19 mmol) in tetrahydrofuran (1 mL) and 
methanol (0.5 mL) was added an aqueous solution of 10% sodium hydroxide (0.3 mL).  
The mixture was stirred for 2 h at room temperature.  The mixture was then diluted with 
 
 
99 
 
water (5 mL) and washed with diethyl ether (5 mL).  The aqueous layer was acidified with 
an aqueous solution of 1 M hydrochloric acid and the product extracted with ethyl acetate 
(3 × 5 mL).  The organic layers were dried (MgSO4), filtered and concentrated in vacuo to 
give 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylic acid (58) as a brown oil (0.049 g, 92%). Spectroscopic data were consistent 
with the literature.
61
  δH (400 MHz, CDCl3) 1.00 (6H, d, J 6.8 Hz, CH(CH3)2), 2.29–2.37 
(1H, m, 2’-H), 3.50 (3H, s, 3-CH3), 3.87 (2H, d, J 7.6 Hz, 1’-H2), 8.03 (1H, s, 6-H), 15.00 
(1H, br s, OH); δC (101 MHz, CDCl3) 20.1 (2 × CH3), 26.9 (CH3), 29.3 (CH), 56.6 (CH2), 
109.8 (C), 127.6 (CH), 131.3 (C), 149.6 (C), 156.3 (C), 160.9 (C), 162.0 (C); m/z (EI) 282 
(M
+
, 100%), 182 (75), 125 (32), 51 (21). 
N-(4’’’-Iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (59) 
 
1-Isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylic 
acid (58)  (0.043 g, 0.15 mmol) was dissolved in N,N’-dimethylformamide (10 mL) and 
then O-(benzotriazol-1-yl)-N,N,N′,N’-tetramethyluronium hexafluorophosphate (0.085 g, 
0.23 mmol), N,N’-diisopropylethylamine (0.052 mL, 0.30 mmol) and 4-iodobenzylamine 
(0.11 g, 0.45 mmol) were added and the mixture stirred for 5 h at 40 °C. The mixture was 
diluted with water (10 mL) and a saturated aqueous sodium bicarbonate solution (10 mL). 
The product was extracted with ethyl acetate (3 × 10 mL). The organic layers were 
combined and washed with an aqueous solution of 5% lithium chloride (30 mL) and brine 
(30 mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to give 
the crude product. Purification by flash column chromatography eluting with 40% ethyl 
acetate in petroleum ether gave N-(4’’’-iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (59) as a yellow solid (0.060 g, 
80%). Mp 178–180 °C; νmax (neat)/cm
−1
 3032 (NH), 2955 (CH), 1697 (CO), 1627 (CO), 
1589 (C=C), 1473, 1296, 1003, 733; δH (400 MHz, CDCl3) 1.01 (6H, d, J 6.7 Hz, 
CH(CH3)2), 2.31–2.37 (1H, m, 2’-H), 3.46 (3H, s, 3-CH3), 3.87 (2H, d, J 7.6 Hz, 1’-H2), 
4.59 (2H, d, J 5.6 Hz, 1’’-H2), 7.14 (2H, d, J 8.4 Hz, 2’’’-H and 6’’’-H), 7.65 (2H, d, J 8.4 
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Hz, 3’’’-H and 5’’’-H), 8.02 (1H, s, 6-H), 11.19 (1H, br s, NH); δC (101 MHz, CDCl3) 20.0 
(2 × CH3), 26.9 (CH3), 29.1 (CH), 43.3 (CH2), 56.2 (CH2), 92.5 (C), 110.4 (C), 124.0 (CH), 
129.7 (2 × CH), 134.7 (C), 137.6 (2 × CH), 138.4 (C), 149.9 (C), 156.4 (C), 160.5 (C), 
160.7 (C); m/z (ESI) 520.0151 (MNa
+
. C19H20IN3NaO3S requires 520.0162). 
N-(3’’’-Iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (60) 
 
The reaction was carried out according to the previously described procedure for N-(4’’’-
iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxamide (59) using 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylic acid (58) (0.047 g, 0.17 mmol) and 3-iodobenzylamine (0.067 
mL, 0.50 mmol) and gave N-(3’’’-iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (60) as a yellow solid (0.050 g, 60%). 
Mp 150–153 °C; νmax (neat)/cm
−1 
3781 (NH), 2962 (CH), 1705 (CO), 1635 (CO), 1581 
(C=C), 1497, 1296, 725; δH (400 MHz, CDCl3) 1.01 (6H, d, J 6.7 Hz, CH(CH3)2), 2.31–
2.37 (1H, m, 2’-H), 3.47 (3H, s, 3-CH3), 3.87 (2H, d, J 7.7 Hz, 1’-H2), 4.60 (2H, d, J 5.6 
Hz, 1’’-H2), 7.06 (1H, t, J 7.7 Hz, 5’’’-H), 7.36 (1H, d, J 7.7 Hz, 6’’’-H), 7.59 (1H, d, J 7.7 
Hz,  4’’’-H), 7.73 (1H, s, 2’’’-H), 8.03 (1H, s, 6-H), 11.20 (1H, br s, NH); δC (101 MHz, 
CDCl3) 20.0 (2 × CH3), 26.9 (CH3), 29.1 (CH), 43.0 (CH2), 56.3 (CH2), 94.5 (C), 110.4 (C), 
124.4 (CH), 126.9 (CH), 130.3 (CH), 134.7 (C), 136.2 (CH), 136.5 (CH), 141.1 (C), 149.9 
(C), 156.4 (C), 160.5 (C), 160.7 (C); m/z (ESI) 520.0153 (MNa
+
. C19H20IN3NaO3S requires 
520.0162). 
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N-(4’’’-Fluorobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (61) 
 
The reaction was carried out according to the previously described procedure for N-(4’’’-
iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxamide (59) using 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylic acid (58) (0.052 g, 0.18 mmol) and 4-fluorobenzylamine (0.069 
mL, 0.55 mmol) and gave N-(4’’’-fluorobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (61) as a yellow solid (0.035 g, 50%). 
Mp 158–161 °C; νmax (neat)/cm
−1
 3245 (NH), 2361 (CH), 1697 (CO), 1636 (CO), 1582 
(C=C), 1466, 1219, 1042, 818, 725; δH (400 MHz, CDCl3) 1.00 (6H, d, J 6.7 Hz, 
CH(CH3)2), 2.30–2.37 (1H, m, 2’-H), 3.45 (3H, s, 3-CH3), 3.87 (2H, d, J 7.6 Hz, 1’-H2), 
4.62 (2H, d, J  5.6 Hz, 1’’-H2), 7.01 (2H, t, J 8.8  Hz, 3’’’-H and 5’’’-H), 7.36 (2H, dd, J  
8.7, 5.4 Hz, 2’’’-H and 6’’’-H), 8.03 (1H, s, 6-H), 11.12 (1H, br s, NH); δC (101 MHz, 
CDCl3) 20.0 (2 × CH3), 26.9 (CH3), 29.1 (CH), 43.1 (CH2), 56.2 (CH2), 110.4 (C), 115.4 (d, 
2
JCF 21.2 Hz, 2 × CH), 124.3 (CH), 129.4 (d, 
3
JCF 8.0 Hz, 2 × CH), 134.8 (d, 
4
JCF 3.0 Hz, 
C), 134.8 (C), 149.9 (C), 156.4 (C), 160.4 (C), 160.6 (C), 163.2 (d, 
1
JCF 247.9 Hz, C); m/z 
(ESI) 412.1082 (MNa
+
. C19H20FN3NaO3S requires 412.1102). 
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N-(2’’’-Fluorobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (62) 
 
The reaction was carried out according to the previously described procedure for N-(4’’’-
iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxamide (59) using 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylic acid (58) (0.066 g, 0.23 mmol) and 2-fluorobenzylamine (0.080 
mL, 0.70 mmol) and gave N-(2’’’-fluorobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (62) as an orange oil (0.061 g, 68%). 
νmax (neat)/cm
−1 
 3241 (NH), 2963 (CH), 1705 (CO), 1636 (CO), 1574 (C=C), 1496, 1296, 
756;  δH (400 MHz, CDCl3) 1.00 (6H, d, J 6.7 Hz, CH(CH3)2), 2.27–2.38 (1H, m, 2’-H), 
3.46 (3H, s, 3-CH3), 3.86 (2H, d, J 7.6 Hz, 1’-H2), 4.71 (2H, d, J 5.7 Hz, 1’’-H2), 7.02–7.07 
(1H, m, 6’’’-H), 7.10 (1H, td, J 7.5, 1.1 Hz, 5’’’-H), 7.21–7.27 (1H, m, 3’’’-H), 7.44 (1H, 
td, J 7.5, 1.6 Hz, 4’’’-H), 8.03 (1H, s, 6-H), 11.19 (1H, br s, NH); δC (101 MHz, CDCl3) 
20.0 (2 × CH3), 26.9 (CH3), 29.1 (CH), 37.5 (CH2), 56.2 (CH2), 110.4 (C), 115.3 (d, 
2
JCF 
21.2 Hz, CH), 124.1 (d, 
4
JCF 3.4 Hz, CH), 124.3 (CH), 125.5 (d, 
2
JCF 14.7 Hz, C), 128.9 (d, 
3
JCF 8.0 Hz, CH), 129.9 (d, 
3
JCF 4.5 Hz, CH), 134.7 (C), 149.9 (C), 156.3 (C), 160.4 (C), 
160.7 (C), 162.1 (d, 
1
JCF 246.1 Hz, C); m/z (ESI) 412.1083 (MNa
+
. C19H20FN3NaO3S 
requires 412.1102). 
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N-(4’’’-Iodobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (63) 
 
N-(4’’’-Iodobenzyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (59)  (0.030 g, 0.060 mmol) and sodium hydride (0.0060 g, 
0.15 mmol) were stirred in dry tetrahydrofuran (5 mL) for 1 h at room temperature. Methyl 
iodide (0.031 mL, 0.48 mmol) was added and the mixture heated to 50 °C and stirred for 
16 h. The reaction mixture was quenched with water (10 mL), acidified with an aqueous 
solution of 1 M hydrochloric acid and the product extracted with ethyl acetate (3 × 10 mL). 
The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography eluting on a gradient from 50–100% ethyl 
acetate in petroleum ether gave N-(4’’’-iodobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (63) as a viscous yellow 
oil (0.023 g, 75%). The compound exists as a 5:1 mixture of rotamers. Data for the major 
rotamer: νmax (neat)/cm
−1 2960 (CH), 1705 (CO), 1645 (CO), 1492, 1467, 1006, 728; δH 
(400 MHz, CDCl3) 1.01 (6H, d, J 6.7 Hz, CH(CH3)2), 2.27–2.37 (1H, m, 2’-H), 2.78 (3H, s, 
NCH3), 3.41 (3H, s, 3-CH3), 3.81 (2H, d, J 7.6 Hz, 1’-H2), 4.73 (2H, s, 1’’-H2), 6.91 (1H, s, 
6-H), 7.21 (2H, d, J 8.4 Hz, 2’’’-H and 6’’’-H), 7.66 (2H, d, J 8.4 Hz, 3’’’-H and 5’’’-H); 
δC (101 MHz, CDCl3) 20.1 (2 × CH3), 27.0 (CH3), 28.3 (CH), 35.8 (CH3), 50.2 (CH2), 56.4 
(CH2), 93.0 (C), 113.5 (C), 129.0 (2 × CH), 130.3 (CH), 134.3 (C), 136.3 (C), 137.7 (2 × 
CH), 150.9 (C), 154.0 (C), 157.7 (C), 165.9 (C); m/z (ESI) 534.0323 (MNa
+
. 
C20H22IN3NaO3S requires 534.0319). 
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N-(3’’’-Iodobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (64) 
 
The reaction was carried out according to the previously described procedure for N-(4’’’-
iodobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (63)  using N-(3’’’-iodobenzylamine)-1-isobutyl-3-methyl-
2,4-dioxo-5-(3-iodo-benzylaminocarbonyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine (60) 
(0.033 g, 0.070 mmol) and gave N-(3’’’-iodobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-
dioxo-tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (64) as a viscous yellow oil 
(0.029 g, 81%). The compound exists as a 5:1 mixture of rotamers. Data for the major 
rotamer: νmax (neat)/cm
−1 
2960 (CH), 1705 (CO), 1662 (CO), 1510 (C=C), 1468, 1453, 
1064, 775; δH (400 MHz, CDCl3) 1.01 (6H, d, J 6.7 Hz, CH(CH3)2), 2.26–2.39 (1H, m, 2’-
H), 2.78 (3H, s, NCH3), 3.43 (3H, s, 3-CH3), 3.78 (2H, d, J 7.8 Hz, 1’-H2), 4.78 (2H, s, 1’’-
H2), 6.90 (1H, s, 6-H), 7.12 (1H, t, J 7.7 Hz, 5’’’-H), 7.44 (1H, d, J 7.7 Hz, 6’’’-H), 7.64 
(1H, d, J 7.7 Hz, 4’’’-H), 7.82 (1H, s, 2’’’-H); δC (101 MHz, CDCl3) 20.1 (2 × CH3), 27.0 
(CH3), 28.3 (CH), 35.8 (CH3), 49.9 (CH2), 56.4 (CH2), 94.6 (C), 112.7 (C), 113.5 (CH), 
126.3 (CH), 127.5 (CH), 130.4 (CH), 134.7 (C), 136.1 (CH), 139.0 (C), 150.8 (C), 153.9 
(C), 157.5 (C), 167.7 (C); m/z (ESI) 534.0307 (MNa
+
. C20H22IN3NaO3S requires 534.0319). 
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N-(4’’’-Fluorobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (65) 
 
The reaction was carried out according to the previously described procedure for N-(4’’’-
iodobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (63) using N-(4’’’-fluorobenzyl)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (61) (0.035 g, 0.090 mmol) 
and gave N-(4’’’-fluorobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (65) as a viscous yellow oil (0.022 g, 
61%). The compound exists as a 5:1 mixture of rotamers. Data for the major rotamer: νmax 
(neat)/cm
−1
 2960 (CH), 1706 (CO), 1644 (CO), 1510 (C=C), 1493, 1221, 725; δH (400 
MHz, CDCl3) 1.01 (6H, d, J 6.7 Hz, CH(CH3)2), 2.27–2.37 (1H, m, 2’-H), 2.77 (3H, s, 
NCH3), 3.42 (3H, s, 3-CH3), 3.74–3.89 (2H, m, 1’-H2), 4.78 (2H, s, 1’’-H2), 6.88 (1H, s, 6-
H), 7.06 (2H, t, J 8.7 Hz, 3’’’-H and 5’’’-H), 7.44 (2H, dd, J 8.6, 5.4 Hz, 2’’’-H and 6’’’-
H); δC (101 MHz, CDCl3) 20.0 (2 × CH3), 27.0 (CH3), 28.3 (CH), 35.6 (CH3), 49.9 (CH2), 
56.4 (CH2), 112.8 (C), 113.4 (d, 
4
JCF 3.1 Hz, C), 115.4 (d, 
2
JCF 21.4 Hz, 2 × CH), 115.9 
(CH), 130.1 (d, 
3
JCF 8.0 Hz, 2 × CH), 132.4 (C), 150.8 (C), 153.9 (C), 157.6 (C), 163.5 (d, 
1
JCF 247.1 Hz, C), 165.7 (C); m/z (ESI) 426.1242 (MNa
+
. C20H22FN3NaO3S requires 
426.1258). 
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N-(2’’’-fluorobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (66) 
 
The reaction was carried out according to the previously described procedure for N-(4’’’-
iodobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxamide (63) using N-(2’’’-fluorobenzyl)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (62) (0.034 g, 0.09 mmol) 
and gave N-(2’’’-fluorobenzyl)-1-isobutyl-3-methyl-N-methyl-2,4-dioxo-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxamide (66) as a yellow oil (0.021 g, 58%). The 
compound exists as a 5:1 mixture of rotamers. Data for the major rotamer: νmax (neat)/cm
−1
 
2961 (CH), 1705 (CO), 1661 (CO), 1510 (C=C), 1491, 1399, 760; δH (400 MHz, CDCl3) 
1.01 (6H, d, J 6.7 Hz, CH(CH3)2), 2.28–2.37 (1H, m, 2’-H), 2.77 (3H, s, NCH3), 3.42 (3H, 
s, 3-CH3), 3.74–3.86 (2H, m, 1’-H2), 4.38–4.57 (2H, m, 1’’-H2), 6.88 (1H, s, 6-H), 7.00–
7.10 (1H, m, J, 6’’’-H), 7.14 (1H, td, J 7.5, 1.6 Hz, 5’’’-H), 7.23–7.29 (1H, m, 3’’’-H), 
7.65 (1H, td, J 7.5, 1.6 Hz, 4’’’-H); δC (101 MHz, CDCl3) 20.1 (2 × CH3), 27.0 (CH3), 28.3 
(CH), 32.8 (CH3), 44.0 (CH2), 56.4 (CH2), 112.8 (C), 115.6 (d, 
2
JCF 22.1 Hz, CH), 123.6 
(CH), 124.5 (d, 
4
JCF 3.4 Hz, CH), 129.1 (d, 
2
JCF 15.4 Hz, C), 129.6 (d, 
3
JCF 8.0 Hz, CH), 
130.8 (d, 
3
JCF 4.0 Hz, CH), 134.8 (C), 150.9 (C), 153.9 (C), 157.6 (C), 162.1 (d, 
1
JCF 248.9 
Hz, C), 165.8 (C); m/z (EI) 403.1366 (M
+
. C20H22F N3O3S requires 403.1369). 
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Ethyl 6-chloro-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (67)
61
 
 
N-Chlorosuccinimide (0.031 g, 0.23 mmol) was added to a stirred solution of ethyl 1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (46) 
(0.060 g, 0.19 mmol) in dichloromethane (0.5 mL) and acetic acid (0.5 mL). The mixture 
was stirred at room temperature for 5 h. The reaction mixture was azeotroped under 
vacuum in the presence of toluene (3 × 2 mL). Purification by flash column 
chromatography eluting with 20% ethyl acetate in petroleum ether gave ethyl 6-chloro-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (67) 
as a white solid (0.054 g, 82%). Mp 81–83 °C. Spectroscopic data were consistent with the 
literature.
61
 δH (400 MHz, CDCl3) 0.99 (6H, d, J 6.7 Hz, CH(CH3)2), 1.42 (3H, t, J 7.2 Hz, 
OCH2CH3), 2.24–2.32 (1H, m, 2’-H), 3.39 (3H, s, 3-CH3), 3.72 (2H, d, J 7.6 Hz, 1’-H2), 
4.47 (2H, q, J 7.2 Hz, OCH2CH3); δC (101 MHz, CDCl3) 14.1 (CH3), 20.0 (2 × CH3), 27.1 
(CH3), 28.4 (CH), 56.5 (CH2), 62.5 (CH2), 112.0 (C), 121.0 (C), 129.4 (C), 150.5 (C), 
150.8 (C), 156.6 (C), 162.0 (C); m/z (ESI) 367 (MNa
+
 100%). 
Ethyl 6-(4’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (69) 
 
Ethyl 6-chloro-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-
5-carboxylate (67) (0.107 g, 0.310 mmol) was dissolved in dry N,N’-dimethylformamide 
(5 mL). Caesium carbonate (0.302 g, 0.930 mmol) and 4-iodophenol (0.103 g, 0.470 mmol) 
were added and the reaction stirred at 100 °C for 16 h. The reaction mixture was then 
diluted with water (10 mL) and the product extracted with ethyl acetate (3 × 10 mL). The 
organic layers were washed with an aqueous solution of 5% lithium chloride (10 mL) and 
brine (10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated 
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in vacuo. Purification by flash column chromatography eluting with 30% diethyl ether in 
petroleum ether gave ethyl 6-(4’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (69) as a colourless oil (0.0850 g, 52%). 
νmax (neat)/cm
−1
 2963 (CH), 1736 (CO), 1667 (CO), 1551 (C=C), 1481, 1173, 1011, 826; 
δH (400 MHz, CDCl3) 0.97 (6H, d, J 6.7 Hz, CH(CH3)2), 1.25 (3H, t, J 7.1 Hz, OCH2CH3), 
2.02–2.29 (1H, m, 2’-H), 3.41 (3H, s, 3-CH3), 3.71 (2H, d, J 7.7 Hz, 1’-H2), 4.32 (2H, q, J 
7.1 Hz, OCH2CH3), 6.89 (2H, d, J 8.8 Hz, 2’’-H and 6’’-H), 7.65 (2H, d, J 8.8 Hz, 3’’-H 
and 5’’-H); δC (101 MHz, CDCl3) 14.0 (CH3), 20.0 (2 × CH3), 27.1 (CH3), 28.3 (CH), 56.3 
(CH2), 62.2 (CH2), 87.8 (C), 109.5 (C), 119.1 (2 × CH), 119.3 (C), 138.8 (2 × CH), 146.6 
(C), 149.2 (C), 150.8 (C), 157.1 (C), 158.2 (C), 161.8 (C); m/z (ESI) 551.0094 (MNa
+
. 
C20H21IN2NaO5S requires 551.0108). 
Ethyl 6-(2’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (70) 
 
The reaction was carried out according to the previously described procedure for 6-(4’’-
iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (69) using ethyl 6-chloro-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (67) (0.119 g, 0.350 mmol) and 2-
iodophenol (0.117 g, 0.530 mmol). The mixture was heated at 120 °C. This gave ethyl 6-
(2’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (70) as a colourless oil (0.040 g, 22%). νmax (neat)/cm
−1
 2926 
(CH), 1708 (CO), 1661 (CO), 1547 (C=C), 1464, 1292, 756; δH (400 MHz, CDCl3) 0.97 
(6H, d, J 6.7 Hz, CH(CH3)2), 1.26 (3H, t, J 7.2 Hz, OCH2CH3), 2.21–2.29 (1H, m, 2’-H), 
3.41 (3H, s, 3-CH3), 3.70 (2H, d, J 7.5 Hz, 1’-H2), 4.33 (2H, q, J 7.2 Hz, OCH2CH3), 6.93 
(1H, td, J 7.9, 1.3 Hz, 5’’-H), 7.12 (1H, dd, J 7.9, 1.3 Hz, 6’’-H), 7.33 (1H, td, J 7.9, 1.3 
Hz, 4’’-H), 7.83 (1H, dd, J 7.9, 1.3 Hz, 3’’-H); δC (101 MHz, CDCl3) 14.0 (CH3), 20.0 (2 × 
CH3), 27.1 (CH3), 28.3 (CH), 56.3 (CH2), 62.2 (CH2), 85.9 (C), 109.5 (C), 117.3 (CH), 
118.8 (C), 126.5 (CH), 129.9 (CH), 140.0 (CH), 146.5 (C), 150.0 (C), 150.8 (C), 157.2 (C), 
157.5 (C), 161.7 (C); m/z (ESI) 551.0090 (MNa
+
. C20H21IN2NaO5S requires 551.0108). 
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Ethyl 6-(4’’-fluorophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (71) 
 
The reaction was carried out according to the previously described procedure for 6-(4’’-
iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (69) using ethyl 6-chloro-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (67) (0.12 g, 0.33 mmol) and 4-
fluorophenol (0.056 mL, 0.50 mmol). This gave ethyl 6-(4’’-fluorophenoxy)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate as a colourless 
oil (71) (0.094 g, 68%). νmax (neat)/cm
−1
 2963 (CH), 1705 (CO), 1667 (CO), 1551 (C=C), 
1497, 1180, 841; δH (400 MHz, CDCl3) 0.96 (6H, d, J 6.7 Hz, CH(CH3)2), 1.28 (3H, t, J 
7.1 Hz, OCH2CH3), 2.20–2.30 (1H, m, 2’-H), 3.41 (3H, s, 3-CH3), 3.70 (2H, d, J 7.7 Hz, 
1’-H2), 4.35 (2H, q, J 7.1 Hz, OCH2CH3), 7.02–7.07 (2H, m, 3’’-H and 5’’-H), 7.11 (2H, 
dd, J 9.3, 4.4 Hz, 2’’-H and 6’’-H); δC (101 MHz, CDCl3) 14.0 (CH3), 20.0 (2 × CH3), 27.1 
(CH3), 28.3 (CH), 56.3 (CH2), 62.2 (CH2), 109.5 (C), 116.6 (d, 
2
JCF 22.3 Hz, 2 × CH), 
118.3 (C), 118.4 (d, 
3
JCF 8.3 Hz, 2 × CH), 146.3 (C), 150.6 (C), 150.8 (C), 154.1 (d, 
4
JCF 
3.2 Hz, C), 157.2 (C), 160.5 (d, 
1
JCF 249.8 Hz, C), 162.0 (C); m/z (ESI) 443.1029 (MNa
+
. 
C20H21FN2NaO5S requires 443.1047). 
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Ethyl 6-(2’’-fluorophenoxy)-1-isopropyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (72) 
 
The reaction was carried out according to the previously described procedure for 6-(4’’-
iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (69) using ethyl 6-chloro-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (67) (0.11 g, 0.31 mmol) and 2-
fluorophenol (0.042 mL, 0.46 mmol). The mixture was heated at 110 °C. This gave ethyl 
6-(2’’-fluorophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (72) as a colourless oil (0.059 g, 45%). νmax (neat)/cm
−1
 2960 
(CH), 1708 (CO), 1661 (CO), 1549 (C=C), 1468, 1387, 1291, 1086; δH (400 MHz, CDCl3) 
0.96 (6H, d, J 6.7 Hz, CH(CH3)2), 1.28 (3H, t, J 7.1 Hz, OCH2CH3), 2.21–2.29 (1H, m, 2’-
H), 3.41 (3H, s, 3-CH3), 3.70 (2H, d, J 7.6 Hz, 1’-H2), 4.33 (2H, q, J 7.1 Hz, OCH2CH3), 
7.11 (1H, td, J 7.9, 1.9 Hz, 5’’-H), 7.14–7.19 (2H, m, 3’’-H and 6’’-H), 7.20 (1H, td, J 7.9, 
2.0 Hz, 4’’-H); δC (101 MHz, CDCl3) 14.0 (CH3), 20.0 (2 × CH3), 27.1 (CH3), 28.3 (CH), 
56.4 (CH2), 62.2 (CH2), 109.5 (C), 117.2 (d, 
2
JCF 18.7 Hz, CH), 118.9 (C) 119.5 (CH), 
124.8 (d, 
3
JCF 3.8 Hz, CH), 125.9 (d, 
3
JCF 7.9 Hz, CH), 145.5 (d, 
2
JCF 11.5 Hz, C), 146.2 
(C), 150.4 (C), 150.8 (C), 153.7 (d, 
1
JCF 248.7 Hz, C), 157.2 (C), 161.8 (C); m/z (ESI) 
443.1037 (MNa
+
. C20H21FN2NaO5S requires 443.1047). 
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6-(4’’-Iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (75) 
 
Ethyl 6-(4’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (69) (0.087 g, 0.16 mmol) was dissolved in tetrahydrofuran 
(0.50 mL) and methanol (0.25 mL). An aqueous solution of 10% sodium hydroxide (0.15 
mL) was added and the mixture stirred for 1 h. The reaction mixture was diluted with 
water (5 mL) and washed with diethyl ether (5 mL). The aqueous layer was acidified with 
an aqueous solution of 1 M hydrochloroic acid (5 mL) and extracted with ethyl acetate (3 × 
5 mL).  The organic layers were combined, dried (MgSO4), filtered and concentrated in 
vacuo. The resulting material was dissolved in acetonitrile (10 mL) then O-(benzotriazol-1-
yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (0.084 g, 0.23 mmol), N,N’-
diisopropylethylamine (0.052 mL 0.30 mmol) and N,O-dimethylhydroxylamine (0.043 g, 
0.45 mmol) were added and the mixture stirred at 40 °C for 16 h. The mixture was diluted 
with water (10 mL) and washed with a saturated aqueous solution of sodium bicarbonate 
(10 mL). The mixture was extracted with ethyl acetate (3 × 10 mL). The organic layers 
were combined and washed with an aqueous solution of 5% lithium chloride (30 mL) and 
brine (30 mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to 
give the crude product. Purification by flash column chromatography eluting with 40% 
ethyl acetate in petroleum ether gave ethyl 6-(4’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide 
(75) as a yellow oil (0.053 g, 64%). νmax (neat)/cm
−1
 2960 (CH), 1707 (CO), 1663 (CO), 
1549 (C=C), 1477, 1223, 1007, 769; The compound exists as a 5:1 mixture of rotamers. 
Data for the major rotamer: δH (400 MHz, CDCl3) 0.97 (6H, d, J 6.7 Hz, CH(CH3)2), 2.21–
2.30 (1H, m, 2’-H), 3.37 (3H, s, NCH3), 3.40 (3H, s, 3-CH3), 3.60 (1H, dd, J 14.3, 7.8 Hz, 
1’-HH), 3.62 (3H, s, OCH3), 3.81 (1H, dd, J 14.3, 7.8 Hz, 1’-HH), 6.94 (2H, d, J 8.9 Hz, 
2’’-H and 6’’-H), 7.64 (2H, d, J 8.9 Hz, 3’’-H and 5’’-H); δC (101 MHz, CDCl3) 20.0 
(CH3), 20.1 (CH3), 27.1 (CH3), 28.3 (CH), 32.8 (CH3), 56.4 (CH2), 61.8 (CH3), 88.0 (C), 
109.8 (C), 119.5 (2 × CH), 120.6 (C), 138.8 (2 × CH), 145.9 (C), 146.6 (C), 150.9 (C), 
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157.5 (C), 158.1(C), 163.1 (C); m/z (ESI) 566.0201 (MNa
+
. C20H22IN3NaO5S requires 
566.0217). 
6-(2’’-Iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (76) 
 
The reaction was carried out according to the previously described procedure for 6-(4’’-
iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
(N-methoxy-N-methyl)carboxamide (75) using ethyl 6-(2’’-iodophenoxy)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (70) (0.038 g, 
0.070 mmol). This gave 6-(2’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (76) as a yellow 
oil (0.021 g, 55%). νmax (neat)/cm
−1
  2926 (CH), 1707 (CO), 1663 (CO), 1545 (C=C), 1464, 
1223, 1105, 769; The compound exists as a 6:1 mixture of rotamers. Data for the major 
rotamer: δH (400 MHz, CDCl3) 0.97 (6H, d, J 6.7 Hz, CH(CH3)2), 2.23–2.29 (1H, m, 2’-H), 
3.39 (3H, s, NCH3), 3.40 (3H, s, 3-CH3), 3.64 (1H, dd, J 14.3, 7.9 Hz, 1’-HH), 3.72 (3H, s, 
OCH3), 3.77 (1H, dd, 14.3, 7.9 Hz, 1’-HH), 6.91 (1H, td, J 7.7, 1.3 Hz, 5’’-H), 7.24 (1H, 
dd, J 7.7, 1.3 Hz, 6’’-H), 7.33 (1H, td, J 7.7, 1.3 Hz, 4’’-H), 7.81 (1H, dd, J 7.7, 1.3 Hz, 
3’’-H); δC (101 MHz, CDCl3) 20.0 (2 × CH3), 27.1 (CH3), 28.3 (CH), 32.9 (CH3), 56.4 
(CH2), 62.1 (CH3), 85.8 (C), 109.9 (C), 117.8 (CH), 120.4 (C), 126.5 (CH), 130.1 (CH), 
139.7 (CH), 146.1 (C), 146.6 (C), 151.0 (C), 152.3 (C), 157.6 (C), 163.3 (C); m/z (ESI) 
566.0202 (MNa
+
. C20H22IN3NaO5S requires 566.0217). 
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6-(4’’-Fluorophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (73) 
 
The reaction was carried out according to the previously described procedure for 6-(4’’-
iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
(N-methoxy-N-methyl)carboxamide (75) using ethyl 6-(4’’-fluorophenoxy)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (71) (0.097 g, 
0.23 mmol). This gave 6-(4’’-fluorophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (73) as a yellow 
oil (0.042 g, 54%). νmax (neat)/cm
−1
  2929 (CH), 1706 (CO), 1656 (CO), 1549 (C=C), 1494, 
1389, 1179, 1107, 729; The compound exists as a 6:1 mixture of rotamers. Data for the 
major rotamer: δH (400 MHz, CDCl3) 0.97 (6H, d, J 6.7 Hz, CH(CH3)2), 2.22–2.28 (1H, m, 
2’-H), 3.38 (3H, s, NCH3), 3.40 (3H, s, 3-CH3), 3.60 (1H, dd, J 14.0, 7.9 Hz, 1’-HH), 3.64 
(3H, s, OCH3), 3.79 (1H, dd, J 14.0, 7.9 Hz, 1’-HH), 7.04 (2H, t, J 8.9 Hz, 3’’-H and 5’’-
H), 7.16 (2H, dd, J 8.9, 4.3 Hz, 2’’-H and 6’’-H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 
(CH3), 27.1 (CH3), 28.3 (CH), 32.8 (CH3), 56.3 (CH2), 61.8 (CH3), 109.8 (C), 116.5 (d, 
2
JCF 23.5 Hz, 2 × CH), 119.1 (d, 
3
JCF 8.6 Hz, 2 × CH), 119.6 (C), 146.3 (C), 147.3 (C), 
151.0 (C), 154.2 (d, 
4
JCF 2.8 Hz, C), 157.6 (C), 160.5 (d, 
1
JCF 247.3 Hz, C), 163.3 (C); m/z 
(ESI) 458.1135 (MNa
+
. C20H22FN3NaO5S requires 458.1156). 
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6-(2’’-Fluorophenoxy)-1-isopropyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (74) 
 
The reaction was carried out according to the previously described procedure for 6-(4’’-
iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
(N-methoxy-N-methyl)carboxamide (75) using ethyl 6-(2’’-fluorophenoxy)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (72) (0.056 g, 
0.13 mmol). This gave 6-(2’’-fluorophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (74) as a yellow 
oil (0.030 g, 57%). νmax (neat)/cm
−1
  2927 (CH), 1708 (CO), 1664 (CO), 1549 (C=C), 1498, 
1257, 1110, 769; δH (400 MHz, CDCl3) 0.96 (6H, d, J 6.7 Hz, CH(CH3)2), 2.22–2.29 (1H, 
m, 2’-H), 3.40 (3H, s, NCH3), 3.40 (3H, s, 3-CH3), 3.62 (1H, dd, J 14.3, 7.7 Hz, 1’-HH), 
3.66 (3H, s, OCH3), 3.79 (1H, dd, J 14.3, 7.7 Hz, 1’-HH), 7.10–7.19 (3H, m, 3’’-H, 5’’-H 
and 6’’-H), 7.31 (1H, td, J 8.2, 2.1 Hz, 4’’-H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 
(CH3), 27.1 (CH3), 28.3 (CH), 32.8 (CH3), 56.3 (CH2), 61.9 (CH3), 109.9 (C), 117.1 (d, 
2
JCF 18.3 Hz, CH), 119.4 (C) 120.2 (CH), 124.9 (d, 
3
JCF 4.2 Hz, CH), 126.0 (d, 
3
JCF 7.5 Hz, 
CH), 145.5 (d, 
2
JCF 11.5 Hz, C), 146.1 (C), 147.1 (C), 151.0 (C), 153.7 (d, 
3
JCF 246.5 Hz, 
C), 157.6 (C), 163.2 (C); m/z (ESI) 458.1136 (MNa
+
. C20H22FN3NaO5S requires 458.1156). 
Ethyl 6-bromo-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (68) 
 
 N-Bromosuccinimide (0.598 g, 3.36 mmol) was added to a stirred solution of ethyl 1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (46) 
(0.870 g, 2.80 mmol) in dichloromethane (15 mL) and acetic acid (15 mL) and stirred at 
room temperature for 5 h. The reaction mixture was azeotroped under vacuum in the 
presence of toluene (3 × 30 mL). Purification by flash column chromatography eluting 
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with 20% ethyl acetate in petroleum ether gave ethyl 6-bromo-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (68) as a white solid (0.911 
g, 84%). Mp 110–114 °C; νmax (neat)/cm
−1
 2961 (CH), 1736 (CO), 1707 (CO), 1661 (CO), 
1481, 1283, 1238; δH (400 MHz, CDCl3) 0.99 (6H, d, J 6.7 Hz, CH(CH3)2), 1.42 (3H, t, J 
7.1 Hz, OCH2CH3), 2.24–2.33 (1H, m, 2’-H), 3.40 (3H, s, 3-CH3), 3.72 (2H, d, J 7.8 Hz, 
1’-H2), 4.48 (2H, q, J 7.1 Hz, OCH2CH3); δC (101 MHz, CDCl3) 14.1 (CH3), 20.0 (2 × 
CH3), 27.0 (CH), 28.4 (CH3), 56.5 (CH2), 62.6 (CH2), 103.5 (C), 113.1 (C), 132.5 (C), 
150.5 (C), 153.2 (C), 156.4 (C), 162.7 (C); m/z (ESI) 410.9972 (MNa
+
. 
C14H17
79
BrN2NaO4S requires 410.9985). 
Ethyl 6-(4”-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (80) 
 
Potassium phosphate (0.18 g, 0.78 mmol) was suspended in a solution of 6-bromo-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (68) 
(0.15 g, 0.39 mmol) and 4-fluorophenylboronic acid (0.070 g, 0.50 mmol) in N,N’-
dimethylformamide (10 mL) and degassed for 1 h. 
Tetrakis(triphenylphosphine)palladium(0) (0.045 g, 0.039 mmol) was added and the 
reaction heated under reflux for 22 h. The reaction mixture was cooled to room 
temperature, extracted with ethyl acetate (30 mL) and washed with an aqueous solution of 
5% lithium chloride (4 × 25 mL) and brine (2 × 20 mL). The organic layers were combined, 
dried (MgSO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography eluting with 20% ethyl acetate in petroleum ether gave ethyl 6-(4’’-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (80) as a white solid (0.13 g, 81%). Mp 143–145 °C; νmax (neat)/cm
−1
 2963 
(CH), 1732 (CO), 1707 (CO), 1663 (CO), 1537, 1483, 1294, 1206; δH (400 MHz, CDCl3) 
1.02 (6H, d, J 7.0 Hz, CH(CH3)2), 1.30 (3H, t, J 7.3 Hz, OCH2CH3), 2.30–2.40 (1H, m, 2’-
H), 3.42 (3H, s, 3-CH3), 3.81 (2H, d, J 7.7 Hz, 1’-CH2), 4.38 (2H, q, J 7.3 Hz, OCH2CH3), 
7.01–7.13 (2H, m, 2”-H and 6”-H), 7.46–7.51 (2H, m, 3”-H and 5”-H); δC (101 MHz, 
CDCl3) 14.0 (CH3), 20.0 (2 × CH3), 27.1 (CH3), 28.3 (CH), 56.4 (CH2), 62.3 (CH2), 114.0 
(C), 116.2 (d, 
2
JCF 22.3 Hz, 2 × CH), 127.2 (d, 
4
JCF 3.8 Hz, C), 128.1 (C), 129.0 (C), 130.2 
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(d, 
3
JCF 9.8 Hz, 2 × CH), 150.7 (C), 152.3 (C), 157.5 (C), 162.8 (d, 
1
JCF 250.7 Hz, C), 
167.7 (C); m/z (ESI) 427.1093 (MNa
+
. C20H21FN2NaO4S requires 427.1098). 
Ethyl 6-(2”-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (81) 
 
The reaction was carried out according to the previously described procedure for ethyl 6-
(4”-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (80) using 6-bromo-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (68) (0.20 g, 0.51 mmol) and 2-
fluorophenylboronic acid (0.11 g, 0.67 mmol). This gave ethyl 6-(2”-fluorophenyl)-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (81) 
as a light pink solid (0.18 g, 86%). Mp 94–98 °C; νmax (neat)/cm
−1
 2963 (CH), 1732 (CO), 
1707 (CO), 1661 (CO), 1487, 1223, 1018, 758; δH (400 MHz, CDCl3) 1.01 (6H, d, J 7.3 Hz, 
CH(CH3)2), 1.26 (3H, t, J 7.1 Hz, OCH2CH3), 2.30–2.40 (1H, m, 2’-H), 3.42 (3H, s, 3-
CH3), 3.82 (2H, d, J 7.5 Hz, 1’-CH2), 4.35 (2H, q, J 7.1 Hz, OCH2CH3), 7.13–7.18 (1H, m, 
3”-H), 7.20 (1H, td, J 7.8, 1.2 Hz, 5”-H), 7.36–7.42 (1H, m, 6”-H), 7.51 (1H, td, J 7.8, 1.6 
Hz, 4”-H); δC (101 MHz, CDCl3) 14.0 (CH3), 20.1 (2 × CH3), 27.0 (CH3), 28.3 (CH), 56.3 
(CH2), 62.1 (CH2), 113.4 (C), 116.1 (d, 
2
JCF 21.7 Hz, CH), 118.9 (d, 
2
JCF 15.1 Hz, C), 
124.5 (d, 
4
JCF 3.9 Hz, CH), 126.2 (C), 129.7 (C), 131.1 (d, 
3
JCF 8.0 Hz, CH), 131.1 (d, 
3
JCF 
9.8 Hz, CH), 150.7 (C), 153.4 (C), 157.4 (C), 159.5 (d, 
1
JCF 251.9 Hz, C), 164.1 (C); m/z 
(ESI) 427.1087 (MNa
+
. C20H21FN2NaO4S requires 427.1098). 
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Ethyl 1-isobutyl-6-(4”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (82) 
 
The reaction was carried out according to the previously described procedure for ethyl 6-
(4”-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (80) using 6-bromo-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (68) (0.20 g, 0.51 mmol) and 4-
methoxyphenylboronic acid (0.10 g, 0.67 mmol). This gave ethyl 1-isobutyl-6-(4”-
methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (82) as a white solid (0.18 g, 85%). Mp 129–131 °C; νmax (neat)/cm
−1
 2961 
(CH), 1730 (CO), 1705 (CO), 1659 (CO), 1537, 1483, 1294, 1252, 1204, 1020, 831, 729; 
δH (400 MHz, CDCl3) 1.01 (6H, d, J 6.7 Hz, CH(CH3)2), 1.31 (3H, t, J 7.3 Hz, OCH2CH3), 
2.30–2.40 (1H, m, 2’-H), 3.41 (3H, s, 3-CH3), 3.80 (2H, d, J 7.7 Hz, 1’-CH2), 3.84 (3H, s, 
4”-OCH3), 4.39 (2H, q, J 7.3 Hz, OCH2CH3), 6.92 (2H, d, J 8.8 Hz, 3”-H and 5”-H), 7.43 
(2H, d, J 8.8 Hz, 2”-H and 6”-H); δC (101 MHz, CDCl3) 14.0 (CH3), 20.0 (2 × CH3), 27.1 
(CH3), 28.3 (CH), 55.4 (CH3), 56.3 (CH2), 62.2 (CH2), 114.0 (C), 114.4 (2 × CH), 123.5 
(C), 126.2 (C), 129.5 (2 × CH), 132.9 (C), 150.8 (C), 151.8 (C), 157.6 (C), 160.3 (C), 
165.0 (C); m/z (ESI) 439.1283  (MNa
+
. C21H24N2NaO5S requires 439.1298). 
Ethyl 1-isobutyl-6-(2”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (83) 
 
The reaction was carried out according to the previously described procedure for ethyl 6-
(4”-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (80) using 6-bromo-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (68) (0.20 g, 0.51 mmol) and 2-
methoxyphenylboronic acid (0.10 g, 0.67 mmol). This gave ethyl 1-isobutyl-6-(2”-
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methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (83) as a yellow solid (0.18 g, 86%). Mp 119–123 °C; νmax (neat)/cm
−1
 2963 
(CH), 1730 (CO), 1705 (CO), 1659 (CO), 1489, 1479, 1244, 1200, 1020, 729; δH (500 
MHz, CDCl3) 1.01 (6H, d, J 6.3 Hz, CH(CH3)2), 1.23 (3H, t, J 7.3 Hz, OCH2CH3), 2.31–
2.41 (1H, m, 2’-H), 3.42 (3H, s, 3-CH3), 3.81 (2H, d, J 7.8 Hz, 1’-CH2), 3.84 (3H, s, 2”-
OCH3), 4.32 (2H, q, J 7.3 Hz, OCH2CH3), 6.95 (1H, br d, J 7.9 Hz, 3”-H), 6.98 (1H, td, J 
7.9, 1.4 Hz, 5”-H), 7.36 (1H, td, J 7.9, 1.4 Hz, 4”-H), 7.43 (1H, dd, J 7.9, 1.4 Hz, 6”-H); δC 
(101 MHz, CDCl3) 13.9 (CH3), 20.0 (2 × CH3), 27.0 (CH3), 28.4 (CH), 55.5 (CH3), 56.1 
(CH2), 61.8 (CH2), 111.2 (CH), 113.0 (C), 119.9 (C), 120.8 (CH), 128.7 (C), 129.8 (C), 
130.6 (CH), 130.9 (CH), 150.9 (C), 153.2 (C), 156.4 (C), 157.5 (C), 164.6 (C); m/z (ESI)  
439.1281  (MNa
+
. C21H24N2NaO5S requires 439.1298). 
6-(4”-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-morpholinecarboxamide (88) 
 
Ethyl 6-(4”-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (80) (0.18 g, 0.44 mmol) was dissolved in ethanol (4 mL) and 
water (4 mL) prior to the addition of 4 M sodium hydroxide (1.5 mL, 2.0 mmol) and stirred 
at 80 °C for 1 h. The reaction mixture was diluted with water (10 mL) and washed with 
diethyl ether (2 × 10 mL). The aqueous layer was acidified with an aqueous solution of 1 
M hydrochloric acid and extracted with ethyl acetate (3 × 10 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated in vacuo. The resulting yellow solid 
was dissolved in dichloromethane (5 mL) and N,N’-dimethylformamide (2 drops) and 
cooled to 0 °C prior to the addition of oxalyl chloride (0.045 mL, 0.53 mmol). The reaction 
mixture was warmed to 40 °C and stirred for 3 h. After being cooled to room temperature, 
the reaction mixture was concentrated in vacuo to yield the acid chloride, which was used 
without further purification. The crude acid chloride was dissolved in dichloromethane (5 
mL) and cooled to 0 °C. Morpholine (0.19 mL, 2.2 mmol) was added dropwise to the 
stirring acid chloride solution. The reaction mixture was stirred at 40 °C for 18 h under 
argon. The reaction mixture was cooled to room temperature, diluted in water (10 mL) and 
extracted with dichloromethane (3 × 10 mL). The organic layers were combined, dried 
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(MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
eluting with 60% ethyl acetate in petroleum ether gave 6-(4”-fluorophenyl)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-morpholinecarboxamide 
(88) (0.094 g, 48%) as a colourless oil. νmax (neat)/cm
−1
 2970 (CH), 1740 (CO), 1724 (CO), 
1366, 1229, 1217; δH (400 MHz, CDCl3) 1.03 (6H, d, J 5.6 Hz, CH(CH3)2), 2.31–2.40 (1H, 
m, 2’-H), 3.05 (1H, ddd, J 8.5, 5.8, 2.4 Hz, NCHH), 3.10 (1H, ddd, J 10.6, 4.6, 2.4 Hz, 
NCHH), 3.26 (1H, ddd, J 10.6, 5.8, 2.4 Hz, NCHH), 3.41 (3H, s, 3-CH3), 3.47–3.57 (2H, 
m, NCHH and OCHH), 3.68 (1H, dd, J 11.4, 6.0 Hz, 1’-HH), 3.74–3.86 (3H, m, OCHH 
and OCH2), 3.97 (1H, dd, J 11.4, 6.4 Hz, 1’-HH), 7.10–7.14 (2H, m, 2”-H and 6”-H), 
7.51–7.54 (2H, m, 3”-H and 5”-H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 27.1 
(CH3), 28.3 (CH), 42.3 (CH2), 47.0 (CH2), 56.5 (CH2), 66.2 (CH2), 66.3 (CH2), 113.9 (C), 
116.4 (d, 
2
JCF 22.3 Hz, 2 × CH), 127.4 (d, 
4
JCF 3.8 Hz, C), 128.9 (C), 129.1 (C), 129.8 (d, 
3
JCF 8.2 Hz, 2 × CH), 150.7 (C), 152.9 (C), 157.7 (C), 163.1 (d, 
1
JCF 250.7 Hz, C), 164.0 
(C); m/z (ESI) 468.1350 (MNa
+
. C22H24FN3NaO4S requires 468.1364). 
6-(2”-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-morpholinecarboxamide (89) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 6-(2”-fluorophenyl)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (81) (0.178 g, 0.440 mmol) 
and morpholine (0.193 mL, 2.21 mmol). This gave 6-(2”-fluorophenyl)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-morpholinecarboxamide 
(89) as a colourless oil (0.105 g, 54%). νmax (neat)/cm
−1
 2961 (CH), 1707 (CO), 1663 (CO), 
1489, 1113, 1001, 762; δH (400 MHz, CDCl3) 1.02 (3H, d, J 5.6 Hz, CH(CH3)), 1.02 (3H, 
d, J 5.2 Hz, CH(CH3)), 2.30–2.40 (1H, m, 2’-H), 3.04 (1H, ddd, J 8.8, 6.0, 2.4 Hz, NCHH), 
3.16 (1H, ddd, J 10.6, 4.4, 2.4 Hz, NCHH), 3.29 (1H, ddd, J 10.6, 6.0, 2.4 Hz, NCHH), 
3.42 (3H, s, 3-CH3), 3.43–3.47 (1H, m, OCHH), 3.56 (1H, ddd, J 8.8, 4.4, 2.4 Hz, NCHH), 
3.65–3.74 (2H, m, OCHH and 1’-HH), 3.77–3.84 (2H, m, OCH2), 3.97 (1H, dd, J 11.2, 6.4 
Hz, 1’-HH), 7.15–7.20 (1H, m, 6”-H), 7.22 (1H, td, J 7.7, 1.3 Hz, 4”-H), 7.38–7.42 (1H, m, 
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3”-H), 7.65 (1H, td, J 7.7, 1.3 Hz, 5”-H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 
27.1 (CH3), 28.3 (CH), 42.2 (CH2), 47.0 (CH2), 56.4 (CH2), 66.2 (CH2), 66.3 (CH2), 113.1 
(C), 116.0 (d, 
2
JCF 22.7 Hz, CH), 118.7 (d, 
2
JCF 14.5 Hz, C), 123.2 (C), 124.9 (d, 
4
JCF 3.8 
Hz, CH), 131.2 (d, 
3
JCF 8.3 Hz, CH), 131.5 (C), 131.5 (d, 
3
JCF 9.3 Hz, CH), 150.8 (C), 
154.2 (C), 157.6 (C), 159.4 (d, 
1
JCF 252.8 Hz, C), 163.6 (C); m/z (EI) 445.1490 (M
+
. 
C22H24FN3O4S requires 445.1472). 
1-Isobutyl-6-(4”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-morpholinecarboxamide (90) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 6-(4”-methoxyphenyl)-1-isobutyl-3-methyl-
2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (82) (0.20 g, 0.48 
mmol) and morpholine (0.21 mL, 2.4 mmol). This gave 1-isobutyl-6-(4”-methoxyphenyl)-
3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-
morpholinecarboxamide (90) (0.11 g, 48%) as a colourless oil. νmax (neat)/cm
−1
 2961 (CH), 
1738 (CO), 1703 (CO), 1659 (CO), 1535 (C=C), 1485, 1252, 1113, 729; δH (400 MHz, 
CDCl3) 1.02 (6H, d, J 6.8 Hz, CH(CH3)2), 2.29–2.41 (1H, m, 2’-H), 3.00 (1H, ddd, J 10.8, 
7.2, 2.8 Hz, NCHH), 3.12 (1H, ddd, J 13.2, 5.2, 2.8 Hz, NCHH), 3.26 (1H, ddd, J 13.2, 7.6, 
3.2 Hz, NCHH), 3.40 (3H, s, 3-CH3), 3.47–3.54 (2H, m, NCHH and OCHH), 3.67 (1H, dd, 
J 14.2, 7.6 Hz, 1’-HH), 3.72–3.90 (6H, m, OCHH, OCH2 and 4”-OCH3), 3.94 (1H, dd, J 
14.2, 7.6 Hz, 1’-HH), 6.93 (2H, d, J 8.8 Hz, 3”-H and 5”-H), 7.46 (2H, d, J 8.8 Hz, 2”-H 
and 6”-H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 27.1 (CH3), 28.3 (CH), 42.2 
(CH2), 47.0 (CH2), 55.4 (CH3), 56.4 (CH2), 66.2 (CH2), 66.3 (CH2), 113.9 (C), 114.6 (2 × 
CH), 123.6 (C), 127.6 (C), 129.2 (2 × CH), 130.5 (C), 150.7 (C), 152.4 (C), 157.6 (C), 
160.3 (C), 164.3 (C); m/z (ESI) 480.1546 (MNa
+
. C23H27N3NaO5S requires 480.1564). 
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1-Isobutyl-6-(2”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-morpholinecarboxamide (91) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 1-isobutyl-6-(2’’-methoxyphenyl)-3-methyl-
2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (83) (0.18 g, 0.44 
mmol) and morpholine (0.19 mL, 2.2 mmol). This gave 1-isobutyl-6-(2”-methoxyphenyl)-
3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-
morpholinecarboxamide (91) (0.082 g, 41%) as a colourless oil. νmax (neat)/cm
−1
 2961 
(CH), 1705 (CO), 1661 (CO), 1532 (C=C), 1489, 1256, 1113, 731; δH (400 MHz, CDCl3) 
1.02 (3H, d, J 6.7 Hz, CH(CH3)2), 2.28–2.42 (1H, m, 2’-H), 2.84 (1H, ddd, J 10.4, 7.6, 2.8 
Hz, NCHH), 3.15 (1H, ddd, J 13.2, 5.2, 3.2 Hz, NCHH), 3.26 (1H, ddd, J 13.2, 6.4, 2.8 Hz, 
NCHH), 3.36 (1H, ddd, J 10.4, 7.6, 2.8 Hz, NCHH), 3.40 (3H, s, 3-CH3), 3.48 (1H, ddd, J 
11.4, 7.6, 2.8 Hz, OCHH), 3.59–3.67 (2H, m, OCHH and 1’-HH), 3.76 (1H, ddd, J 11.4, 
6.4, 3.2 Hz, OCHH), 3.81–3.87 (4H, m, OCHH and 2”-OCH3), 4.01 (1H, dd, J 14.0, 8.0 
Hz, 1’-HH), 6.97 (1H, br d, J 7.9 Hz, 3”-H), 7.01 (1H, td, J 7.9, 1.4 Hz, 5”-H), 7.38 (1H, td, 
J 7.9, 1.4 Hz, 4”-H), 7.58 (1H, dd, J 7.9, 1.4 Hz, 6”-H); δC (101 MHz, CDCl3) 20.0 (CH3), 
20.2 (CH3), 27.1 (CH3), 28.2 (CH), 42.2 (CH2), 47.0 (CH2), 55.6 (CH3), 56.1 (CH2), 66.3 
(CH2), 66.3 (CH2), 111.0 (CH), 112.7 (C), 119.7 (C), 121.3 (CH), 126.7 (C), 130.1 (C), 
130.8 (CH), 131.4 (CH), 150.9 (C), 154.1 (C), 156.2 (C), 157.7 (C), 164.1 (C); m/z (ESI) 
480.1544 (MNa
+
. C23H27N3NaO5S requires 480.1564). 
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6-(4”-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-diethylcarboxamide (92) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 6-(4”-fluorophenyl)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (80) (0.12 g, 0.30 mmol) 
and diethylamine (0.16 mL, 1.5 mmol). This gave 6-(4”-fluorophenyl)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-diethylcarboxamide (92) 
(0.040 g, 31%) as a colourless oil. νmax (neat)/cm
−1
 2963 (CH), 1707 (CO), 1665 (CO), 
1636 (CO), 1533 (C=C), 1487, 1294, 1238, 841; δH (400 MHz, CDCl3) 0.80 (3H, t, J 7.2 
Hz, NCH2CH3), 1.02 (3H, d, J 6.4 Hz, CH(CH3)), 1.03 (3H, d, J 6.8 Hz, CH(CH3)), 1.21 
(3H, t, J 7.2 Hz, NCH2CH3), 2.30–2.41 (1H, m, 2’-H), 3.03–3.14 (2H, m, NCH2CH3) 3.40 
(3H, s, 3-CH3), 3.43–3.52 (1H, m, NCHHCH3), 3.60–3.71 (2H, m, NCHHCH3 and 1’-HH), 
3.96 (1H, dd, J 14.0, 7.6 Hz, 1’-HH), 7.06–7.10 (2H, m, 2”-H and 6”-H), 7.54–7.58 (2H, m, 
3”-H and 5”-H); δC (101 MHz, CDCl3) 12.2 (CH3), 13.5 (CH3), 20.0 (CH3), 20.1 (CH3), 
27.1 (CH3), 28.3 (CH), 39.2 (CH2), 43.0 (CH2) 56.4 (CH2), 114.0 (C), 116.1 (d, 
2
JCF 21.6 
Hz, 2 × CH), 127.8 (d, 
4
JCF 3.8 Hz, C), 128.4 (C), 129.8 (d, 
3
JCF 9.8 Hz, 2 × CH), 130.3 (C), 
150.8 (C), 152.7 (C), 157.6 (C), 162.8 (d, 
1
JCF 250.7 Hz, C), 164.7 (C); m/z (ESI) 454.1560 
(MNa
+
. C22H26FN3NaO3S requires 454.1571). 
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6-(2”-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-diethylcarboxamide (93) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 6-(2”-fluorophenyl)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (81) (0.178 g, 0.440 mmol) 
and diethylamine (0.228 mL, 2.20 mmol). This gave 6-(2”-fluorophenyl)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-diethylcarboxamide (93) 
(0.0710 g, 38%) as a colourless oil. νmax (neat)/cm
−1
 2961 (CH), 1707 (CO), 1663 (CO), 
1643 (CO), 1533 (C=C), 1485, 1227, 1113, 839; δH (400 MHz, CDCl3) 0.82 (3H, t, J 7.2 
Hz, NCH2CH3), 1.02 (3H, d, J 6.8 Hz, CH(CH3)), 1.03 (3H, d, J 6.4 Hz, CH(CH3)), 1.14 
(3H, t, J 7.2 Hz, NCH2CH3), 2.32–2.40 (1H, m, 2’-H), 3.03–3.17 (2H, m, NCH2CH3), 
3.34–3.43 (4H, m, 3-CH3 and NCHHCH3), 3.59–3.70 (2H, m, NCHHCH3 and 1’-HH), 
4.00 (1H, dd, J 14.0, 8.0 Hz, 1’-HH), 7.11–7.20 (2H, m, 4”-H and 6”-H), 7.33–7.39 (1H, m, 
3”-H), 7.75 (1H, td, J 7.6, 1.6 Hz, 5”-H); δC (101 MHz, CDCl3) 12.2 (CH3), 13.4 (CH3), 
20.0 (CH3), 20.2 (CH3), 27.0 (CH3), 28.3 (CH), 39.0 (CH2), 43.0 (CH2), 56.3 (CH2), 113.1 
(C), 115.7 (d, 
2
JCF 21.7 Hz, CH), 119.1 (d, 
2
JCF 15.1 Hz, C), 122.3 (C), 124.7 (d, 
4
JCF 3.9 
Hz, CH), 130.7 (d, 
3
JCF 8.4 Hz, CH), 131.7 (d, 
3
JCF 9.8 Hz, CH), 132.7 (C), 150.9 (C), 
154.1 (C), 157.6 (C), 158.9 (d, 
1
JCF 251.9 Hz, C), 164.5 (C); m/z (ESI) 454.1558 (MNa
+
. 
C22H26FN3NaO3S requires 454.1571). 
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1-Isobutyl-6-(4’’-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-diethylcarboxamide (94) 
 
The reaction was carried out according to the previously described procedure for 6-(2”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
(N-methoxy-N-methyl)carboxamide (88) using ethyl 1-isobutyl-6-(4”-methoxyphenyl)-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (82) (0.083 g, 
0.20 mmol). This gave 1-isobutyl-6-(4”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-N-diethylcarboxamide (94) (0.026 g, 34%) as a green 
oil. νmax (neat)/cm
−1
 2963 (CH), 1778 (CO), 1705 (CO), 1665 (CO), 1439, 1294, 1254, 
1182; δH (400 MHz, CDCl3) 0.81 (3H, t, J 7.2 Hz, NCH2CH3), 1.01 (3H, d, J 6.8 Hz, 
CH(CH3)), 1.02 (3H, d, J 6.8 Hz, CH(CH3)), 1.20 (3H, t, J 7.2 Hz, NCH2CH3), 2.32–2.39 
(1H, m, 2’-H), 3.02–3.14 (2H, m, NCH2CH3), 3.40 (3H, s, 3-CH3), 3.48 (1H, dt, J 13.6, 7.2 
Hz, NCHHCH3),  3.61–3.70 (2H, m, NCHHCH3 and 1’-HH), 3.82 (3H, s, 4”-OCH3), 3.96 
(1H, dd, J 14.0, 8.0 Hz, 1’-HH), 6.89 (2H, d, J 8.9 Hz, 3”-H and 5”-H), 7.49 (2H, d, J 8.9 
Hz, 2”-H and 6”-H); δC (101 MHz, CDCl3) 12.3 (CH3), 13.5 (CH3), 20.1 (CH3), 20.2 (CH3), 
27.1 (CH3), 28.3 (CH), 39.2 (CH2), 43.0 (CH2), 55.3 (CH3), 56.3 (CH2), 114.0 (C), 114.4 
(2 × CH), 124.1 (C), 129.0 (C), 129.2 (2 × CH), 129.7 (C), 150.9 (C), 152.3 (C), 157.6 (C), 
160.0 (C), 165.0 (C); m/z (ESI) 466.1764 (MNa
+
. C23H29N3NaO4S requires 466.1771). 
1-Isobutyl-6-(2”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-N-diethylcarboxamide (95) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 1-isobutyl-6-(2”-methoxyphenyl)-3-methyl-
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2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (83) (0.182 g, 0.440 
mmol) and diethylamine (0.227 mL, 2.20 mmol). This gave 1-isobutyl-6-(2”-
methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-
diethylcarboxamide (95) as a colourless oil (0.0680 g, 32%). νmax (neat)/cm
−1
 2963 (CH), 
1705 (CO), 1661 (CO), 1634 (CO), 1487, 1251, 1020, 750; δH (400 MHz, CDCl3) 0.78 (3H, 
t, J 7.2 Hz, NCH2CH3), 1.01 (3H, d, J 6.8 Hz, CH(CH3)), 1.02 (3H, d, J 6.8 Hz, CH(CH3)), 
1.11 (3H, t, J 7.2 Hz, NCH2CH3), 2.30–2.41 (1H, m, 2’-H), 3.00–3.19 (2H, m, NCH2CH3), 
3.31–3.43 (4H, m, 3-CH3 and NCHHCH3), 3.59–3.68 (2H, m, NCHHCH3 and 1’-HH), 
3.88 (3H, s, 2”-OCH3), 4.03 (1H, dd, J 14.0, 8.0 Hz, 1’-HH), 6.92–6.99 (2H, m, 3”-H and 
5”-H), 7.33 (1H, td, J 7.8, 1.6 Hz, 4”-H), 7.68 (1H, dd, J 7.8, 1.6 Hz, 6”-H); δC (101 MHz, 
CDCl3) 12.2 (CH3), 13.4 (CH3), 20.0 (CH3), 20.2 (CH3) 27.1 (CH3), 28.2 (CH), 39.0 (CH2), 
42.9 (CH3) 55.6 (CH2), 56.1 (CH2), 110.8 (CH), 112.7 (C), 120.1 (C), 121.1 (CH), 125.7 
(C), 130.3 (CH), 131.5 (CH and C), 151.0 (C), 154.0 (C), 156.0 (C), 157.7 (C), 165.0 (C); 
m/z (EI) 443.1867 (M
+
.C23H29N3O4S requires 443.1879), 371 (28%), 344 (8), 315 (19), 
230 (9), 155 (7), 117 (9), 105 (12), 84 (82), 72 (100). 
6-(4”-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (96) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 6-(4”-fluorophenyl)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (80) (0.080 g, 0.20 mmol) 
and a combination of N,O-dimethylhydroxylamine hydrochloride (0.064 g, 0.66 mmol) and 
N,N’-diisopropylethylamine (0.23 mL, 1.3 mmol). This gave 6-(4”-fluorophenyl)-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-
methyl)carboxamide (96) as a viscous yellow oil (0.040 g, 38%). νmax (neat)/cm
−1 
2959 
(CH), 1707 (CO), 1662 (CO), 1535, 1486, 1390, 991, 773; The compound exists as a 3:1 
mixture of rotamers. Data for the major rotamer: δH (400 MHz, CDCl3) 1.02 (6H, d, J 6.8 
Hz, CH(CH3)2), 2.31–2.42 (1H, m, 2’-H), 3.35 (3H, s, NCH3), 3.36 (3H, s, OCH3), 3.41 
(3H, s, 3-CH3), 3.68 (1H, dd, J 14.1, 7.7 Hz, 1’-HH), 3.95 (1H, dd, J 14.1, 7.7 Hz, 1’-HH), 
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7.10 (2H, t, J 8.8 Hz, 2”-H and 6”-H), 7.57 (2H, dd, J 8.8, 5.2 Hz, 3”-H and 5”-H); δC (101 
MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 27.1 (CH3), 28.3 (CH), 33.1 (CH3), 56.5 (CH2), 61.5 
(CH3), 114.4 (C), 116.3 (d, 
2
JCF 22.2 Hz, 2 × CH), 127.7 (d, 
4
JCF 3.1 Hz, C), 128.7 (C), 
129.2 (C), 129.8 (d, 
3
JCF 8.4 Hz, 2 × CH), 150.8 (C), 152.1 (C), 157.8 (C), 162.9 (d, 
1
JCF 
248.9 Hz, C), 166.4 (C); m/z (ESI) 442.1191 (MNa
+
. C20H22FN3NaO4S requires 442.1207). 
6-(2’’-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (97) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 6-(2”-fluorophenyl)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (81) (0.070 g, 0.17 mmol) 
and a combination of N,O-dimethylhydroxylamine hydrochloride (0.017 g, 0.18 mmol) and 
N,N’-diisopropylethylamine (0.080 mL, 0.48 mmol). This gave 6-(2”-fluorophenyl)-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-
methyl)carboxamide (97) as a viscous yellow oil (0.038 g, 57%). νmax (neat)/cm
−1
  2970 
(CH), 1740 (CO), 1728 (CO), 1663 (CO), 1533 (C=C), 1366, 1217, 1119, 991; The 
compound exists as a 3:1 mixture of rotamers. Data for the major rotamer: δH (400 MHz, 
CDCl3) 1.02 (6H, d, J 6.7 Hz, CH(CH3)2), 2.31–2.41 (1H, m, 2’-H), 3.32 (3H, s, NCH3), 
3.37 (3H, s, OCH3), 3.42 (3H, s, 3-CH3), 3.68 (1H, dd, J 14.1, 7.5 Hz, 1’-HH), 3.97 (1H, 
dd, J 14.1, 7.5 Hz, 1’-HH), 7.13–7.22 (2H, m, 4”-H and 6”-H), 7.33–7.41 (1H, m, 3”-H), 
7.72 (1H, td, J 8.0, 1.6 Hz, 5”-H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 27.0 
(CH3), 28.3 (CH), 33.1 (CH3), 56.3 (CH2), 61.4 (CH3), 113.5 (C), 115.9 (d, 
2
JCF 21.8 Hz, 
CH), 119.2 (d, 
2
JCF 14.0 Hz, C), 123.2 (C), 124.8 (d, 
3
JCF 3.5 Hz, CH), 130.8 (d, 
3
JCF 9.0 
Hz, CH), 131.1 (C), 131.5 (d, 
2
JCF 2.8 Hz, CH), 150.7 (C), 153.4 (C), 157.7 (C), 159.3 (d, 
1
JCF 250.4 Hz, C), 166.1 (C);  m/z (ESI) 442.1191 (MNa
+
. C20H22FN3NaO4S requires 
442.1207). 
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1-Isobutyl-6-(4”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (98) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 1-isobutyl-6-(4”-methoxyphenyl)-3-methyl-
2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (82) (0.296 g, 0.710 
mmol) and a combination of N,O-dimethylhydroxylamine hydrochloride (0.227 g, 2.32 
mmol) and N,N’-diisopropylethylamine (0.930 mL, 4.64 mmol). This gave 1-isobutyl-6-
(4”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(N-
methoxy-N-methyl)carboxamide (98) as a viscous yellow oil (0.102 g, 51%). νmax 
(neat)/cm
−1 
2961 (CH), 1705 (CO), 1657 (CO), 1537, 1485, 1254, 1180, 733; The 
compound exists as a 3:1 mixture of rotamers. Data for the major rotamer: δH (400 MHz, 
CDCl3) 1.02 (3H, d, J 6.0 Hz, CH(CH3)2), 2.29–2.42 (1H, m, 2’-H), 3.35 (3H, s, NCH3), 
3.37 (3H, s, OCH3), 3.41 (3H, s, 3-CH3), 3.68 (1H, dd, J 14.1, 7.5 Hz, 1’-HH), 3.83 (3H, s, 
4”-OCH3), 3.95 (1H, dd, J 14.1, 7.5 Hz, 1’-HH), 6.92 (2H, d, J 8.8 Hz, 3”-H and 5”-H), 
7.52 (2H, d, J 8.8 Hz, 2”-H and 6”-H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 27.1 
(CH3), 28.3 (CH), 33.2 (CH3), 55.4 (CH3), 56.4 (CH2), 61.5 (CH3), 114.4 (C), 114.6 (2 × 
CH), 124.0 (C), 127.5 (C), 129.2 (2 × CH), 130.5 (C), 150.8 (C), 151.7 (C), 157.9 (C), 
160.0 (C), 166.8 (C); m/z (ESI) 454.1393 (MNa
+
. C21H25N3NaO5S requires 454.1407) 
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1-Isobutyl-6-(2”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (99) 
 
The reaction was carried out according to the previously described procedure for 6-(4”-
fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
N-morpholinecarboxamide (88) using ethyl 1-isobutyl-6-(2”-methoxyphenyl)-3-methyl-
2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (83) (0.119 g, 0.29 
mmol) and a combination of N,O-dimethylhydroxylamine hydrochloride (0.0933 g, 0.960 
mmol) and N,N’-diisopropylethylamine (0.334 mL, 1.92 mmol). This gave 1-isobutyl-6-
(2”-methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(N-
methoxy-N-methyl)carboxamide (99) (0.070 g, 56%). νmax (neat)/cm
−1 
2961 (CH), 1703 
(CO), 1657 (CO), 1533 (C=C), 1489, 1252, 1123, 991, 729; The compound exists as a 3:1 
mixture of rotamers. Data for the major rotamer: δH (400 MHz, CDCl3) 1.01 (6H, d, J 6.8 
Hz, CH(CH3)2), 2.29–2.41 (1H, m, 2’-H), 3.31 (3H, s, NCH3), 3.34 (3H, s, OCH3),  3.41 
(3H, s, 3-CH3), 3.64 (1H, dd, J 14.1, 7.7 Hz, 1’-HH), 3.87 (3H, s, 2”-OCH3), 4.00 (1H, dd, 
J 14.1, 7.7 Hz, 1’-HH), 6.95 (1H, d, J 7.8 Hz, 3”-H), 7.00 (1H, t, J 7.8 Hz, 5”-H), 7.34 (1H, 
td, J 7.8, 1.6 Hz, 4”-H), 7.66 (1H, dd, J 7.8, 1.6 Hz, 6”-H); δC (101 MHz, CDCl3), 20.0 
(CH3), 20.2 (CH3), 27.1 (CH3), 28.2 (CH), 33.1 (CH3), 55.6 (CH2), 56.1 (CH3), 61.3 (CH3), 
111.1 (CH), 113.0 (C), 120.3 (C), 121.2 (CH), 128.1 (C), 129.9 (C), 130.3 (CH), 131.2 
(CH), 151.0 (C), 153.3 (C), 156.1 (C), 157.8 (C), 166.8 (C); m/z (ESI) 454.1389 (MNa
+
. 
C21H25N3NaO5S requires 454.1407). 
Methyl 3-bromo-2-oxobutanoate (102)
66
 
 
Bromine solution (0.500 mL, 9.50 mmol) was added dropwise to neat methyl 2-
oxobutanoate (101) (1.10 mL, 9.50 mmol) at 0 °C. The mixture was warmed to room 
temperature and stirred for 1 h. An aqueous saturated solution of sodium bicarbonate (20 
mL) was added and the mixture was extracted with ethyl acetate (3 × 20 mL). The organic 
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layers were combined and washed with an aqueous solution of 1 M sodium thiosulfate (30 
mL) and brine (30 mL). The organic layer was dried (MgSO4), filtered and concentrated in 
vacuo to give methyl 3-bromo-2-oxobutanoate (102) as a colourless liquid (1.85 g, 100%). 
Spectroscopic data were consistent with the literature.
66
 δH (400 MHz, CDCl3) 1.82 (3H, d, 
J 6.7 Hz, CHCH3), 3.93 (3H, s, OCH3), 5.17 (1H, q, J 6.7 Hz, CHCH3); δC (101 MHz, 
CDCl3) 18.4 (CH3), 42.3 (CH), 53.4 (CH3), 161.0 (C), 185.7 (C). 
Methyl 3,6-dimethyl-1-isobutyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-
5-carboxylate (103)
61
 
 
Methyl-3-bromo-2-oxobutanoate (102) (0.650 g, 3.36 mmol) was added to a solution of 1-
isobutyl-6-mercapto-3-methyl-2,4-(1H,3H)-pyrimidinedione (52) (0.600 g, 2.80 mmol) in 
methanol (20 mL) and stirred at room temperature for 12 h. The reaction mixture was 
concentrated in vacuo to give the crude product. Purification by flash column 
chromatography eluting with 20% ethyl acetate in petroleum ether gave methyl 3,6-
dimethyl-1-isobutyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate 
(103) as viscous yellow oil (0.322 g, 37%). Spectroscopic data were consistent with the 
literature.
61
 δH (400 MHz, CDCl3) 0.98 (6H, d, J 6.6 Hz, CH(CH3)2), 2.26–2.32 (1H, m, 2’-
H), 2.45 (3H, s, 6-CH3), 3.39 (3H, s, 3-CH3), 3.75 (2H, d, J 7.6 Hz, 1-H2), 3.96 (3H, s, 
OCH3); δC (101 MHz, CDCl3) 13.4 (CH3), 20.0 (2 × CH3), 27.1 (CH3), 28.3 (CH), 52.5 
(CH3), 56.3 (CH2), 113.0 (C), 127.6 (C), 131.7 (C), 150.8 (C), 151.4 (C), 157.2 (C), 164.7 
(C); m/z (ESI) 333 (MNa
+
. 100%). 
Methyl 6-(bromomethyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (104)
61
 
 
Methyl 3,6-dimethyl-1-isobutyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (103) (1.20 g, 3.87 mmol), N-bromosuccinimide (0.760 g, 4.25 mmol) and 
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azobisisobutyronitrile (0.0450 g, 0.270 mmol) were dissolved in ethyl acetate (70 mL) and 
stirred under reflux for 24 h. The solution was cooled to room temperature and washed 
with an aqueous solution of 0.5 M sodium hydroxide (35 mL). The organic layer was 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by flash 
column chromatography eluting with 80% ethyl acetate in petroleum ether gave methyl 6-
(bromomethyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-
5-carboxylate (104) as a colourless oil (0.865 g, 57%). Spectroscopic data were consistent 
with the literature.
61
 δH (400 MHz, CDCl3) 1.00 (6H, d, J 6.7 Hz, CH(CH3)2), 2.26–2.36 
(1H, m, 2’-H), 3.39 (3H, s, 3-CH3), 3.78 (2H, d J 7.7 Hz, 1’-H2), 4.00 (3H, s, OCH3), 4.67 
(2H, s, 6-CH2); δC (101 MHz, CDCl3) 20.0 (2 × CH3), 23.2 (CH2), 27.0 (CH3), 28.4 (CH), 
53.1 (CH3), 56.5 (CH2), 112.7 (C), 130.0 (C), 132.2 (C), 150.1 (C), 153.3 (C), 157.0 (C), 
163.6 (C); m/z (ESI) 411 (MNa
+
, 100%). 
Methyl 6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (105)
61
 
 
4,5-Dichloro-2-methylimidazole (0.0370 g, 0.240 mmol) in a solution of tetrahydrofuran (2 
mL) was added dropwise to a suspension of sodium hydride (0.0100 g, 0.240 mmol) in 
tetrahydrofuran (2 mL) and stirred for 0.25 h. Methyl 6-(bromomethyl)-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (104) (0.087 g, 
0.22 mmol) was then added dropwise as a solution in tetrahydrofuran (2 mL) and the 
mixture stirred under argon at room temperature for 3 h. The resulting mixture was diluted 
with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The organic layers were 
combined, dried (MgSO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography eluting with 50 % ethyl acetate in petroleum ether gave methyl 6-[(4,5-
dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (105) as a white solid (0.0680 g, 67%). 
Mp 175–178 °C; Spectroscopic data were consistent with the literature.61 δH (400 MHz, 
CDCl3) 0.97 (6H, d, J 6.7 Hz, CH(CH3)2), 2.19–2.30 (1H, m, 2’-H), 2.38 (3H, s, 2’’-CH3), 
3.40 (3H, s, 3-CH3), 3.73 (2H, d, J 7.8 Hz, 1’-H2), 4.00 (3H, s, OCH3), 5.26 (2H, s, 6-CH2); 
δC (101 MHz, CDCl3) 13.9 (CH3), 19.9 (2 × CH3), 27.0 (CH3), 28.5 (CH), 41.6 (CH2), 53.2 
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(CH3), 56.5 (CH2), 111.8 (C), 112.7 (C), 125.3 (C), 129.1 (C), 129.9 (C), 143.3 (C), 150.5 
(C), 153.1 (C), 157.0 (C), 163.7 (C); m/z (ESI) 481 (MNa
+
, 100%) 
6-[(4,5-Dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1-isobutyl-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno-[2,3-d]pyrimidine-5(-N-methoxy-N-methyl)-carboxamide 
(100)
61
 
 
The reaction was carried out according to the previously described procedure for 6-(4’’-
iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
(N-methoxy-N-methyl)carboxamide (75) using methyl 6-[(4,5-dichloro-2-methyl-1H-
imidazol-1-yl)methyl]-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (105) (0.030 g, 0.07 mmol). This gave 6-[(4,5-dichloro-2-
methyl-1H-imidazol-1-yl)methyl]-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno-
[2,3-d]pyrimidine-5(-N-methoxy-N-methyl)-carboxamide (100) as a yellow oil (0.013 g, 
38%). Spectroscopic data were consistent with the literature.
61
 The compound exists as a 
3:1 mixture of rotamers. Data for the major rotamer: δH (400 MHz, CDCl3) 0.96 (3H, d, J 
6.7 Hz, CHCH3), 0.97 (3H, d, J 6.7 Hz, CHCH3), 2.21–2.29 (1H, m, 2’-H), 2.39 (3H, s, 
2’’-H), 3.38 (3H, s, NCH3), 3.42 (3H, s, 3-CH3), 3.48 (3H, s, OCH3), 3.62 (1H, dd, J 14.1, 
7.8 Hz, 1’-HH), 3.82 (1H, dd, J 14.1, 7.8 Hz, 1’-HH), 5.11 (1H, d, J 16.8 Hz, 6-CHH), 
5.20 (1H, d, J 16.8 Hz, 6-CHH); δC (101 MHz, CDCl3) 19.9 (CH3), 20.1 (CH3), 27.0 (CH3), 
28.4 (CH), 30.9 (CH3), 32.8 (CH3), 41.6 (CH2), 56.2 (CH2), 61.6 (CH3), 112.0 (C), 113.2 
(C), 124.8 (C), 125.5 (C), 131.3 (C), 143.7 (C), 150.6 (C), 152.7 (C), 157.4 (C), 164.2 (C); 
m/z (ESI) 510 (MNa
+
, 100%). 
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Methyl (4’S)-2-(4’-hydroxyisoxazolidine-2-carbonyl)benzoate (108)73 
 
Triethylamine (0.050 mL, 0.35 mmol) was added to a solution of N-hydroxyphthalimide 
(107) (0.47 g, 2.88 mmol) and (4R)-epichlorohydrin (0.40 mL, 4.32 mmol) in anhydrous 
1,4-dioxane (15 mL) and the mixture was stirred under argon at 50 °C for 48 h. 
Triethylamine (0.80 mL, 2.88 mmol) and methanol (15 mL) were added to the mixture and 
stirring continued at 50 °C for a further 2 h. The mixture was concentrated in vacuo to give 
the crude product. Purification by flash column chromatography eluting with 60% ethyl 
acetate in petroleum ether gave methyl (4S)-2-(4’-hydroxyisoxazolidine-2-
carbonyl)benzoate (108) as a yellow oil (0.39 g, 54%). [α]D
24
 -31.1 (c 1.0, CHCl3); 
Spectroscopic data was consistent with the literature.
73
 δH (400 MHz, CDCl3) 3.84–3.91 
(4H, m, OCH3 and 5’-HH), 3.98 (2H, d, J 8.7 Hz, 3’-H2), 4.13–4.21 (1H, m, 5’-HH), 4.73–
4.81 (1H, m, 4’-H), 7.45 (1H, d, J 7.5 Hz, 3-H), 7.48 (1H, t, J 7.5 Hz, 4-H), 7.61 (1H, t, J 
7.5 Hz, 5-H), 7.99 (1H, d, J 7.5 Hz, 6-H); δC (101 MHz, CDCl3) 52.8 (CH3), 53.6 (CH2), 
73.1 (CH), 77.1 (CH2), 127.0 (C), 128.0 (CH), 129.3 (CH), 129.9 (CH), 132.9 (CH), 137.5 
(C), 167.0 (C), 170.9 (C); m/z (ESI) 274 (MNa
+
. 100%).  
(4S)-Hydroxyisoxazolidine hydrochloride (109)
73 
 
A solution of methyl (4’S)-2-(4’-hydroxyisoxazolidine-2-carbonyl)benzoate (108) (0.400 g, 
1.59 mmol) in 4 M hydrochloric acid (10 mL) was heated under reflux for 3 h. The 
resulting mixture was filtered and the filtrate concentrated in vacuo. The residue was 
recrystallised from propan-2-ol to give (4S)-hydroxyisoxazolidine hydrochloride (109) as a 
pink solid (0.140 g, 68%). Mp 152−155 °C; [α]D
24
 + 13.8 (c 1.0, MeOH); Spectroscopic 
data was consistent with the literature.
73
 δH (400 MHz, DMSO-d6) 3.37 (1H, d, J 11.4 Hz, 
5-HH), 3.49 (1H, dd, J 11.4, 4.6 Hz, 5-HH), 4.04 (1H, dd, J 8.6, 3.5 Hz, 3-HH), 4.09 (1H, 
d, J 8.6 Hz, 3-HH), 4.79–4.81 (1H, m, 4-H), 5.83 (1H, br s, OH), 12.39 (2H, br s, NH2); δC 
(101 MHz, DMSO-d6) 54.0 (CH2), 71.9 (CH), 78.0 (CH2); m/z (CI) 90 (MH
+
. 100%), 79 
(10), 113 (5). 
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(4’’S)-6-(4’’’-fluorophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-(4’’-hydroxyisoxazolidine)-carboxamide (112) 
 
The reaction was carried out according to the previously described procedure for ethyl 6-
(4’’-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (75) using ethyl 6-(4’’-
fluorophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-
5-carboxylate (71) (0.13 g, 0.34 mmol) and (4S)-hydroxyisoxazolidine hydrochloride (109) 
(0.051 g, 0.41 mmol). This gave (4’’S)-6-(4’’’-fluorophenoxy)-1-isobutyl-3-methyl-2,4-
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(4’’-hydroxyisoxazolidine)-
carboxamide (112) as an orange oil (0.062 g, 40%). νmax (neat)/cm
−1
 3435 (OH), 2961 (CH), 
1705 (CO), 1655 (CO), 1551 (C=C), 1466, 1180, 747; [α]D
24 
-12.4 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 0.97 (6H, d, J 6.7 Hz, CH(CH3)2), 2.23–2.29 (1H, m, 2’-H), 3.40 (3H, s, 3-
CH3), 3.50 (1H, dd, J 12.0, 4.3 Hz, 5’’-HH), 3.63 (1H, dd, J 14.2, 7.6 Hz, 1’-HH), 3.80 
(1H, dd, J 14.2, 7.6 Hz, 1’-HH), 4.04 (1H, d, J 8.8 Hz, 3’’-HH), 4.10 (1H, dd, J 8.8, 4.0 Hz, 
3’’-HH), 4.52 (1H, d, J 12.0 Hz, 5’’-HH), 4.68–4.71 (1H, m, 4’’-H), 4.91 (1H, d, J 12.0 Hz, 
OH), 7.03 (2H, t, J 8.8 Hz, 3’’’-H and 5’’’-H ), 7.17 (2H, dd, J 8.8, 4.2 Hz, 2’’’-H and 6’’’-
H); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 27.1 (CH3), 28.6 (CH), 54.0 (CH2), 56.6 
(CH2), 73.1 (CH), 77.4 (CH2), 109.0 (C), 116.5 (d, 
2
JCF 23.0 Hz, 2 × CH), 119.0 (C), 119.1 
(d, 
3
JCF 9.5 Hz, 2 × CH), 147.1 (C), 148.6 (C), 150.5 (C), 154.2 (d, 
4
JCF 2.8 Hz, C), 158.5 
(C), 160.8 (d, 
1
JCF 244.3 Hz, C), 161.9 (C); m/z (ESI) 486.1109 (MNa
+
. C21H22FN3NaO6S 
requires 486.1106). 
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Methyl 6-[(4’’-fluoro-1H-indol-3’-yl)methyl]-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (113) 
 
Methyl 6-(bromomethyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (104) (0.10 g, 0.26 mmol) and 4-fluoroindole (0.053 g, 0.39 
mmol) were dissolved in chloroform (2 mL) and water (2 mL). Sodium bicarbonate (0.066 
g, 0.78 mmol) was added and the reaction mixture stirred for 72 h at room temperature. 
The solution was diluted with water (10 mL) and extracted with dichloromethane (3 × 10 
mL). The organic layers were combined, dried (MgSO4), filtered and concentrated in 
vacuo. Purification by flash column chromatography eluting with 50% ethyl acetate in 
petroleum ether gave methyl 6-[(4’’-fluoro-1H-indol-3’-yl)methyl]-1-isobutyl-3-methyl-
2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (113) as a viscous 
yellow oil (0.035 g, 30%). νmax (neat)/cm
−1 
3204 (NH), 2962 (CH), 1707 (CO), 1663 (CO), 
1486, 1282, 1141, 1016; δH (400 MHz, CDCl3) 0.91 (6H, d, J 6.7 Hz, CH(CH3)2), 2.18–
2.25 (1H, m, 2’-H), 3.38 (3H, s, 3-CH3), 3.67 (2H, d, J 7.7 Hz, 1’-H2), 3.94 (3H, s, OCH3), 
4.38 (2H, s, 6-CH2), 6.76 (1H, dd, J 11.0, 7.4 Hz, 5’’-H), 7.05 (1H, d, J 1.8 Hz, 2’’-H), 
7.08–7.15 (2H, m, 6’’-H and 7’’-H), 8.34 (1H, br s, NH); δC (101 MHz, CDCl3) 19.9 (2 × 
CH3), 25.1 (CH2), 26.9 (CH3), 28.3 (CH), 52.8 (CH3), 56.2 (CH2), 105.1 (d, 
2
JCF 19.2 Hz, 
CH), 107.5 (d, 
4
JCF 3.7 Hz, CH), 111.7 (d, 
3
JCF 3.3 Hz, C), 112.8 (C), 115.6 (d, 
2
JCF 19.8 
Hz, C), 123.0 (d, 
3
JCF 7.5 Hz, CH), 123.3 (d, 
4
JCF 1.1 Hz, CH), 126.5 (C), 138.0 (C), 139.0 
(d, 
3
JCF 10.7 Hz, C), 150.8 (C), 151.9 (C), 157.5 (C), 158.3 (d, 
1
JCF 249.0 Hz, C), 164.9 (C); 
m/z (ESI) 466.1202 (MNa
+
. C22H22FN3NaO4S requires 466.1207).  
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(4’’’S)-6-[(4’’-fluoro-1H-indol-3’’-yl)methyl]-5-(4’’’-hydroxyisoxazolidine-2-
carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (114) 
 
The reaction was carried out according to the previously described procedure for ethyl 6-
(4-iodophenoxy)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-(N-methoxy-N-methyl)carboxamide (75) using methyl 6-((4’’-fluoro-1H-
indol-3’-yl)methyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
d]pyrimidine-5-carboxylate (113) (0.041 g, 0.090 mmol) and (4S)-isoxazolidin-4-ol 
hydrochloride (109) (0.010 g, 0.080 mmol). This gave (4S)-6-((4''-fluoro-1H-indol-3''-
yl)methyl)-5-(4'''-hydroxyisoxazolidine-2-carbonyl)-1-isobutyl-3-methylthieno[2,3-
d]pyrimidine-2,4(1H,3H)-dione (114) as an orange oil (0.016 g, 41%). νmax (neat)/cm
−1 
 
3203 (NH/OH), 2924 (CH), 1635 (CO), 1431, 1267, 1005, 731; [α]D
24 
-40.4 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 0.92 (6H, d, J 6.7 Hz, CH(CH3)2), 2.20–2.28 (1H, m, 2’-H), 3.37 
(3H, s, 3-CH3), 3.52 (1H, dd,  J 12.1, 4.5 Hz, 5’’’-HH), 3.60 (1H, dd, J  14.1, 7.8 Hz, 1’-
HH), 3.78 (1H, dd, J 14.1, 7.8 Hz, 1’-HH), 4.00–4.02 (2H, m, 3’’’-H2), 4.36 (2H, s, 6-CH2), 
4.58 (1H, d, J 12.1 Hz, 5’’’-HH), 4.70 (1H, m, 4’’’-H), 5.07 (1H, d, J 12.1 Hz, OH), 6.76 
(1H, dd, J 10.8, 7.7 Hz, 5’’-H), 7.05–7.14 (3H, m, 2’’-H, 6’’-H and 7’’-H), 8.45 (1H, br s, 
NH); δC (101 MHz, CDCl3) 20.0 (CH3), 20.1 (CH3), 24.9 (CH2), 26.9 (CH3), 28.5 (CH), 
54.0 (CH2), 56.3 (CH2), 73.1 (CH), 76.7 (CH2), 104.8 (d, 
2
JCF 19.2 Hz, CH), 107.4 (d, 
4
JCF 
3.8 Hz, CH), 111.5 (d, 
3
JCF 3.3 Hz, C), 112.2 (C), 115.7 (d, 
2
JCF 20.0 Hz, C), 122.8 (d, 
3
JCF 
7.6 Hz, CH), 123.8 (CH), 127.6 (C), 135.7 (C), 138.8 (d, 
3
JCF 11.6 Hz, C), 150.5 (C), 152.5 
(C), 158.3 (d, 
1
JCF 248.9 Hz, C), 158.6 (C), 164.2 (C); m/z (ESI) 523.1411 (MNa
+
. 
C24H25FN4NaO5S requires 523.1422). 
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6.3 HPLC methods for physicochemical analysis
67
 
All physicochemical analyses were performed using a Dionex Ultimate 3000 series, and 
data acquisition and processing performed using Chromeleon 6.8 Chromatography 
software. Standard and test compounds were dissolved in 1:1 organic/aqueous phases, and 
prepared to a concentration of 0.5 mg/mL. The HPLC system was set to 25 °C, and UV 
detection achieved using a diode array detector (190–800 nm). Analysis was performed 
using 5 μL sample injections. 
C18 chromatography for determination of lipophilicity (LogP)
67
 
LogP values were determined using a Phenomenex Luna 5 micron C18 100 A (50 + 3 mm) 
column. The retention time for each compound of interest was measured using filtered 
acetonitrile and 0.01 mM phosphate buffered saline as the mobile phase at pH 7.4, pH 4.0 
and pH 10.0, and pH was adjusted by the addition of concentrated hydrochloric acid or 
0.05 M sodium hydroxide solution, respectively. The mobile phase flow rate was set at 1.0 
mL/min. The CHI value for all compounds of interest was determined by measuring the 
retention time of each compound under the following mobile phase conditions: 0–10.5 min, 
0–100% acetonitrile; 10.5–11.5 min, 100% acetonitrile; 11.5–12.0 min, 100–0% 
acetonitrile; 12.0–15.0 min, 0% acetonitrile. System calibration was achieved using the 
following compounds and plotting their mean CHI values against the measured retention 
time under all three pH conditions: theophylline (CHI = 15.76), phenyltetrazole (CHI = 
20.18), benzimidazole (CHI = 30.71), colchicine (CHI = 41.37), acetophenone (CHI = 
64.90), indole (CHI = 69.15), butyrophenone (CHI = 88.49) and valerophenone (CHI = 
97.67). Using the calibration curves obtained and the following equations from a validated 
study, the LogP of the compounds were calculated using Excel 2016 Software. 
CHI LogD = 0.054 CHI ˗ 1.467 
Where CHI Log D is the CHI value projected to the logarithmic scale 
LogP = 0.047CHIN + 0.36HBC ˗ 1.10 
Where CHIN is the gradient chromatographic hydrophobicity index of the nonionised 
compound and HBC is hydrogen bond donor count.  
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Immobilised Artificial Membrane (IAM) chromatography for determination of 
membrane permeability (Pm) and membrane partition coefficient (Km)
67
 
Pm and Km values were determined using previously developed methodology on a 
Registech IAM.PC.DD2 (15 cm × 4.6 mm) column. Acetonitrile and 0.01 mM phosphate 
buffered saline at pH 7.4 was used as the mobile phase, with a flow rate of 1.0 mL/min. 
The retention time of each compound was measured under an isocratic mobile phase with 
the percentage acetonitrile ranging from 30–70%. The retention time of citric acid, as an 
unretained compound, under an isocratic mobile phase of 100% phosphate buffered saline 
was used for system corrections. The following equations were used to calculate Pm and 
Km of the compounds of interest using Excel 2016 Software. 
kIAM = 
(tr ˗ t0)
t0
 
Where kIAM = solute capacity factor on the column, tr = compound retention time and t0 = 
unretained compound retention time. 
kIAM = (
Vs
Vm
) × Km 
Where Vs = volume of the IAM interphase created by the immobilised phospholipids, Vm = 
total volume of the solvent within the IAM column and Km = membrane partition 
coefficient. 
Vm= 
WPhC
∂PhC
+ 
WC10
∂C10
+ 
WC3
∂C3
 
Where the specific weight of PhC (∂PhC) = 1.01779 g/mL and C10/C3 (∂C10/C3) = 0.86 g/mL; 
WPhC = 133 mg, WC10 = 12.73 mg and WC3 = 2.28 mg. 
Vm = fr × t0  
Where fr = flow rate. 
Pm= 
Km
MW
  
Where Pm = permeability and MW = molecular weight. 
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Human Serum Albumin (HSA) chromatography for determination of percentage of 
plasma protein binding (%PPB)
67
 
%PPB values were determined using previously developed methodology on a ChromTech 
HSA 5 μm (3.0 × 50 mm) column. Isopropanol and 0.01 mM phosphate buffered saline at 
pH 7.4 was used as the mobile phase, with a flow rate of 1.8 mL/min. The retention time of 
each compound was measured under the following mobile phase conditions: 0–3 min, 0–
30% isopropanol; 3–10 min, 30% isopropanol; 10.5–11.0 min, 30–0% isopropanol; 11.0–
15.0 min, 0% isopropanol. System calibration was achieved using the following 
compounds and plotting %PPB values against their mean retention times: warfarin (%PPB 
= 98.0), nizatidine (%PPB = 35.0), bromazepam (%PPB = 60.0), carbamazepine (%PPB = 
75.0), nicardipine (%PPB = 95.0), ketoprofen (%PPB = 98.7), indomethacin (%PPB = 99.0) 
and diclofenac (%PPB = 99.8). For each standard compound, the literature %PPB value 
was converted to its corresponding Log k value, which when plotted against tr on the HSA 
column, afforded a line equation from which the Logk value of the unknown compounds 
could be extracted. The Logk values of the unknown compounds could then be converted 
to %PPB. Logk and subsequent %PPB calculations for the compounds of interest were 
performed using Excel 2016 Software. 
Log
k
= Log [
%PPB
101 ˗ %PPB
] 
 
%PPB= [
(101 ˗ 10logk)
(1 + 10logk)
] 
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6.4 PARP-1 experimental 
(±)-3-Dimethoxyphosphoryl-3H-2-benzofuran-1-one (134)
78
  
 
A solution of sodium methoxide (1.73 g, 32.0 mmol) in methanol (30 mL) was cooled to 
0 °C, and to this was added dimethyl phosphite (133) (2.70 mL, 30.0 mmol) dropwise. 2-
Carboxybenzaldehyde (132) (3.00 g, 20.0 mmol) was then added in portions to the reaction 
mixture, which was gradually warmed to ambient temperature and stirred for 2 h. 
Methanesulfonic acid (2.30 mL, 36.0 mmol) was added dropwise to the reaction mixture 
and a white suspension formed. The mixture was concentrated in vacuo and resuspended in 
water (30 mL). The crude product was extracted with dichloromethane (3 × 30 mL). The 
organic layers were combined, dried (MgSO4), filtered and concentrated in vacuo. 
Purification by trituration with diethyl ether gave (±)-3-dimethoxyphosphoryl-3H-2-
benzofuran-1-one (134) as a white solid (4.20 g, 87%). Mp 90–93 °C (lit.78  90−91 °C); δH 
(400 MHz, CD3OD) 3.72 (3H, d, J 11.2 Hz, OCH3), 3.91 (3H, d, J 11.2 Hz, OCH3), 6.10 
(1H, d, J 10.8 Hz, 3-H), 7.64–7.70 (1H, m, 5-H), 7.73–7.77 (1H, m, 4-H), 7.83 (1H, t, J 7.6 
Hz, 6-H), 7.94 (1H, dd, J 7.6, 0.8 Hz, 7-H); δC (101 MHz, CD3OD) 53.7 (CH3, d, 
2
JC-O-P 
7.1 Hz), 54.1(d, 
2
JC-O-P 6.7 Hz, CH3), 75.3 (d, 
1
JCP 166.1 Hz, CH), 123.5 (CH), 125.1 (d, 
2
JCP 4.2 Hz, C), 125.6 (CH), 130.0 (CH), 134.7 (CH), 144.0 (d, 
3
JCP 4.0 Hz, C), 170.1 (C); 
m/z (CI) 243.0423 (MH
+
. C10H12O5P requires 243.0422), 242 (33%), 213 (8), 133 (87), 105 
(6). 
2-Fluoro-5-[(Z/E)-(3’’-oxo-2’’-benzofuran-1’’-ylidene)methyl]benzonitrile (136)78 
 
A solution of (±)-3-dimethoxyphosphoryl-3H-2-benzofuran-1-one (134) (5.30 g, 21.9 
mmol) and 2-fluoro-5-formylbenzonitrile (135) (3.00 g, 19.9 mmol) in tetrahydrofuran (60 
mL) was cooled to 0 °C, and to this was added triethylamine (3.10 mL, 21.9 mmol) 
dropwise. The resultant solution was allowed to warm to ambient temperature and 
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vigorously stirred for 24 h. The resultant suspension was concentrated in vacuo and water 
(40 mL) was added to the residue. The product was collected by vacuum filtration and 
washed with water (2 × 50 mL), hexane (2 × 50 mL) and diethyl ether (2 × 50 mL) before 
drying under high vacuum to give 2-fluoro-5-[(Z/E)-(3’’-oxo-2’’-benzofuran-1’’-
ylidene)methyl]benzonitrile (136) as a white solid (5.27 g, 100%). NMR spectra showed a 
75:25 mixture of E and Z isomers, of which only the signals for the major isomer are 
recorded. The product was carried forward without prior separation of the isomers. Mp 
163–165 °C (lit.78164−167 °C); δH (500 MHz, DMSO-d6) 6.96 (1H, s, 1’-H), 7.63 (1H, t, J 
9.1 Hz, ArH), 7.70–7.74 (1H, m, ArH), 7.90–7.94 (1H, m, ArH), 7.99 (1H, dt, J 8.0, 1.0 Hz, 
ArH), 8.08 (1H, dt, J 8.0, 1.0 Hz, ArH), 8.15–8.21 (2H, m, 2 × ArH); δC (126 MHz, 
DMSO-d6) 100.9 (d, 
2
JCF 16.2 Hz, C), 103.4 (CH), 113.7 (C), 117.3 (d, 
2
JCF 20.1 Hz, CH), 
120.9 (CH), 122.6 (C), 125.3 (CH), 130.9 (CH), 131.0 (d, 
4
JCF 3.8 Hz, C), 134.2 (CH), 
135.3 (CH), 136.7 (d, 
3
JCF 9.0 Hz, CH), 139.6 (C), 145.4 (C), 161.5 (d, 
1
JCF 258.3 Hz, C), 
165.9 (C); m/z (EI) 265.0543 (M
+
. C16H8FNO2 requires 265.0539), 237 (15%), 208 (93), 
182 (12), 133 (24), 104 (28), 84 (41). 
2-Fluoro-5-[(4’’-oxo-3’’H-phthalazin-1’’-yl)methyl]benzoic acid (137)78 
 
To a suspension of 2-fluoro-5-[(Z/E)-(3’’-oxo-2’’-benzofuran-1’’-
ylidene)methyl]benzonitrile (136) (3.50 g, 13.2 mmol) in water (130 mL) was added a 13 
M sodium hydroxide solution (20 mL), and the resultant mixture stirred vigorously at 
90 °C for 24 h. After cooling to 70 °C, hydrazine monohydrate (9.00 mL, 0.185 mol) was 
added to the reaction mixture dropwise and stirred for a further 72 h. On cooling to 
ambient temperature, the mixture was acidified with an aqueous solution of 6 M 
hydrochloric acid. The resultant precipitate was collected by vacuum filtration and washed 
with water (3 × 100 mL) and diethyl ether (3 × 100 mL) before drying under high vacuum 
to afford 2-fluoro-5-[(4’’-oxo-3’’H-phthalazin-1’’-yl)methyl]benzoic acid (137) as a pale 
pink solid (4.31 g, 100%). Mp 251–252 °C. Spectroscopic data were consistent with the 
literature.
78
 δH (500 MHz, DMSO-d6) 4.34 (2H, s, 1’-H2), 7.21 (1H, dd, J 8.5, 2.0 Hz, 3-H), 
7.53–7.58 (1H, m, 4-H), 7.78–7.84 (2H, m, 6-H and 6’’-H), 7.89 (1H, td, J 8.0, 1.5 Hz, 7’’-
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H), 7.96 (1H, d, J 8.0 Hz, 8’’-H), 8.26 (1H, dd, J 8.0, 1.5 Hz, 5’’-H), 12.50 (1H, s, NH); δC 
(126 MHz, DMSO-d6) 36.3 (CH2), 116.9 (d, 
2
JCF 22.6 Hz, CH), 119.3 (d, 
2
JCF 10.9 Hz, C), 
125.4 (CH), 126.0 (CH), 127.9 (C), 129.1 (C), 131.5 (CH), 131.7 (CH), 133.5 (CH), 134.2 
(d, 
4
JCF 3.7 Hz, C), 134.7 (d, 
3
JCF 8.7 Hz, CH), 144.8 (C), 159.3 (C), 159.8 (d, 
1
JCF 255.5 
Hz, C), 164.8 (d, 
4
JCF 2.8 Hz, C); m/z (CI) 299.0828 (MH
+
. C16H12FN2O3 requires 
299.0832), 287 (10%), 255 (21), 147 (7), 127 (31), 113 (18). 
tert-Butyl 4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-
yl)methyl]benzoyl}piperazine-1-carboxylate (138)
78
 
 
To a solution of 2-fluoro-5-[(4’’-oxo-3’’H-phthalazin-1’’-yl)methyl]benzoic acid (137) 
(1.10 g, 3.68 mmol) in N,N’-dimethylformamide (50 mL) was added triethylamine (0.769 
mL, 5.52 mmol) followed by O-benzotriazole-N,N,N’,N’-
tetramethyluroniumhexafluorophosphate (1.50 g, 4.05 mmol). The reaction mixture was 
stirred at ambient temperature for 1 h, after which tert-butyl piperazine-1-carboxylate 
(0.687 g, 3.68 mmol) was added. The solution was heated to 50 °C and stirred for 48 h. 
The reaction mixture was washed with an aqueous saturated solution of sodium 
bicarbonate (30 mL) and the product extracted with ethyl acetate (3 × 30 mL). The organic 
layers were washed with an aqueous solution of 5% lithium chloride (60 mL) and brine (60 
mL). The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo 
to give the crude product. Purification by flash column chromatography eluting with 5% 
methanol in dichloromethane gave tert-butyl 4-{2’-fluoro-5’-[(4’’’-oxo 3’’’H-phthalazin-
1’’’-yl)methyl]benzoyl}piperazine-1-carboxylate (138) as a pale yellow solid (1.23 g, 
72%). Mp 215–216 °C (lit.78 214−216 °C); δH (400 MHz, CDCl3) 1.47 (9H, s, O
t
Bu), 3.27 
(2H, br s, NCH2), 3.38 (2H, t, J 4.8 Hz, NCH2), 3.51 (2H, br s, NCH2), 3.75 (2H, br s, 
NCH2), 4.27 (2H, s, 1’’-H2), 7.04 (1H, t, J 9.2 Hz, 3’-H), 7.27–7.37 (2H, m, 4’-H and 6’-
H), 7.68–7.79 (3H, m, 6’’’-H, 7’’’-H and 8’’’-H), 8.44–8.48 (1H, m, 5’’’-H), 9.69 (1H, s, 
NH); δC (101 MHz, CDCl3) 28.4 (3 × CH3), 37.7 (CH2), 42.0 (2 × CH2), 46.9 (2 × CH2), 
80.4 (C), 116.2 (d, 
2
JCF 22.3 Hz, CH), 123.9 (d, 
2
JCF 17.3 Hz, C), 125.1 (CH), 127.2 (CH), 
128.3 (C), 129.2 (d, 
3
JCF 3.5 Hz, CH), 129.5 (C), 131.6 (d, 
3
JCF 8.3 Hz, CH), 131.7 (CH), 
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133.7 (CH), 134.3 (d, 
4
JCF 3.8 Hz, C), 145.6 (C), 154.5 (C), 157.0 (d, 
1
JCF 247.8 Hz, C), 
160.4 (C), 165.1 (C); m/z (EI) 466.2018 (M
+
. C25H27FN4O4 requires 466.2016), 393 (12%), 
366 (38), 281 (100), 254 (33), 196 (13), 166 (40), 91 (90). 
4-[4’’-Fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one (131)78 
 
To a suspension of tert-butyl 4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-
yl)methyl]benzoyl}piperazine-1-carboxylate (138) (0.278 g, 0.60 mmol) in ethanol (8 mL) 
was added an aqueous solution of 6 M hydrochloric (16 mL), and the resultant reaction 
mixture stirred vigorously at ambient temperature for 18 h. The ethanol was removed in 
vacuo and the aqueous layer made alkaline by the dropwise addition of an aqueous solution 
of 4 M sodium hydroxide. The solution was extracted with dichloromethane (3 × 20 mL) 
and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. 
Purification by trituration using a 1:1 diethyl ether/petroleum ether mixture gave 4-[4’’-
fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one (131) as a white solid 
(0.150 g, 68%). Mp 193–195 °C. Spectroscopic data were consistent with the literature.78 
δH (400 MHz, CDCl3) 2.07 (1H, br s, NH), 2.81 (2H, br s, NCH2), 2.95 (2H, t, J 4.4 Hz, 
NCH2), 3.28 (2H, br s, NCH2), 3.77 (2H, br s, NCH2), 4.29 (2H, s, 1’-H2), 7.02 (1H, t, J 
8.8 Hz, 5’’-H), 7.26–7.37 (2H, m, 2’’-H and 6’’-H), 7.70–7.80 (3H, m, 5-H, 6-H and 7-H), 
8.45–8.50 (1H, m, 8-H), 11.46 (1H, br s, NH); δC (101 MHz, CDCl3) 37.7 (CH2), 43.1 
(CH2), 45.7 (CH2), 46.2 (CH2), 48.2 (CH2), 116.1 (d, 
2
JCF 22.1 Hz, CH), 124.3 (d, 
2
JCF 18.2 
Hz, C), 125.1 (CH), 127.1 (CH), 128.3 (C), 129.1 (d, 
3
JCF 3.7 Hz, CH), 129.6 (C), 131.2 (d, 
3
JCF 8.1 Hz, CH), 131.6 (CH), 133.6 (CH), 134.2 (d, 
4
JCF 3.1 Hz, C), 145.6 (C), 157.0 (C, d, 
1
JCF 247.6 Hz), 160.8 (C), 165.0 (C); m/z (EI) 366.1486 (M
+
. C20H19FN4O2 requires 
366.1492), 325 (13%), 298 (27), 281 (100), 254 (29), 85 (17). 
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4-{3’’-[4’’’-(2’’’’-bromo-5’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (139) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.11 g, 0.22 mmol) and 2-bromo-5-nitrobenzoic acid (0.050 g, 0.20 mmol). 
This gave 4-{3’’-[4’’’-(2’’’’-bromo-5’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (139) as a white solid (0.061 g, 52%). Mp 137–140 °C; 
νmax (neat)/cm
−1 
3204 (NH), 2970 (CH), 1777 (CO), 1643 (CO), 1437, 1263, 1007, 739; δH 
(400 MHz, CDCl3) 3.25–3.45 (8H, m, 4 × CH2), 4.37 (2H, s, 1’-H2), 6.99 (1H, t, J 8.6 Hz, 
5’’-H), 7.34–7.37 (3H, m, 2’’-H, 6’’-H and 3’’’’-H), 7.71–7.79 (3H, m, 5-H, 6-H and 7-H), 
8.12 (1H, dd, J 8.6, 2.5 Hz, 4’’’’-H), 8.15 (1H, br s, 6’’’’-H), 8.44–8.48 (1H, m, 8-H), 
11.49 (1H, s, NH); δC (101 MHz, CDCl3) 37.7 (CH2), 41.7 (CH2), 42.1 (CH2), 46.6 (CH2), 
47.2 (CH2), 116.3 (d, 
2
JCF 22.2 Hz, CH), 123.0 (CH), 123.3 (d 
2
JCF 18.0 Hz, C), 124.9 
(CH), 125.2 (CH), 126.5 (C), 127.3 (CH), 128.3 (C), 129.3 (d, 
3
JCF 3.7 Hz, CH), 129.5 (C), 
131.7 (CH), 131.9 (d, 
3
JCF 8.1 Hz, CH), 133.8 (CH), 134.3 (CH), 134.5 (d, 
4
JCF 3.2 Hz, C), 
138.8 (C), 145.5 (C), 147.4 (C), 158.0 (d, 
1
JCF 248.0 Hz, C), 160.5 (C), 165.0 (C), 165.6 
(C); m/z (ESI) 616.0588 (MNa
+
. C27H21
79
BrFN5NaO5 requires 616.0602). 
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4-{3’’-[4’’’-(2’’’’-chloro-5’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (140) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.092 g, 0.25 mmol) and 2-chloro-5-nitrobenzoic acid (0.044 g,  0.22 mmol). 
This gave 4-{3’’-[4’’’-(2’’’’-chloro-5’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (140) as a yellow solid (0.052 g, 42%). Mp 139–
141 °C; νmax (neat)/cm
−1 
3457 (NH), 2970 (CH), 1728 (CO), 1636 (CO), 1437, 1229, 909, 
806; The compound exists as a 1.2:1 mixture of rotamers. Data for the major rotamer: δH 
(400 MHz, CDCl3) 3.66–4.11 (8H, m, 4 × NCH2), 4.32 (2H, s, 1’-H2), 7.08 (1H, t, J 8.6 Hz, 
5’’-H), 7.35–7.36 (2H, m, 2’’-H and 6’’-H), 7.64 (1H, d, J 8.6 Hz, 3’’’-H), 7.73–7.79 (3H, 
m, 5-H, 6-H and 7-H), 8.21–8.25 (2H, m, 4’’’-H and 6’’’-H), 8.45–8.49 (1H, m, 8-H), 
11.41 (1H, s, NH); δC (101 MHz, CDCl3) 37.7 (CH2), 42.1 (2 × CH2), 47.1 (2 × CH2), 
116.3 (d, 
2
JCF 22.6 Hz, CH), 123.3 (CH), 124.9 (CH), 125.2 (d, 
2
JCF 18.2 Hz, C), 127.2 
(CH), 128.3 (CH), 129.3 (d, 
3
JCF 3.9 Hz, CH), 129.5 (C), 131.1 (CH), 131.7 (CH), 132.0 (d, 
3
JCF 8.3 Hz, CH), 133.7 (CH), 134.6 (C), 135.6 (d, 
4
JCF 3.3 Hz, C), 136.6 (C), 137.2 (C), 
145.5 (C), 146.8 (C), 158.3 (d 
1
JCF 248.9 Hz, C), 160.8 (C), 164.7 (C), 165.2 (C); m/z (ESI) 
572.1083 (MNa
+
. C27H21
35
ClFN5NaO5 requires 572.1107). 
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4-{3’’-[4’’’-(4’’’’-Bromo-3’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (142) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.081 g, 0.22 mmol) and 4-bromo-3-nitrobenzoic acid (0.050 g, 0.20 mmol). 
This gave 4-{3’’-[4’’’-(4’’’’-bromo-3’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (142) as a white solid (0.067 g, 56%). Mp 122–126 °C; 
νmax (neat)/cm
−1 
3215 (NH), 2900 (CH), 1638 (CO), 1539, 1433, 1352, 1010, 731; The 
compound exists as a 1.5:1 mixture of rotamers. Data for the major rotamer: δH (400 MHz, 
CDCl3) 3.38–3.99 (8H, m, 4 × NCH2), 4.30 (2H, s, 1’-H2), 7.01–7.06 (1H, m, 5’’-H), 7.34–
7.36 (2H, m, 2’’-H and 6’’-H), 7.72–7.80 (4H, m, ArH), 8.12 (1H, d, J 8.6 Hz, ArH), 8.20 
(1H, s, 2’’’-H), 8.44–8.45 (1H, m, 8-H), 11.43 (1H, s, NH); δC (101 MHz, CDCl3) 37.6 
(CH2), 41.9 (2 × CH2), 47.5 (2 × CH2), 108.6 (CH), 116.2 (d 
2
JCF 21.8 Hz, CH), 120.8 
(CH), 123.3 (d, 
2
JCF 17.4 Hz, C), 125.0 (CH), 125.8 (CH), 128.2 (C), 129.4 (d, 
3
JCF 3.1 Hz, 
CH), 129.5 (C). 131.7 (CH), 132.0 (d, 
3
JCF 7.9 Hz, CH), 133.7 (CH), 134.5 (d, 
4
JCF 3.6 Hz, 
C), 135.6 (CH), 137.9 (C), 143.3 (C), 145.5 (C), 152.7 (C), 158.2 (d 
1
JCF 248.1 Hz, C), 
160.8 (C), 165.2 (C), 166.8 (C); m/z (ESI) 616.0583 (MNa
+
. C27H21
79
BrFN5NaO5 requires 
616.0602). 
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4-{4’’-Fluoro-3’’-[4’’’-(3’’’’-bromonicotinoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (144) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.14 g, 0.39 mmol) and 2-bromo-4-pyridinecarboxylic acid (0.050 g, 0.35 
mmol). This gave 4-{4’’-fluoro-3’’-[4’’’-(3’’’’-bromonicotinoyl)piperazine-1’’’-carbonyl]-
4’’-fluorobenzyl}-2H-phthalazin-1-one (144) as a yellow solid (0.074 g, 42%). Mp 130–
133 °C; νmax (neat)/cm
−1 
3194 (NH), 2970 (CH), 1726 (CO), 1638 (CO), 1433, 1366, 1229; 
δH (400 MHz, CDCl3) 3.31–3.46 (4H, m, 2 × NCH2), 3.74–3.86 (4H, m, 2 × NCH2), 4.31 
(2H, s, 1’-H2), 7.02–7.08 (1H, m, 5’’-H), 7.25 (1H, br s, 2’’’’-H), 7.35–7.38 (2H, m, 2’’-H 
and 6’’-H), 7.47–7.51 (1H, m, 6’’’’-H), 7.73–7.78 (3H, m, 5-H, 6-H and 7-H), 8.41–8.49 
(2H, m, 8-H and 5’’’’-H), 11.36 (1H, br s, NH); δC (101 MHz, CDCl3) 37.6 (CH2), 41.9 
(CH2), 42.3 (CH2), 46.8 (CH2), 47.4 (CH2), 116.2 (d, 
2
JCF 24.1 Hz, CH), 123.3 (d, 
2
JCF 17.6 
Hz, C), 125.0 (CH), 125.7 (CH), 127.2 (CH), 128.2 (C), 129.3 (d, 
3
JCF 3.5 Hz, CH), 129.5 
(C), 131.7 (CH), 132.0 (d, 
3
JCF 8.1 Hz, CH), 133.7 (CH), 134.5 (d, 
4
JCF 3.4 Hz, C), 142.9 
(C), 145.3 (C), 145.5 (CH), 150.8 (CH), 156.0 (C), 158.0 (d, 
1
JCF 250.0 Hz, C), 160.8 (C), 
165.3 (C), 166.3 (C); m/z (ESI) 572.0686 (MNa
+
. C26H21
79
BrFN5NaO3 requires 572.0704). 
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4-{4’’-Fluoro-3’’-[4’’’-(4’’’’-bromonicotinoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (146) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-bromo-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-
phthalazin-1-one (131) (0.10 g, 0.28 mmol) and 6-bromopyridine-3-carboxylic acid (0.050 
g, 0.25 mmol). This gave 4-{4’’-fluoro-3’’-[4’’’-(4’’’’-bromonicotinoyl)piperazine-1’’’-
carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (146) as a yellow solid (0.058 g, 41%). 
Mp 135–138 °C; νmax (neat)/cm
−1 
3025 (NH), 2970 (CH), 1730 (CO), 1600 (CO), 1428, 
1228, 1002, 888; δH (400 MHz, CDCl3) 3.33–3.80 (8H, m, 4 × NCH2), 4.30 (2H, s, 1’-H2), 
7.02–7.08 (1H, m, 5’’-H), 7.34–7.36 (2H, m, 2’’-H and 6’’-H), 7.56–7.64 (2H, m, 5’’’’-H 
and 6’’’’-H), 7.71–7.73 (1H, m, 5-H), 7.75–7.80 (2H, m, 6-H and 7-H), 8.43 (1H, s, 2’’’’-
H), 8.46–8.48 (1H, m, 8-H), 11.07 (1H, s, NH); δC (101 MHz, CDCl3) 37.8 (CH2), 42.2 (2 
× CH2), 47.2 (2 × CH2), 116.2  (d, 
2
JCF 22.7 Hz, CH), 123.3 (d, 
2
JCF 17.6 Hz, C), 125.0 
(CH), 127.2 (CH), 128.3 (C), 128.4 (CH), 129.4 (d, 
3
JCF 3.2 Hz, CH), 129.5 (C), 130.0 (C), 
131.7 (CH), 132.0 (d, 
3
JCF 8.1 Hz, CH), 133.7 (CH), 134.5 (d, 
4
JCF 3.6 Hz, C), 137.6 (CH), 
143.9 (C), 145.5 (CH), 148.4 (C), 158.2 (d, 
1
JCF 250.0 Hz, C), 160.6 (C), 165.2 (C), 167.0 
(C); m/z (ESI) 572.0731 (MNa
+
. C26H21
79
BrFN5NaO3 requires 572.0704). 
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4-{3’’-[4’’’-(2’’’’-Fluoro-5’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (141) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.050 g, 0.14 mmol) and 2-fluoro-5-nitrobenzoic acid (0.028 g,  0.14 mmol). 
This gave 4-{3’’-[4’’’-(2’’’’-fluoro-5’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (141) as a yellow solid (0.042 g, 55%). Mp 140–
142 °C; νmax (neat)/cm
−1 
3400 (NH), 2980 (CH), 1782 (CO), 1643 (CO), 1437, 1259, 1170, 
1008; The compound exists as a 1.2:1 mixture of rotamers. Data for the major rotamer: δH 
(400 MHz, CDCl3) 3.34–3.42 (8H, m, 4 × NCH2), 4.31 (2H, s, 1-H2), 7.08 (1H, t, J 8.6 Hz, 
5’’-H), 7.35–7.37 (3H, m, 2’’-H, 6’’-H and 3’’’’-H), 7.75–7.79 (3H, m, 4’’’’-H and 2 × 
ArH), 8.34–8.37 (2H, m, 6’’’’-H and ArH), 8.46 (1H, td, J 7.2, 1.6 Hz, 8-H), 10.88 (1H, s, 
NH); δC (101 MHz, CDCl3) 37.7 (CH2), 41.7 (CH2), 42.1 (CH2), 46.8 (CH2), 47.3 (CH2), 
116.2 (d, 
2
JCF 22.4 Hz, CH), 117.3 (d, 
2
JCF 15.6 Hz, CH), 123.4 (d, 
2
JCF 17.6 Hz, C), 125.0 
(d, 
3
JCF 7.9 Hz, CH), 125.8 (CH), 127.2 (d, 
3
JCF 2.6 Hz, CH), 127.4 (CH), 128.3 (C), 129.3 
(d, 
3
JCF 3.2 Hz, CH), 129.5 (C), 131.7 (CH), 132.0 (d, 
3
JCF 7.5 Hz, CH), 133.7 (CH), 134.5 
(d, 
4
JCF 3.7 Hz, C), 144.7 (d, 
2
JCF 11.8 Hz, C), 145.5 (C), 158.2 (d, 
1
JCF 249.2 Hz, C), 160.5 
(C), 162.6 (d, 
1
JCF 252.0 Hz, C), 162.7 (C), 162.8 (C), 165.2 (C); m/z (ESI) 556.1393 
(MNa
+
. C27H21F2N5NaO5 requires 556.1403). 
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4-{3’’-[4’’’-(4’’’’-Fluoro-3’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (143) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.11 g, 0.30 mmol) and 4-fluoro-3-nitrobenzoic acid (0.050 g, 0.27 mmol). 
This gave 4-{3’’-[4’’’-(4’’’’-fluoro-3’’’’-nitrobenzoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (143) as a yellow solid (0.069 g, 48%). Mp 143–
146 °C; νmax (neat)/cm
−1 
2920 (NH), 2359 (CH), 1634 (CO), 1594, 1436, 1350, 1008, 811; 
δH (400 MHz, CDCl3) 3.39–4.04 (8H, m, 4 × NCH2), 4.30 (2H, s, 1’-H2), 7.05–7.12 (1H, m, 
5’’-H), 7.35–7.38 (3H, m, 2’’-H, 6’’-H and 5’’’’-H), 7.71–7.80 (4H, m, 5-H, 6-H, 7-H and 
6’’’’-H), 8.15 (1H, s, 2’’’’-H), 8.46 (1H, d, J 6.7 Hz, 8-H), 10.89 (1H, s, NH); δC (101 
MHz, CDCl3) 37.6 (CH2), 42.0 (2 × CH2), 46.9 (2 × CH2), 116.2 (d, 
2
JCF 21.5 Hz, CH), 
119.1 (d, 
2
JCF 21.4 Hz, CH), 123.3 (d, 
2
JCF 17.8 Hz, C), 125.0 (CH), 125.5 (d, 
3
JCF 2.4 Hz, 
CH), 127.2 (CH), 128.3 (C), 129.3 (d, 
3
JCF 2.8 Hz, CH), 129.5 (C), 131.7 (CH), 131.8 (d, 
4
JCF 4.7 Hz, C), 132.0 (d, 
3
JCF 8.1 Hz, CH),  133.7 (CH), 134.5 (d, 
4
JCF 2.8 Hz, C), 134.6 
(CH), 137.2 (C), 145.5 (C), 157.3 (d, 
1
JCF 266.9 Hz, C), 158.0 (d, 
1
JCF 246.6 Hz, C), 160.5 
(C), 165.2 (C), 167.0 (C); m/z (ESI) 556.1384 (MNa
+
. C27H21F2N5NaO5 requires 556.1403). 
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4-{4’’-Fluoro-3’’-[4’’’-(3’’’’-fluoronicotinoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (145) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.14 g, 0.39 mmol) and 2-fluoro-4-pyridinecarboxylic acid (0.050 g, 0.35 
mmol). This gave 4-{4’’-fluoro-3’’-[4’’’-(3’’’’-fluoronicotinoyl)piperazine-1’’’-carbonyl]-
4’’-fluorobenzyl}-2H-phthalazin-1-one (145) as a yellow solid (0.074 g, 43%). Mp 128–
134 °C; νmax (neat)/cm
−1 
3199 (NH), 2900 (CH), 1632 (CO), 1431, 1252, 1004, 727; δH 
(400 MHz, CDCl3) 3.34–3.46 (4H, m, 2 × NCH2), 3.75–3.88 (4H, m, 2 × NCH2), 4.30 (2H, 
s, 1’-H2), 6.93–7.08 (2H, m, 5’’-H and 6’’’’-H), 7.18 (1H, s, 2’’’’-H), 7.34–7.36 (2H, m, 
2’’-H and 6’’-H), 7.73–7.78 (3H, m, 5-H, 6-H and 7-H), 8.29–8.34 (1H, m, 5’’’’-H), 8.46–
8.48 (1H, m, 8-H), 11.29 (1H, s, NH); δC (101 MHz, CDCl3) 37.6 (CH2), 41.7 (CH2), 42.3 
(CH2), 47.0 (CH2), 47.5 (CH2), 107.8 (d, 
2
JCF 36.7 Hz, CH), 116.3 (d, 
2
JCF 21.9 Hz, CH), 
119.0 (d, 
4
JCF 4.3 Hz, CH), 123.3 (d, 
2
JCF 17.5 Hz, C), 125.0 (CH), 127.2 (CH), 128.3 (C), 
129.3 (d, 
3
JCF 3.5 Hz, CH), 129.5 (C), 131.7 (CH), 132.0 (d, 
3
JCF 7.8 Hz, CH), 133.7 (CH), 
134.6 (d, 
3
JCF 3.5 Hz, C), 145.5 (C), 148.2 (C), 148.8 (d, 
3
JCF 14.9 Hz, CH), 158.2 (d, 
1
JCF 
250.0 Hz, C), 160.8 (C), 164.9 (d, 
1
JCF 245.6 Hz, C), 165.1 (C), 166.5 (C); m/z (ESI) 
512.1487 (MNa
+
. C26H21F2N5NaO3 requires 512.1505). 
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4-{4’’-Fluoro-3’’-[4’’’-(4’’’’-fluoronicotinoyl)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (147) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.114 g, 0.310 mmol) and 6-fluoropyridine-3-carboxylic acid (0.0400 g, 
0.280 mmol). This gave 4-{4’’-fluoro-3’’-[4’’’-(4’’’’-fluoronicotinoyl)piperazine-1’’’-
carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (147) as a white solid (0.0660 g, 48%). 
Mp 141–145 °C; νmax (neat)/cm
−1 
3227 (NH), 2866 (CH), 1637 (CO), 1612 (CO), 1435, 
1288, 1011, 729; δH (400 MHz, CDCl3) 3.38–3.82 (8H, m, 4 × NCH2), 4.31 (2H, s, 1’-H2), 
7.00–7.07 (2H, m, 5’’-H and 5’’’’-H), 7.33–7.35 (2H, m, 2’’-H and 6’’-H), 7.71–7.79 (3H, 
m, 5-H, 6-H and 7-H), 7.91 (1H, td, J 8.2, 2.2 Hz, 6’’’’-H), 8.32 (1H, br s, 2’’’’-H), 8.46–
8.48 (1H, m, 8-H), 11.55 (1H, s, NH); δC (101 MHz, CDCl3) 37.7 (CH2), 42.1 (2 × CH2), 
47.0 (2 × CH2), 110.0 (d, 
2
JCF 36.1 Hz, CH), 116.2 (d, 
2
JCF 23.3 Hz, CH), 123.4 (d, 
2
JCF 
18.8 Hz, C), 125.0 (CH), 127.2 (C), 128.3 (C), 128.9 (d, 
4
JCF 4.7 Hz, C), 129.3 (d, 
3
JCF 3.9 
Hz, CH), 129.5 (C), 131.6 (CH), 131.9 (d 
3
JCF 8.5 Hz, CH), 133.7 (CH), 134.5 (d, 
4
JCF 3.4 
Hz, C), 140.9 (d 
3
JCF 8.7 Hz, CH), 145.5 (CH), 146.8 (d 
3
JCF 15.5 Hz, CH), 158.2 (d 
1
JCF 
250.0 Hz, C), 160.9 (C), 165.2 (C), 165.3 (d 
1
JCF 244.6 Hz, C), 167.0 (C); m/z (EI) 
512.1487 (MNa
+
. C26H21F2N5NaO3 requires 512.1505) 
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4-{3’’-[4’’’-(1’’’’-oxo-4’’’’-butanoic acid)-piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-
2H-phthalazin-1-one (149) 
 
4-[4’’-Fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-1-one (131) (0.030 g, 
0.080 mmol) and succinic anhydride (0.016 g, 0.16 mmol) were dissolved in acetonitrile (2 
mL). 4-(Dimethylamino)pyridine (0.0010 g, 0.0080 mmol) was added and the mixture 
stirred for 24 hours at 80 °C. The solvent was removed in vacuo and the reaction mixture 
was diluted with a saturated aqueous solution of sodium bicarbonate (10 mL) and was 
washed with ethyl acetate (3 × 10 mL). The aqueous layer was acidified with an aqueous 
solution of 1 M hydrochloric acid and the product extracted with ethyl acetate (3 × 10 mL). 
The organic layers were combined, washed with brine (30 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Purification by flash column chromatography eluting with 10% 
methanol and 0.1% acetic acid in dichloromethane gave 4-{3’’-[4’’’-(1’’’’-oxo-4’’’’-
butanoic acid)-piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (149) as a 
white foam (0.037 g, 72%). Mp 200–205 °C; νmax (neat)/cm
−1
 3169 (NH/OH), 2922 (CH), 
1782 (CO), 1636 (CO), 1439, 1247, 842; δH (400 MHz, CD3OD) 2.57–2.61 (3H, m, 2’’’’-
H2 and 3’’’’-HH), 2.70 (1H, t, J 6.7 Hz, 3’’’’-HH), 3.27 (1H, br s, NCHH), 3.36 (1H, br s, 
NCHH), 3.51 (2H, t, J 5.0 Hz, NCH2), 3.65–3.68 (2H, m, NCH2), 3.73 (1H, t, J 5.0 Hz, 
NCHH), 3.81 (1H, t, J 5.0 Hz, NCHH), 4.38 (2H, s, 1’-H2), 7.15 (1H, t, J 8.9 Hz, 5’’-H), 
7.37–7.39 (1H, m, 2’’-H), 7.46–7.49 (1H, m, 6’’-H), 7.82 (1H, t, J 7.7 Hz, 7-H), 7.87 (1H, 
t, J 7.7 Hz, 6-H), 7.94 (1H, m, 5-H), 8.36 (1H, d, J 7.7 Hz, 8-H); δC (101 MHz, CD3OD) 
27.5 (CH2), 29.3 (CH2), 36.8 (CH2), 40.9 (CH2), 41.8 (CH2), 44.6 (CH2), 46.5 (CH2), 115.8 
(d, 
2
JCF 21.8 Hz, CH), 123.3 (d 
2
JCF 18.5 Hz, C), 125.4 (CH), 126.1 (CH), 127.8 (C), 128.7 
(d, 
3
JCF 3.6 Hz, CH), 128.5 (C), 131.4 (CH), 132.0 (d, 
3
JCF  8.1 Hz, CH), 133.6 (CH), 135.0 
(d, 
4
JCF 3.5 Hz, C), 146.3 (C), 158.2 (d, 
1
JCF 248.0 Hz, C), 160.9 (C), 165.9 (C), 166.0 (C), 
171.6 (C); m/z (ESI) 489.1563 (MNa
+
. C24H23FN4NaO5 requires 489.1545). 
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6.5 Radioiododeboronation experiemental 
General experimental for radioiodination of aryl boronic acids with [
125
I]NaI 
Reductant free [
125
I]NaI was purchased from Perkin Elmer (product number 
NEZ033H005MC) with a specific radioactivity of 643.8 GBq/mg in 0.1 M NaOH (pH 12–
14) aqueous solution. All radiochemical yields were determined by radio-HPLC analysis of 
the crude product. Radiochemical yield refers to the amount of radioactive iodide 
converted into the desired product. Radioactivity yield refers to the isolated yield of 
radioactive product after purification. 
Analytical radio-HPLC method for determination of radioiodide incorporation 
Analytical HPLC was performed with a Dionex Ultimate 3000 HPLC system equipped 
with a Flowstar LB 513 NaI scintillation detector and a DAD-3000 UV detector using a 
Synergi 4 μm Hydro-RP 80 Å column (150 × 4.6 mm) with 10 mm guard cartridge, UV 
254 nm and flow 1 mL/min. The mobile phase for the analysis of substrates was 
water/acetonitrile. Analysis of the reaction mixture (to assess radioiodide incorporation) 
used a gradient profile of water and acetonitrile, as shown below. 
Time (mins) %MeCN 
0–20 10–95 
20–24 95 
24–25 95–10 
25–30 10 
 
Co-elution with the UV signal from the 
127
I-compound was used to confirm identity of the 
125
I-product from each reaction described. 
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General method A for radioiodination: 4-[
125
I]Iodoanisole (21) 
 
To a solution of N-chlorosuccinimide (0.50 mg, 3.9 µmol) in dimethylcarbonate (0.1 mL) 
was added a 4–6 MBq solution of [125I]NaI in water (0.01 mL). A solution of 4-
methoxybenzeneboronic acid (0.60 mg, 3.9 µmol) and Ph3PAuNTf2 (3.0 mg, 2.0 µmol) in 
dimethylcarbonate (0.1 mL) was added and the reaction mixture heated to 90 °C for 20 
minutes. The reaction mixture was then removed by syringe and diluted with a 1:1 mixture 
of acetonitrile and water (0.5 mL). Analysis of this solution by analytical radio-HPLC 
showed a radiochemical yield of 100%. 
4-Bromo-[
125
I]iodobenzene (154) 
 
The reaction was carried out using 4-bromobenzeneboronic acid (0.60 mg, 3.0 µmol) as 
described in  general method A, except that the reaction was complete in 10 minutes. 
Analysis by radio-HPLC gave a radiochemical yield of 97%. 
3-Nitro-[
125
I]iodobenzene (155) 
 
The reaction was carried out using 3-nitrobenzeneboronic acid (0.6 mg, 3.6 µmol) as 
described in general procedure A. Analysis by radio-HPLC gave a radiochemical yield of 
100%. 
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[
125
I]Iodo-2-methylbenzene (156) 
 
The reaction was carried out using 2-methylbenzeneboronic acid (0.60 mg, 4.4 µmol) as 
described in general procedure A, except that the reaction was complete in 10 minutes. 
Analysis by radio-HPLC gave a radiochemical yield of 92%. 
2-Chloro-4-[
125
I]iodoanisole (157) 
 
The reaction was carried out using 3-chloro-4-methoxybenzeneboronic acid (0.60 mg, 3.2 
µmol) as described in general procedure A. Analysis by radio-HPLC gave a radiochemical 
yield of 95%. 
3-Trifluoromethyl-[
125
I]iodobenzene (158) 
 
The reaction was carried out using 3-(trifluoromethyl)benzeneboronic acid (0.60 mg, 3.2 
µmol) as described in general procedure A, except that the reaction was heated to 80 °C for 
30 minutes. Analysis by radio-HPLC gave a radiochemical yield of 94%. 
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Ethyl 4-[
125
I]iodobenzoate (159) 
 
The reaction was carried out using 4-ethoxycarbonylbenzeneboronic acid (0.60 mg, 3.1 
µmol) as described in general procedure A, except that the reaction was heated to 80 °C for 
30 minutes. Analysis by radio-HPLC gave a radiochemical yield of 100%. 
N-(3-[
125
I]Iodobenzyl)guanidine (169) 
 
The radio-iododeboronation reaction was carried out using {3-[2,3-bis(tert-
butoxycarbonyl)guanidino]methylphenyl}boronic acid (167) (0.60 mg, 1.5 µmol) as 
described in general procedure A, except that Ph3PAuNTf2 (2.3 mg, 1.5 µmol) was used 
and the reaction was heated to 80 °C for 30 minutes. Analysis by radio-HPLC gave a 
radiochemical yield of 100% for N’,N”-bis(tert-butoxycarbonyl)-N-3-
[
125
I]iodobenzylguanidine (168). Hydrochloric acid (0.2 mL) was added and the reaction 
mixture stirred at 90 °C for 20 minutes. Analysis by radio-HPLC gave a radiochemical 
yield of 97%. 
4-{3’-[4’’-(4’’’-[125I]Iodobenzoyl)piperazine-1’’-carbonyl]-4’-fluorobenzyl}-2H-
phthalazin-1-one (120) 
 
The reaction was carried out using 4-{3’-[4’’-(benzoyl-4’’’-boronic acid)piperazine-1’’-
carbonyl]-4’-fluorobenzyl}-2H-phthalazin-1-one (162) (0.60 mg, 1.2 µmol) as described in 
general procedure A, except that Ph3PAuNTf2 (1.9 mg, 1.2 µmol) was used and the 
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reaction was heated to 100 °C for 40 minutes. Analysis by radio-HPLC gave a 
radiochemical yield of 41%. 
Semi-Preparative Radio-HPLC Method for Purification of N-(3-
[
125
I]iodobenzyl)guanidine (169) 
Semi-preparative HPLC was performed with a Dionex Ultimate 3000 HPLC system 
equipped with a Knauer Advanced Scientific Instruments Smartline UV Detector 2500, a 
photomultiplier tube (PMT) connected to a Lab Logic Flow-Count radiodetector and using 
a Synergi 4 μm Hydro-RP 80 Å column (150 × 10 mm, with 10 mm guard cartridge, UV 
254 nm and flow 3 mL/min). A gradient profile of water and acetonitrile was used, as 
shown below. 
Time (mins) %MeCN 
0–20 10–95 
20–24 95 
24–25 95–10 
25–30 10 
 
Synthesis and Purification of N-(3-[
125
I]iodobenzyl)guanidine (169) 
 
To a solution of N-chlorosuccinimide (0.5 mg, 3.9 µmol, 1.0) in dimethylcarbonate (0.1 
mL) was added a 10.16 MBq solution of [
125
I]NaI in water (0.01 mL). A solution of {3-
[2,3-bis(tert-butoxycarbonyl)guanidino]methylphenyl}boronic acid (0.6 mg, 1.5 µmol) and 
Ph3PAuNTf2 (2 mg, 1.5 µmol) in dimethylcarbonate (0.1 mL) was added and the reaction 
mixture heated to 80 °C for 30 minutes. Hydrochloric acid (0.2 mL) was added and the 
reaction was heated to 90 °C for 20 minutes. The mixture was diluted in a 1:1 mixture of 
acetonitrile and water (0.5 mL) and the crude product was purified by semi-preparative 
HPLC. The fraction containing N-(3-[
125
I]iodobenzyl)guanidine was evaporated to dryness, 
then reconstituted in 10.0% ethanol in 0.9% saline to afford N-(3-
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[
125
I]iodobenzyl)guanidine (169) in 28% radioactivity yield (estimated using the measured 
radioactivity of the isolated product). The injected MIBG was below the UV detection 
limits and therefore the molar activity was calculated using the lowest concentration of N-
(3-[
127
I]iodobenzyl)guanidine which could be detected. Using this value, the molar activity 
was estimated to be greater than 2.73 GBq/µmol. The radiochemical purity of the final 
product was determined by analytical HPLC and was >98%. The identity of the product 
was confirmed by comparing the retention time of N-(3-[
125
I]iodobenzyl)guanidine against 
the retention time N-(3-[
127
I]iodobenzyl)guanidine. 
General Method B for Radioiodination: 4-[
125
I]Iodoanisole (21) 
 
To a solution of N-chlorosuccinimide (1.8 mg, 13 µmol) in dimethylcarbonate (0.2 mL) 
was added a 4–6 MBq solution of [125I]NaI in water (0.01 mL). After 20 minutes, a 
solution of 4-methoxybenzeneboronic acid (2.0 mg, 13 µmol) and potassium acetate (2.6 
mg, 2.6 µmol) in dimethylcarbonate (0.2 mL) was added and the reaction mixture heated to 
100 °C for 1.5 h. The reaction mixture was then removed by syringe and diluted with a 1:1 
mixture of acetonitrile and water (0.5 mL). Analysis of this solution by analytical radio-
HPLC showed a radiochemical yield of 93%. 
2-Chloro-4-[
125
I]iodoanisole (157) 
 
The reaction was carried out using 3-chloro-4-methoxybenzeneboronic acid (2.0 mg, 11 
µmol) as described in general procedure B except that the reaction was complete after 2 h. 
Analysis by radio-HPLC gave a radiochemical yield of 95%. 
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[
125
I]Iodo-2-methylbenzene (156) 
 
The reaction was carried out using 2-methylbenzeneboronic acid (2.0 mg, 9.0 µmol) as 
described in general procedure B except that the reaction was complete in 3 h. Analysis by 
radio-HPLC gave a radiochemical yield of 94%. 
[
125
I]Iodo-3-trifluoromethylbenzene (158) 
 
The reaction was carried out using 3-(trifluoromethyl)benzeneboronic acid (0.60 mg, 3.2 
µmol) as described in general procedure B except that the reaction was complete in 3 h. 
Analysis by radio-HPLC gave a radiochemical yield of 61%. 
4-[
125
I]Iodobenzyl bromide (175) 
 
The reaction was carried out using 4-(bromomethyl)phenylboronic acid (2.0 mg, 6.8 µmol) 
as described in general procedure B except that the reaction was complete in 2.5 h. 
Analysis by radio-HPLC gave a radiochemical yield of 74%. 
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2-Fluoro-4-[
125
I]iodoanisole (176) 
 
The reaction was carried out using 3-fluoro-4-methoxybenzeneboronic acid (2.0 mg, 12 
µmol) as described in general procedure B except that the reaction was complete in 2.5 h. 
Analysis by radio-HPLC gave a radiochemical yield of 96%. 
1-[
125
I]Iodonaphthalene (19) 
 
The reaction was carried out using naphthalene-1-boronic acid (2.0 mg, 8.0 µmol) as 
described in general procedure B except that the reaction was complete in 2.5 h. Analysis 
by radio-HPLC gave a radiochemical yield of 90%. 
2-Bromo-[
125
I]iodobenzene (177) 
 
The reaction was carried out using 2-bromobenzeneboronic acid (2.0 mg, 7.0 µmol) as 
described in general procedure B except that the reaction was complete in 3 h. Analysis by 
radio-HPLC gave a radiochemical yield of 61%. 
[
125
I]Iodo-3-nitrobenzene (155) 
 
The reaction was carried out using 3-nitrobenzeneboronic acid (2.0 mg, 8.0 µmol) as 
described in general procedure B, except that acetonitrile (0.2 mL) was added and the 
reaction was complete after 2.5 h. Analysis by radio-HPLC gave a radiochemical yield of 
92%. 
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3-Bromo-[
125
I]iodobenzene (178) 
 
The reaction was carried out using 3-bromobenzeneboronic acid (2.0 mg, 7.0 µmol) as 
described in general procedure B, except that acetonitrile (0.2 mL) was added and the 
reaction was complete after 3 h. Analysis by radio-HPLC gave a radiochemical yield of 
72%. 
3-[
125
I]Iodobenzaldehyde (179) 
 
The reaction was carried out using 3-formylphenylboronic acid (2.0 mg, 9.0 µmol) as 
described in general procedure B except that the reaction was complete in 3 h. Analysis by 
radio-HPLC gave a radiochemical yield of 15%. 
N,N’-bis(tert-butyloxycarbonyl)-N”-(3-[125I]iodobenzyl)guanidine (168) 
 
The reaction was carried out using {3-[2,3-bis(tert-
butoxycarbonyl)guanidino]methylphenyl}boronic acid (167) (3.0 mg, 8.0 µmol) as 
described in general procedure B, except that potassium acetate (0.4 mg, 4 µmol) was 
added and the reaction was complete after 3.5 h. Analysis by radio-HPLC gave a 
radiochemical yield of 51%. 
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4-{3’-[4’’-(4’’’-[125I]Iodobenzoyl)piperazine-1’’-carbonyl]-4’-fluorobenzyl}-2H-
phthalazin-1-one (120) 
 
The reaction was carried out using 4-{3’-[4’’-(benzoyl-4’’’-boronic acid)piperazine-1’’-
carbonyl]-4’-fluorobenzyl}-2H-phthalazin-1-one (162) (2 mg, 4 µmol) as described in 
general procedure B, except that potassium acetate (0.4 mg, 4 µmol) was added and the 
reaction was heated to 80 °C for 4 h. Analysis by radio-HPLC gave a radiochemical yield 
of 38%. 
Experimental for 
127
I compounds 
4-Iodoanisole (21)
105
 
 
General procedure C: 4-Methoxybenzeneboronic acid (153) (0.050 g, 0.33 mmol) and N-
iodosuccinimide (0.074 g, 0.33 mmol) were dissolved in dimethyl carbonate (1.5 mL) and 
Ph3PAuNTf2 (0.025 g, 0.017 mmol) was added. The mixture was stirred for 5 minutes at 
90 °C. The crude mixture was passed through a silica plug and washed with 20:1 
hexane/diethyl ether to give 4-iodoanisole (21) as a white solid (0.068 g, 88%). Mp 56–
58 °C (lit.
105
 53–55 °C); δH (400 MHz, CDCl3) 3.78 (3H, s, OCH3), 6.68 (2H, d, J 6.8 Hz, 
2-H and 6-H), 7.56 (2H, d, J 6.8 Hz, 3-H and 5-H); δC (101 MHz, CDCl3) 55.5 (CH3), 82.8 
(C), 116.5 (2 × CH), 138.3 (2 × CH), 159.6 (C); m/z (EI) 234 (M
+
, 100%), 219 (29). 
General procedure D: N-Chlorosuccinimide (0.044 g, 0.33 mmol) and sodium iodide 
(0.049 g, 0.33 mmol) were dissolved in dimethyl carbonate (1.5 mL) and stirred at room 
temperature for 10 minutes. 4-Methoxybenzeneboronic acid (153) (0.050 g, 0.33 mmol) 
and Ph3PAuNTf2 (0.025 g, 0.017 mmol) were added and the mixture was heated to 90 °C 
and stirred for 5 minutes. The crude mixture was passed through a silica plug and washed 
with 20:1 hexane/diethyl ether to give 4-iodoanisole (21) as a white solid (0.057 g, 74%).  
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General procedure E: N-Chlorosuccinimide (0.029 g, 0.22 mmol) and sodium iodide 
(0.032 g, 0.22 mmol) were dissolved in dimethyl carbonate (1.5 mL) and stirred at room 
temperature for 10 minutes. 4-Methoxybenzeneboronic acid (153) (0.030 g, 0.20 mmol) 
and potassium acetate (0.002 g, 0.020 mmol) were added and the mixture stirred at 50 °C 
for 2 h. The crude mixture was passed through a silica plug and washed with 20:1 
hexane/diethyl ether to give 4-iodoanisole (21) as a white solid (0.030 g, 65%).  
4-Bromoiodobenzene (154)
106
 
 
The reaction was carried out according to general procedure D using 4-
bromobenzeneboronic acid (0.030 g, 0.15 mmol) and gave 4-bromoiodobenzene (154) as a 
white solid (0.032 g, 75%). Mp 94–96 °C (lit.106 91–92 °C); δH (400 MHz, CDCl3) 7.23 
(2H, d, J 8.6 Hz, 2-H and 6-H), 7.54 (2H, d, J 8.6 Hz, 3-H and 5-H); δC (101 MHz, CDCl3) 
92.2 (C), 122.3 (C), 133.6 (2 × CH), 139.2 (2 × CH); m/z (EI) 282 (M
+
, 100%), 157 (35), 
75 (40). 
Iodo-3-nitrobenzene (155)
107
 
 
The reaction was carried out according to general procedure D using 3-
nitrobenzeneboronic acid (0.015 g, 0.090 mmol) and gave iodo-3-nitrobenzene (155) as a 
yellow oil (0.010 g, 45%). Spectroscopic data were consistent with the literature.
107
 δH 
(400 MHz, CDCl3) 7.26 (1H, t, J 7.9 Hz, 5-H), 8.03 (1H, ddd, J 7.9, 1.9, 1.0 Hz, 6-H), 8.21 
(1H, ddd, J 7.9, 1.9, 1.0 Hz, 4-H), 8.57 (1H, t, J 1.9 Hz, 2-H); δC (101 MHz, CDCl3) 93.6 
(C), 122.9 (CH), 130.8 (CH), 132.6 (CH), 143.6 (CH), 148.7 (C); m/z (EI) 249 (M
+
, 45%), 
203 (20), 78 (80). 
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Iodo-2-methylbenzene (156)
108
 
 
The reaction was carried out according to general procedure D using 2-
methylbenzeneboronic acid (0.020 g, 0.10 mmol) and gave iodo-2-methylbenzene (156) as 
a yellow oil (0.011 g, 39 %). Spectroscopic data were consistent with the literature.
108
 δH 
(400 MHz, CDCl3) 2.44 (3H, s, 2-CH3), 6.84–6.96 (1H, m, ArH), 7.23–7.25 (2H, m, ArH), 
7.81 (1H, d, J 7.6 Hz, 6-H); δC (101 MHz, CDCl3) 28.3 (CH3), 101.3 (C), 127.5 (CH), 
128.3 (CH), 129.9 (CH), 139.1 (CH), 141.5 (C); m/z (EI) 218 (M
+
, 48%), 234 (90). 
2-Chloro-4-iodoanisole (157)
109
 
 
The reaction was carried out according to general procedure D using 3-chloro-4-
methoxyphenylboronic acid (0.020 g, 0.11 mmol) and gave 2-chloro-4-iodoanisole (157) 
as a white solid (0.018 g, 62%). Mp 96–97 °C (lit.109 93–95 °C); δH (400 MHz, CDCl3) 
3.88 (3H, s, OCH3), 6.68 (1H, d, J 8.6 Hz, 6-H), 7.51 (1H, dd, J 8.6, 2.2 Hz, 5-H), 7.65 
(1H, d, J 2.2 Hz, 3-H); δC (101 MHz, CDCl3) 56.3 (CH3), 82.0 (C), 114.1 (CH), 123.9 (C), 
136.7 (CH), 138.3 (CH), 155.2 (C); m/z (EI) 268 (M
+
, 100%), 253 (42), 225 (20). 
Iodo-3-trifluoromethylbenzene (158)
110
 
 
The reaction was carried out according to general procedure D using 3-
trifluoromethylbenzeneboronic acid (0.020 g, 0.11 mmol) and gave iodo-3-
trifluoromethylbenzene (158) as a yellow oil (0.010 g, 33%).
110
 Spectroscopic data were 
consistent with the literature. δH (400 MHz, CDCl3) 7.22 (1H, t, J 7.9 Hz, 5-H), 7.60 (1H, d, 
J 7.9 Hz, 4-H), 7.90 (1H, d, J 7.9 Hz, 6-H), 7.96 (1H, br s, 2-H); δC (101 MHz, CDCl3) 
94.0 (C), 124.6 (q, 
3
JCF 3.7 Hz, CH), 130.5 (CH), 132.8 (q, 
2
JCF 32.8 Hz, C), 134.4 (q, 
3
JCF 
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3.9 Hz, CH), 141.0 (q, 
4
JCF 1.1 Hz, CH) (signal for carbon directly attached to fluorine is 
not observed); m/z (EI) 272 (M
+
, 30%), 213 (60), 103 (25). 
Ethyl 4-iodobenzoate (159)
110
 
 
The reaction was carried out according to general procedure D using 4-
ethoxycarbonylphenylboronic acid (0.020 g, 0.10 mmol) and gave ethyl 4-iodobenzoate 
(159) as a colourless oil (0.015 g, 54%). Spectroscopic data were consistent with the 
literature.
110
 δH (400 MHz, CDCl3) 1.39 (3H, t, J 7.1 Hz, OCH2CH3), 4.36 (2H, q, J 7.1 Hz, 
OCH2CH3), 7.74 (2H, d, J 8.8 Hz, 3-H and 5-H), 7.80 (2H, d, J 8.8 Hz, 2-H and 6-H); δC 
(101 MHz, CDCl3) 14.4 (CH3), 61.4 (CH2), 100.7 (C), 130.2 (C), 131.1 (2 × CH), 137.9 (2 
× CH), 166.2 (C); m/z (EI) 276 (M
+
, 60%), 248 (30), 231 (90), 76 (50), 57 (55). 
4-Iodobenzyl bromide (175)
111
 
 
The reaction was carried out according to general procedure E using 4-
(bromomethyl)phenylboronic acid (0.030 g, 0.14 mmol) and gave 4-iodobenzyl bromide 
(175) as a yellow solid (0.031 g, 75%). Mp 80–83 °C (lit.111 79–81 °C); δH (400 MHz, 
CDCl3) 4.42 (2H, s, CH2Br), 7.13 (2H, d, J 8.4 Hz, 2-H and 6-H), 7.67 (2H, d, J 8.4 Hz, 3-
H and 5-H); δC (101 MHz, CDCl3) 35.5 (CH2), 94.1 (C), 130.8 (2 × CH), 137.4 (C), 138.0 
(2 × CH); m/z (EI) 298 (M
+
, 20%), 217 (90), 84 (42). 
 
 
 
 
 
 
 
166 
 
2-Fluoro-4-iodoanisole (176)
112
 
 
The reaction was carried out according to general procedure E using 3-fluoro-4-
methoxybenzeneboronic acid (0.030 g, 0.18 mmol) and gave 2-fluoro-4-iodoanisole (176) 
as a white foam (0.032 g, 71%). Spectroscopic data were consistent with the literature.
112
 
δH (400 MHz, CDCl3) 3.87 (3H, s, OCH3), 6.71 (1H, t, J 8.4 Hz, 6-H), 7.36–7.40 (2H, m, 
3-H and 5-H); δC (101 MHz, CDCl3) 56.3 (CH3), 80.9 (d, 
3
JCF 7.1 Hz, C), 115.2 (d, 
4
JCF 2.1 
Hz, CH), 125.1 (d, 
2
JCF 20.4 Hz, CH), 133.3 (d, 
3
JCF 4.0 Hz, CH), 147.9 (d, 
2
JCF 10.3 Hz, 
C), 153.6 (d, 
1
JCF 251.2 Hz, C); m/z (EI) 252 (M
+
, 100%) 237 (41), 172 (25), 84 (45). 
1-Iodonaphthalene (19)
107
 
 
The reaction was carried out according to general procedure E using naphthalene-1-
boronic acid (0.030 g, 0.17 mmol) and gave 1-iodonaphthalene (19) as a yellow oil (0.019 
g, 46%). Spectroscopic data were consistent with the literature.
107
 δH (400 MHz, CDCl3) 
7.18 (1H, t, J 8.0 Hz, ArH), 7.52 (1H, td, J 8.0, 1.2 Hz, ArH), 7.57 (1H, td, J 8.0, 1.2 Hz, 
ArH), 7.77 (1H, d, J 8.0 Hz, ArH), 7.84 (1H, d, J 8.0 Hz, ArH), 8.09 (2H, d, J 8.0 Hz, 
ArH); δC (101 MHz, CDCl3) 99.6 (C), 126.7 (CH), 126.9 (CH), 127.7 (CH), 128.6 (CH), 
129.0 (CH), 132.1 (CH), 134.1 (C), 134.4 (C), 137.4 (CH); m/z (EI) 254 (M
+
, 100%), 127 
(61), 62 (30). 
2-Bromoiodobenzene (177)
113
 
 
 
The reaction was carried out according to general procedure E using 2-
bromobenzeneboronic acid (0.030 g, 0.15 mmol) and gave 2-bromoiodobenzene (177) as a 
white foam (0.018 g, 43%). Spectroscopic data were consistent with the literature.
113
 δH 
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(400 MHz, CDCl3) 7.00 (1H, td, J 7.8, 1.6 Hz, 5-H), 7.21 (1H, td, J 7.8, 1.6 Hz, 4-H), 7.63 
(1H, dd, J 7.8, 1.6 Hz, 6-H), 7.87 (1H, dd, J 7.8, 1.6 Hz, 3-H); δC (101 MHz, CDCl3) 101.1 
(C), 128.4 (CH), 129.4 (CH), 132.8 (CH), 139.3 (C), 140.4 (CH); m/z (EI) 282 (M
+
, 15%), 
84 (85), 66 (95). 
3-Bromoiodobenzene (178)
114
 
 
 
The reaction was carried out according to general procedure E using 3-
bromobenzeneboronic acid (0.030 g, 0.15 mmol) and gave 3-bromoiodobenzene (178) as a 
white foam (0.019 g, 45%). Spectroscopic data were consistent with the literature.
114
 δH 
(400 MHz, CDCl3) 6.97 (1H, t, J 8.0 Hz, 5-H), 7.47 (1H, ddd, J 8.0, 1.7, 0.9 Hz, 6-H), 7.63 
(1H, ddd, J 8.0, 1.7, 0.9 Hz, 4-H), 7.87 (1H, t, J 1.7 Hz, 2-H); δC (101 MHz, CDCl3) 94.5 
(C), 123.1 (C), 130.8 (CH), 131.3 (CH), 136.1 (CH), 139.7 (CH); m/z (EI) 284 (M
+
, 52%), 
78 (80), 62 (95). 
3-Iodobenzaldehyde (179)
115
 
 
The reaction was carried out according to general procedure E using 3-
formylphenylboronic acid (0.030 g, 0.20 mmol) and gave 3-iodobenzaldehyde as a yellow 
solid (0.030 g, 65%). Mp 59–61 °C (lit.115 55–57 °C); δH (400 MHz, CDCl3) 7.29 (1H, t, J 
7.8 Hz, 5-H), 7.84 (1H, dt, J 7.8, 1.2 Hz, 4-H), 7.96 (1H, ddd, J 7.8, 1.6, 1.2 Hz, 6-H), 8.21 
(1H, t, J 1.6 Hz, 2-H), 9.93 (1H, s, CHO); δC (101 MHz, CDCl3) 94.6 (C), 128.9 (CH), 
130.7 (CH), 138.0 (C), 138.4 (CH), 143.2 (CH), 190.7 (C); m/z (EI) 232 (M
+
, 100%), 77 
(30), 51 (22). 
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{3-[2,3-Bis(tert-butoxycarbonyl)guanidino]methylphenyl}boronic acid (167)
96
 
 
N,N’-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (166) (0.050 g, 0.16 mmol) 
and 3-(aminomethyl)benzeneboronic acid hydrochloride (165) (0.033 mg, 0.18 mmol) 
were dissolved in methanol (5 mL). Triethylamine (0.10 mL, 0.48 mmol) was added and 
the mixture stirred for 12 h at room temperature. The solvent was removed in vacuo and 
the crude material was purified by flash column chromatography, eluting with 50% ethyl 
acetate in petroleum ether to give {3-[2,3-
bis(tertbutoxycarbonyl)guanidino]methylphenyl}boronic acid (167) as a yellow solid 
(0.047 g, 75%). Mp 111–113 °C. Spectroscopic data were consistent with the literature.96 
δH (400 MHz, CD3OD) 1.47 (9H, s, O
t
Bu), 1.50 (9H, s, O
t
Bu), 4.55 (2H, s, CH2), 7.29–
7.39 (2H, m, 2 × ArH), 7.53–7.75 (2H, m, 2 × ArH); δC (101 MHz, CD3OD) 26.9 (3 × 
CH3), 27.2 (3 × CH3), 44.2 (CH2), 79.1 (C), 83.2 (C), 127.6 (CH), 128.8 (d, 
3
JC-B 50.2 Hz, 
CH), 132.6 (d, 
2
JC-B 39.3 Hz, 2 × CH), 136.5 (CH), 152.8 (C), 156.1 (C), 163.2 (C) (signal 
for carbon directly attached to boron is not observed); m/z (ESI) 394 (MH
+
, 20%). 
4-{3’’-[4’’’-(4’’’’-iodobenzoyl)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-2H-
phthalazin-1-one (120)
85
 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.30 g, 0.082 mmol) and 4-iodobenzoic acid (0.028 g, 0.074 mmol). This 
gave 4-[3’-[4’’-(4’’’-iodobenzoyl)piperazine-1’’-carbonyl]-4’-fluorobenzyl]-2Hphthalazin-
1-one (120) as a white foam (0.015 g, 34%). Spectroscopic data were consistent with the 
literature.
85
 δH (400 MHz, CDCl3) 3.14–4.02 (8H, m, 4 × NCH2), 4.28 (2H, s, 1’-H2), 7.04 
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(1H, t, J 7.8 Hz, 5’’-H), 7.14 (2H, d, J 8.0 Hz, 3’’’’-H and 5’’’’-H), 7.29–7.37 (2H, m, 2’’-
H and 6’’-H), 7.67–7.84 (5H, m, 5-H, 6-H, 7-H, 2’’’’-H and 6’’’’-H), 8.42–8.51 (1H, m, 8-
H), 10.96 (1H, br s, NH); δc (101 MHz, CDCl3) 37.7 (CH2), 42.1 (2 × CH2), 47.1 (2 × 
CH2), 96.6 (C), 116.2 (d, 
2
JCF 21.7 Hz, CH), 123.6 (d, 
2
JCF 17.7 Hz, C), 125.0 (CH), 127.2 
(CH), 128.4 (C), 128.9 (2 × CH), 129.3 (d, 
3
JCF 3.6 Hz, CH), 129.5 (C), 131.7 (CH), 131.9 
(d, 
3
JCF 8.0 Hz, CH), 133.7 (CH), 134.4 (C), 134.6 (d, 
4
JCF 3.7 Hz, C), 137.9 (2 × CH), 
145.5 (C), 157.1 (d, 
1
JCF 247.1 Hz, C), 160.4 (C), 165.2 (C), 169.7 (C); m/z (ESI) 619.0597 
(MNa
+
. C27H22FIN4NaO3 requires 619.0613). 
4-{3’’-[4’’’-(Benzoyl-4’’’’-boronic acid)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-
2H-phthalazin-1-one (162) 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.11 g, 0.30 mmol) and 4-carboxyphenylboronic acid (161) (0.050, 0.30 
mmol). This gave 4-{3’’-[4’’’-(benzoyl-4’’’’-boronic acid)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (162) as a white solid (0.050 g, 33%). Mp 166–168 °C; 
νmax (neat)/cm
−1
 3017 (NH), 2970 (CH), 1740 (CO), 1729 (CO), 1366, 1229, 1217; δH (400 
MHz, CD3OD) 3.46–3.82 (8H, m, 4 × NCH2), 4.37 (2H, s, 1’-H2), 6.84 (2H, d, J 7.5 Hz, 
3’’’’-H and 5’’’’-H), 7.15 (1H, t, J 8.8 Hz, 5’’-H), 7.31 (2H, d, J 7.5 Hz, 2’’’’-H and 6’’’’-
H), 7.36 (1H, d, J 6.1 Hz, 6’’-H), 7.45–7.50 (1H, m, 2’’-H), 7.80 (1H, t, J 7.8 Hz, 7-H), 
7.85 (1H, t, J 7.8 Hz, 6-H), 7.93 (1H, d, J 7.8 Hz, 5-H), 8.35 (1H, d, J 7.8 Hz, 8-H); δC 
(101 MHz, CD3OD) 29.4 (2 × CH2), 36.8 (CH2), 41.7 (2 × CH2), 114.9 (2 × CH), 115.8 (d, 
2
JCF  21.8 Hz, CH), 123.2 (d, 
2
JCF 17.1 Hz, C), 125.3 (C), 125.4 (CH), 126.1 (CH), 127.9 
(C), 128.7 (d, 
3
JCF 3.8 Hz, CH), 129.1 (2 × CH), 129.5 (C), 131.4 (CH), 132.0 (d, 
3
JCF 8.0 
Hz, CH), 133.6 (CH), 135.0 (d, 
4
JCF 3.8 Hz, C), 146.2 (C), 157.0 (d, 
1
JCF 247.2 Hz, C), 
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159.6 (C), 160.9 (C), 165.9 (C), 171.8 (C); m/z (ESI) 537.1718 (MNa
+
. C27H24BFN4NaO5 
requires 537.1716). 
4-{3’’-[4’’’-(Benzoyl-4’’’’-boronic acid pinacol ester)piperazine-1’’’-carbonyl]-4’’-
fluorobenzyl}-2H-phthalazin-1-one (164)
116
 
 
The reaction was carried out according to the previously described procedure for tert-butyl 
4-{2’-fluoro-5’-[(4’’’-oxo-3’’’H-phthalazin-1’’’-yl)methyl]benzoyl}piperazine-1-
carboxylate (138) using 4-[4’’-fluoro-3’’-(piperazine-1’’’-carbonyl)benzyl]-2H-phthalazin-
1-one (131) (0.13 g, 0.35 mmol) and 4-carboxylphenylboronic acid pinacol ester (163) 
(0.80 g, 0.32 mmol). This gave 4-{3’’-[4’’’-(benzoyl-4’’’’-boronic acid pinacol 
ester)piperazine-1’’’-carbonyl]-4’’-fluorobenzyl}-2H-phthalazin-1-one (164) as a yellow 
solid (0.078 g, 50%). Mp 278–282 °C (lit.116 288−291 °C); δH (400 MHz, CDCl3) 1.35 
(12H, s, 4 × OCCH3), 3.09–3.88 (8H, m, 4 × NCH2), 4.30 (2H, s, 1’-H2), 7.03 (1H, br s, 
5’’-H), 7.33–7.42 (4H, m, 2’’-H, 6’’-H, 3’’’’-H and 5’’’’-H), 7.69–7.89 (5H, m, 5-H, 6-H, 
7-H, 2’’’’-H and 6’’’’-H), 8.49 (1H, br s, 8-H), 11.25 (1H, br s, NH); δC (101 MHz, CDCl3) 
24.9 (4 × CH3), 37.7 (CH2), 42.2 (2 × CH2), 47.1 (2 × CH2), 84.1 (2 × C), 116.2 (d, 
2
JCF 
21.5 Hz, CH), 123.6 (d, 
2
JCF 17.2 Hz, C), 125.0 (C), 126.2 (2 × CH), 127.2 (CH), 128.3 
(CH), 129.2 (d, 
3
JCF 3.2 Hz, CH), 129.5 (C), 131.6 (CH), 131.7 (d, 
3
JCF 7.8 Hz, CH), 133.7 
(CH), 134.5 (d, 
4
JCF 3.3 Hz, C), 135.0 (2 × CH), 137.5 (C), 145.5 (C), 158.2 (d, 
1
JCF 249.0 
Hz, C), 160.7 (C), 165.2 (C), 170.5 (C) (signal for carbon directly attached to boron is not 
observed); m/z (ESI) 619.2483 (MNa
+
. C33H34BFN4NaO5 requires 619.2499). 
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8. Appendix 
8.1 Radio-HPLC and UV/Vis HPLC chromatograms 
The following chromatograms were obtained by analytical radio-HPLC (blue) of the 
reaction mixtures following radioiodination of the corresponding boronic acids. Overlays 
of the UV/Vis HPLC traces (black) of the unlabelled products are also shown. 
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